id	sid	tid	token	lemma	pos
cuesj-1446	1	1	tx_1	tx_1	PROPN
cuesj-1446	1	2	~	~	X
cuesj-1446	1	3	abs	ab	NOUN
cuesj-1446	1	4	:	:	PUNCT
cuesj-1446	1	5	at	at	ADP
cuesj-1446	1	6	/	/	SYM
cuesj-1446	1	7	add	add	VERB
cuesj-1446	1	8	:	:	PUNCT
cuesj-1446	1	9	tx_2	tx_2	PROPN
cuesj-1446	1	10	~	~	NOUN
cuesj-1446	1	11	abs	ab	NOUN
cuesj-1446	1	12	:	:	PUNCT
cuesj-1446	1	13	at	at	ADP
cuesj-1446	1	14	1	1	NUM
cuesj-1446	1	15	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1446	1	16	cuesj	cuesj	NOUN
cuesj-1446	1	17	2025	2025	NUM
cuesj-1446	1	18	,	,	PUNCT
cuesj-1446	1	19	9	9	NUM
cuesj-1446	1	20	(	(	PUNCT
cuesj-1446	1	21	2	2	NUM
cuesj-1446	1	22	):	):	PUNCT
cuesj-1446	1	23	1	1	NUM
cuesj-1446	1	24	-	-	SYM
cuesj-1446	1	25	6	6	NUM
cuesj-1446	1	26	research	research	NOUN
cuesj-1446	1	27	article	article	NOUN
cuesj-1446	1	28	impact	impact	NOUN
cuesj-1446	1	29	of	of	ADP
cuesj-1446	1	30	sglt2	sglt2	ADJ
cuesj-1446	1	31	inhibitors	inhibitor	NOUN
cuesj-1446	1	32	on	on	ADP
cuesj-1446	1	33	induced	induced	ADJ
cuesj-1446	1	34	benign	benign	ADJ
cuesj-1446	1	35	prostatic	prostatic	ADJ
cuesj-1446	1	36	hyperplasia	hyperplasia	NOUN
cuesj-1446	1	37	in	in	ADP
cuesj-1446	1	38	rats	rat	NOUN
cuesj-1446	1	39	balen	balen	PROPN
cuesj-1446	1	40	m.	m.	NOUN
cuesj-1446	1	41	khudhur	khudhur	PROPN
cuesj-1446	1	42	,	,	PUNCT
cuesj-1446	1	43	nidhal	nidhal	PROPN
cuesj-1446	1	44	a.m.	a.m.	PROPN
cuesj-1446	1	45	ali	ali	PROPN
cuesj-1446	1	46	department	department	PROPN
cuesj-1446	1	47	of	of	ADP
cuesj-1446	1	48	pharmacology	pharmacology	PROPN
cuesj-1446	1	49	,	,	PUNCT
cuesj-1446	1	50	medical	medical	ADJ
cuesj-1446	1	51	physics	physics	NOUN
cuesj-1446	1	52	and	and	CCONJ
cuesj-1446	1	53	biochemistry	biochemistry	NOUN
cuesj-1446	1	54	,	,	PUNCT
cuesj-1446	1	55	college	college	NOUN
cuesj-1446	1	56	of	of	ADP
cuesj-1446	1	57	medicine	medicine	NOUN
cuesj-1446	1	58	,	,	PUNCT
cuesj-1446	1	59	hawler	hawler	PROPN
cuesj-1446	1	60	medical	medical	PROPN
cuesj-1446	1	61	university	university	PROPN
cuesj-1446	1	62	,	,	PUNCT
cuesj-1446	1	63	erbil	erbil	PROPN
cuesj-1446	1	64	,	,	PUNCT
cuesj-1446	1	65	iraq	iraq	PROPN
cuesj-1446	1	66	abstract	abstract	ADJ
cuesj-1446	1	67	benign	benign	ADJ
cuesj-1446	1	68	prostatic	prostatic	ADJ
cuesj-1446	1	69	hyperplasia	hyperplasia	NOUN
cuesj-1446	1	70	(	(	PUNCT
cuesj-1446	1	71	bph	bph	NOUN
cuesj-1446	1	72	)	)	PUNCT
cuesj-1446	1	73	is	be	AUX
cuesj-1446	1	74	a	a	DET
cuesj-1446	1	75	non	non	ADJ
cuesj-1446	1	76	-	-	ADJ
cuesj-1446	1	77	cancerous	cancerous	ADJ
cuesj-1446	1	78	proliferation	proliferation	NOUN
cuesj-1446	1	79	of	of	ADP
cuesj-1446	1	80	the	the	DET
cuesj-1446	1	81	prostate	prostate	NOUN
cuesj-1446	1	82	tissue	tissue	NOUN
cuesj-1446	1	83	,	,	PUNCT
cuesj-1446	1	84	predominantly	predominantly	ADV
cuesj-1446	1	85	impacting	impact	VERB
cuesj-1446	1	86	the	the	DET
cuesj-1446	1	87	transitional	transitional	ADJ
cuesj-1446	1	88	zone	zone	NOUN
cuesj-1446	1	89	and	and	CCONJ
cuesj-1446	1	90	periurethral	periurethral	ADJ
cuesj-1446	1	91	area	area	NOUN
cuesj-1446	1	92	,	,	PUNCT
cuesj-1446	1	93	resulting	result	VERB
cuesj-1446	1	94	in	in	ADP
cuesj-1446	1	95	lower	low	ADJ
cuesj-1446	1	96	urinary	urinary	ADJ
cuesj-1446	1	97	tract	tract	NOUN
cuesj-1446	1	98	symptoms	symptom	NOUN
cuesj-1446	1	99	in	in	ADP
cuesj-1446	1	100	elderly	elderly	ADJ
cuesj-1446	1	101	males	male	NOUN
cuesj-1446	1	102	.	.	PUNCT
cuesj-1446	2	1	chronic	chronic	ADJ
cuesj-1446	2	2	inflammation	inflammation	NOUN
cuesj-1446	2	3	plays	play	VERB
cuesj-1446	2	4	a	a	DET
cuesj-1446	2	5	widely	widely	ADV
cuesj-1446	2	6	acknowledged	acknowledge	VERB
cuesj-1446	2	7	significant	significant	ADJ
cuesj-1446	2	8	role	role	NOUN
cuesj-1446	2	9	in	in	ADP
cuesj-1446	2	10	the	the	DET
cuesj-1446	2	11	etiology	etiology	NOUN
cuesj-1446	2	12	of	of	ADP
cuesj-1446	2	13	bph	bph	NOUN
cuesj-1446	2	14	.	.	PUNCT
cuesj-1446	3	1	current	current	ADJ
cuesj-1446	3	2	pharmacological	pharmacological	ADJ
cuesj-1446	3	3	interventions	intervention	NOUN
cuesj-1446	3	4	comprise	comprise	VERB
cuesj-1446	3	5	5	5	NUM
cuesj-1446	3	6	-	-	PUNCT
cuesj-1446	3	7	alpha	alpha	NOUN
cuesj-1446	3	8	-	-	PUNCT
cuesj-1446	3	9	reductase	reductase	NOUN
cuesj-1446	3	10	inhibitors	inhibitor	NOUN
cuesj-1446	3	11	and	and	CCONJ
cuesj-1446	3	12	alphaadrenergic	alphaadrenergic	ADJ
cuesj-1446	3	13	antagonists	antagonist	NOUN
cuesj-1446	3	14	,	,	PUNCT
cuesj-1446	3	15	both	both	PRON
cuesj-1446	3	16	of	of	ADP
cuesj-1446	3	17	which	which	PRON
cuesj-1446	3	18	are	be	AUX
cuesj-1446	3	19	linked	link	VERB
cuesj-1446	3	20	to	to	ADP
cuesj-1446	3	21	considerable	considerable	ADJ
cuesj-1446	3	22	adverse	adverse	ADJ
cuesj-1446	3	23	effects	effect	NOUN
cuesj-1446	3	24	.	.	PUNCT
cuesj-1446	4	1	thus	thus	ADV
cuesj-1446	4	2	,	,	PUNCT
cuesj-1446	4	3	there	there	PRON
cuesj-1446	4	4	is	be	VERB
cuesj-1446	4	5	an	an	DET
cuesj-1446	4	6	increasing	increase	VERB
cuesj-1446	4	7	demand	demand	NOUN
cuesj-1446	4	8	for	for	ADP
cuesj-1446	4	9	alternate	alternate	ADJ
cuesj-1446	4	10	therapy	therapy	NOUN
cuesj-1446	4	11	modalities	modality	NOUN
cuesj-1446	4	12	with	with	ADP
cuesj-1446	4	13	reduced	reduced	ADJ
cuesj-1446	4	14	adverse	adverse	ADJ
cuesj-1446	4	15	effects	effect	NOUN
cuesj-1446	4	16	.	.	PUNCT
cuesj-1446	5	1	sodium	sodium	NOUN
cuesj-1446	5	2	-	-	PUNCT
cuesj-1446	5	3	glucose	glucose	NOUN
cuesj-1446	5	4	co	co	NOUN
cuesj-1446	5	5	-	-	NOUN
cuesj-1446	5	6	transporter-2	transporter-2	PRON
cuesj-1446	5	7	(	(	PUNCT
cuesj-1446	5	8	sglt2	sglt2	X
cuesj-1446	5	9	)	)	PUNCT
cuesj-1446	5	10	inhibitors	inhibitor	NOUN
cuesj-1446	5	11	were	be	AUX
cuesj-1446	5	12	initially	initially	ADV
cuesj-1446	5	13	developed	develop	VERB
cuesj-1446	5	14	for	for	ADP
cuesj-1446	5	15	glycemic	glycemic	ADJ
cuesj-1446	5	16	regulation	regulation	NOUN
cuesj-1446	5	17	in	in	ADP
cuesj-1446	5	18	type	type	NOUN
cuesj-1446	5	19	 	 	SPACE
cuesj-1446	5	20	2	2	NUM
cuesj-1446	5	21	diabetes	diabetes	NOUN
cuesj-1446	5	22	mellitus	mellitus	NOUN
cuesj-1446	5	23	while	while	SCONJ
cuesj-1446	5	24	also	also	ADV
cuesj-1446	5	25	providing	provide	VERB
cuesj-1446	5	26	benefits	benefit	NOUN
cuesj-1446	5	27	in	in	ADP
cuesj-1446	5	28	diminishing	diminish	VERB
cuesj-1446	5	29	significant	significant	ADJ
cuesj-1446	5	30	cardiovascular	cardiovascular	ADJ
cuesj-1446	5	31	incidents	incident	NOUN
cuesj-1446	5	32	,	,	PUNCT
cuesj-1446	5	33	enhancing	enhance	VERB
cuesj-1446	5	34	heart	heart	NOUN
cuesj-1446	5	35	failure	failure	NOUN
cuesj-1446	5	36	results	result	NOUN
cuesj-1446	5	37	,	,	PUNCT
cuesj-1446	5	38	and	and	CCONJ
cuesj-1446	5	39	decelerating	decelerate	VERB
cuesj-1446	5	40	the	the	DET
cuesj-1446	5	41	advancement	advancement	NOUN
cuesj-1446	5	42	of	of	ADP
cuesj-1446	5	43	chronic	chronic	ADJ
cuesj-1446	5	44	renal	renal	ADJ
cuesj-1446	5	45	disease	disease	NOUN
cuesj-1446	5	46	.	.	PUNCT
cuesj-1446	6	1	recent	recent	ADJ
cuesj-1446	6	2	research	research	NOUN
cuesj-1446	6	3	indicates	indicate	VERB
cuesj-1446	6	4	that	that	SCONJ
cuesj-1446	6	5	sglt2	sglt2	ADJ
cuesj-1446	6	6	inhibitors	inhibitor	NOUN
cuesj-1446	6	7	have	have	VERB
cuesj-1446	6	8	antiinflammatory	antiinflammatory	NOUN
cuesj-1446	6	9	and	and	CCONJ
cuesj-1446	6	10	antiproliferative	antiproliferative	ADJ
cuesj-1446	6	11	properties	property	NOUN
cuesj-1446	6	12	.	.	PUNCT
cuesj-1446	7	1	this	this	DET
cuesj-1446	7	2	study	study	NOUN
cuesj-1446	7	3	examines	examine	VERB
cuesj-1446	7	4	the	the	DET
cuesj-1446	7	5	impact	impact	NOUN
cuesj-1446	7	6	of	of	ADP
cuesj-1446	7	7	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	7	8	and	and	CCONJ
cuesj-1446	7	9	empagliflozin	empagliflozin	PROPN
cuesj-1446	7	10	on	on	ADP
cuesj-1446	7	11	testosterone	testosterone	NOUN
cuesj-1446	7	12	-	-	PUNCT
cuesj-1446	7	13	induced	induce	VERB
cuesj-1446	7	14	bph	bph	NOUN
cuesj-1446	7	15	in	in	ADP
cuesj-1446	7	16	rats	rat	NOUN
cuesj-1446	7	17	.	.	PUNCT
cuesj-1446	8	1	bph	bph	NOUN
cuesj-1446	8	2	was	be	AUX
cuesj-1446	8	3	induced	induce	VERB
cuesj-1446	8	4	in	in	ADP
cuesj-1446	8	5	rats	rat	NOUN
cuesj-1446	8	6	with	with	ADP
cuesj-1446	8	7	the	the	DET
cuesj-1446	8	8	administration	administration	NOUN
cuesj-1446	8	9	of	of	ADP
cuesj-1446	8	10	testosterone	testosterone	NOUN
cuesj-1446	8	11	enanthate	enanthate	NOUN
cuesj-1446	8	12	.	.	PUNCT
cuesj-1446	9	1	the	the	DET
cuesj-1446	9	2	treatment	treatment	NOUN
cuesj-1446	9	3	groups	group	NOUN
cuesj-1446	9	4	were	be	AUX
cuesj-1446	9	5	administered	administer	VERB
cuesj-1446	9	6	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	9	7	,	,	PUNCT
cuesj-1446	9	8	empagliflozin	empagliflozin	PROPN
cuesj-1446	9	9	,	,	PUNCT
cuesj-1446	9	10	and	and	CCONJ
cuesj-1446	9	11	finasteride	finasteride	ADJ
cuesj-1446	9	12	.	.	PUNCT
cuesj-1446	10	1	prostate	prostate	NOUN
cuesj-1446	10	2	mass	mass	PROPN
cuesj-1446	10	3	,	,	PUNCT
cuesj-1446	10	4	prostate	prostate	NOUN
cuesj-1446	10	5	index	index	NOUN
cuesj-1446	10	6	,	,	PUNCT
cuesj-1446	10	7	serum	serum	NOUN
cuesj-1446	10	8	testosterone	testosterone	NOUN
cuesj-1446	10	9	concentrations	concentration	NOUN
cuesj-1446	10	10	,	,	PUNCT
cuesj-1446	10	11	and	and	CCONJ
cuesj-1446	10	12	histological	histological	ADJ
cuesj-1446	10	13	alterations	alteration	NOUN
cuesj-1446	10	14	were	be	AUX
cuesj-1446	10	15	assessed	assess	VERB
cuesj-1446	10	16	.	.	PUNCT
cuesj-1446	11	1	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	11	2	,	,	PUNCT
cuesj-1446	11	3	empagliflozin	empagliflozin	PROPN
cuesj-1446	11	4	,	,	PUNCT
cuesj-1446	11	5	and	and	CCONJ
cuesj-1446	11	6	finasteride	finasteride	ADV
cuesj-1446	11	7	significantly	significantly	ADV
cuesj-1446	11	8	(	(	PUNCT
cuesj-1446	11	9	p	p	X
cuesj-1446	11	10	<	<	X
cuesj-1446	11	11	0.05	0.05	NUM
cuesj-1446	11	12	)	)	PUNCT
cuesj-1446	11	13	decreased	decrease	VERB
cuesj-1446	11	14	mean	mean	ADJ
cuesj-1446	11	15	prostate	prostate	NOUN
cuesj-1446	11	16	weight	weight	NOUN
cuesj-1446	11	17	,	,	PUNCT
cuesj-1446	11	18	prostate	prostate	NOUN
cuesj-1446	11	19	index	index	NOUN
cuesj-1446	11	20	,	,	PUNCT
cuesj-1446	11	21	and	and	CCONJ
cuesj-1446	11	22	blood	blood	NOUN
cuesj-1446	11	23	testosterone	testosterone	NOUN
cuesj-1446	11	24	levels	level	NOUN
cuesj-1446	11	25	.	.	PUNCT
cuesj-1446	12	1	histological	histological	ADJ
cuesj-1446	12	2	investigation	investigation	NOUN
cuesj-1446	12	3	revealed	reveal	VERB
cuesj-1446	12	4	a	a	DET
cuesj-1446	12	5	reduction	reduction	NOUN
cuesj-1446	12	6	of	of	ADP
cuesj-1446	12	7	testosterone	testosterone	NOUN
cuesj-1446	12	8	-	-	PUNCT
cuesj-1446	12	9	induced	induce	VERB
cuesj-1446	12	10	bph	bph	NOUN
cuesj-1446	12	11	to	to	ADP
cuesj-1446	12	12	mild	mild	ADJ
cuesj-1446	12	13	prostatic	prostatic	ADJ
cuesj-1446	12	14	hyperplasia	hyperplasia	NOUN
cuesj-1446	12	15	in	in	ADP
cuesj-1446	12	16	the	the	DET
cuesj-1446	12	17	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	12	18	and	and	CCONJ
cuesj-1446	12	19	finasteride	finasteride	ADJ
cuesj-1446	12	20	groups	group	NOUN
cuesj-1446	12	21	.	.	PUNCT
cuesj-1446	13	1	however	however	ADV
cuesj-1446	13	2	,	,	PUNCT
cuesj-1446	13	3	mild	mild	ADJ
cuesj-1446	13	4	-	-	PUNCT
cuesj-1446	13	5	to	to	ADP
cuesj-1446	13	6	-	-	PUNCT
cuesj-1446	13	7	moderate	moderate	ADJ
cuesj-1446	13	8	prostatic	prostatic	ADJ
cuesj-1446	13	9	hyperplasia	hyperplasia	NOUN
cuesj-1446	13	10	was	be	AUX
cuesj-1446	13	11	observed	observe	VERB
cuesj-1446	13	12	in	in	ADP
cuesj-1446	13	13	the	the	DET
cuesj-1446	13	14	empagliflozin	empagliflozin	PROPN
cuesj-1446	13	15	group	group	NOUN
cuesj-1446	13	16	.	.	PUNCT
cuesj-1446	14	1	both	both	PRON
cuesj-1446	14	2	sglt2	sglt2	ADJ
cuesj-1446	14	3	inhibitors	inhibitor	NOUN
cuesj-1446	14	4	,	,	PUNCT
cuesj-1446	14	5	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	14	6	and	and	CCONJ
cuesj-1446	14	7	empagliflozin	empagliflozin	PROPN
cuesj-1446	14	8	,	,	PUNCT
cuesj-1446	14	9	exhibited	exhibit	VERB
cuesj-1446	14	10	efficacy	efficacy	NOUN
cuesj-1446	14	11	in	in	ADP
cuesj-1446	14	12	alleviating	alleviating	NOUN
cuesj-1446	14	13	bph	bph	NOUN
cuesj-1446	14	14	development	development	NOUN
cuesj-1446	14	15	,	,	PUNCT
cuesj-1446	14	16	indicating	indicate	VERB
cuesj-1446	14	17	a	a	DET
cuesj-1446	14	18	possible	possible	ADJ
cuesj-1446	14	19	role	role	NOUN
cuesj-1446	14	20	in	in	ADP
cuesj-1446	14	21	bph	bph	NOUN
cuesj-1446	14	22	therapy	therapy	NOUN
cuesj-1446	14	23	.	.	PUNCT
cuesj-1446	15	1	additional	additional	ADJ
cuesj-1446	15	2	research	research	NOUN
cuesj-1446	15	3	is	be	AUX
cuesj-1446	15	4	necessary	necessary	ADJ
cuesj-1446	15	5	to	to	PART
cuesj-1446	15	6	clarify	clarify	VERB
cuesj-1446	15	7	their	their	PRON
cuesj-1446	15	8	specific	specific	ADJ
cuesj-1446	15	9	processes	process	NOUN
cuesj-1446	15	10	in	in	ADP
cuesj-1446	15	11	bph	bph	NOUN
cuesj-1446	15	12	and	and	CCONJ
cuesj-1446	15	13	clinical	clinical	ADJ
cuesj-1446	15	14	relevance	relevance	NOUN
cuesj-1446	15	15	.	.	PUNCT
cuesj-1446	16	1	keywords	keyword	NOUN
cuesj-1446	16	2	:	:	PUNCT
cuesj-1446	16	3	benign	benign	ADJ
cuesj-1446	16	4	prostatic	prostatic	ADJ
cuesj-1446	16	5	hyperplasia	hyperplasia	NOUN
cuesj-1446	16	6	,	,	PUNCT
cuesj-1446	16	7	testosterone	testosterone	NOUN
cuesj-1446	16	8	,	,	PUNCT
cuesj-1446	16	9	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	16	10	,	,	PUNCT
cuesj-1446	16	11	empagliflozin	empagliflozin	PROPN
cuesj-1446	16	12	,	,	PUNCT
cuesj-1446	16	13	finasteride	finasteride	ADJ
cuesj-1446	16	14	introduction	introduction	NOUN
cuesj-1446	16	15	benign	benign	ADJ
cuesj-1446	16	16	prostatic	prostatic	ADJ
cuesj-1446	16	17	hyperplasia	hyperplasia	NOUN
cuesj-1446	16	18	(	(	PUNCT
cuesj-1446	16	19	bph	bph	NOUN
cuesj-1446	16	20	)	)	PUNCT
cuesj-1446	16	21	denotes	denote	VERB
cuesj-1446	16	22	the	the	DET
cuesj-1446	16	23	nonmalignant	nonmalignant	ADJ
cuesj-1446	16	24	proliferation	proliferation	NOUN
cuesj-1446	16	25	of	of	ADP
cuesj-1446	16	26	prostate	prostate	NOUN
cuesj-1446	16	27	tissue	tissue	NOUN
cuesj-1446	16	28	and	and	CCONJ
cuesj-1446	16	29	is	be	AUX
cuesj-1446	16	30	a	a	DET
cuesj-1446	16	31	prevalent	prevalent	ADJ
cuesj-1446	16	32	etiology	etiology	NOUN
cuesj-1446	16	33	of	of	ADP
cuesj-1446	16	34	symptoms	symptom	NOUN
cuesj-1446	16	35	related	relate	VERB
cuesj-1446	16	36	to	to	ADP
cuesj-1446	16	37	the	the	DET
cuesj-1446	16	38	lower	low	ADJ
cuesj-1446	16	39	urinary	urinary	ADJ
cuesj-1446	16	40	tract	tract	NOUN
cuesj-1446	16	41	in	in	ADP
cuesj-1446	16	42	elderly	elderly	ADJ
cuesj-1446	16	43	male	male	ADJ
cuesj-1446	16	44	individuals	individual	NOUN
cuesj-1446	16	45	.	.	PUNCT
cuesj-1446	17	1	the	the	DET
cuesj-1446	17	2	prevalence	prevalence	NOUN
cuesj-1446	17	3	of	of	ADP
cuesj-1446	17	4	the	the	DET
cuesj-1446	17	5	disease	disease	NOUN
cuesj-1446	17	6	has	have	AUX
cuesj-1446	17	7	been	be	AUX
cuesj-1446	17	8	demonstrated	demonstrate	VERB
cuesj-1446	17	9	to	to	PART
cuesj-1446	17	10	rise	rise	VERB
cuesj-1446	17	11	with	with	ADP
cuesj-1446	17	12	age	age	NOUN
cuesj-1446	17	13	,	,	PUNCT
cuesj-1446	17	14	especially	especially	ADV
cuesj-1446	17	15	in	in	ADP
cuesj-1446	17	16	lowand	lowand	ADJ
cuesj-1446	17	17	middle	middle	ADJ
cuesj-1446	17	18	-	-	PUNCT
cuesj-1446	17	19	income	income	NOUN
cuesj-1446	17	20	countries.[1	countries.[1	NOUN
cuesj-1446	17	21	]	]	PUNCT
cuesj-1446	17	22	the	the	DET
cuesj-1446	17	23	primary	primary	ADJ
cuesj-1446	17	24	pathological	pathological	ADJ
cuesj-1446	17	25	feature	feature	NOUN
cuesj-1446	17	26	of	of	ADP
cuesj-1446	17	27	bph	bph	NOUN
cuesj-1446	17	28	is	be	AUX
cuesj-1446	17	29	the	the	DET
cuesj-1446	17	30	excessive	excessive	ADJ
cuesj-1446	17	31	growth	growth	NOUN
cuesj-1446	17	32	and	and	CCONJ
cuesj-1446	17	33	restructuring	restructuring	NOUN
cuesj-1446	17	34	of	of	ADP
cuesj-1446	17	35	epithelial	epithelial	ADJ
cuesj-1446	17	36	and	and	CCONJ
cuesj-1446	17	37	fibromuscular	fibromuscular	ADJ
cuesj-1446	17	38	structures	structure	NOUN
cuesj-1446	17	39	in	in	ADP
cuesj-1446	17	40	the	the	DET
cuesj-1446	17	41	prostate	prostate	NOUN
cuesj-1446	17	42	’s	’s	PART
cuesj-1446	17	43	transitional	transitional	ADJ
cuesj-1446	17	44	zone	zone	NOUN
cuesj-1446	17	45	surrounding	surround	VERB
cuesj-1446	17	46	the	the	DET
cuesj-1446	17	47	urethra	urethra	NOUN
cuesj-1446	17	48	,	,	PUNCT
cuesj-1446	17	49	leading	lead	VERB
cuesj-1446	17	50	to	to	ADP
cuesj-1446	17	51	prostatic	prostatic	ADJ
cuesj-1446	17	52	enlargement.[2	enlargement.[2	NOUN
cuesj-1446	17	53	]	]	PUNCT
cuesj-1446	17	54	chronic	chronic	ADJ
cuesj-1446	17	55	inflammation	inflammation	NOUN
cuesj-1446	17	56	’s	’s	PART
cuesj-1446	17	57	significant	significant	ADJ
cuesj-1446	17	58	role	role	NOUN
cuesj-1446	17	59	in	in	ADP
cuesj-1446	17	60	the	the	DET
cuesj-1446	17	61	pathophysiology	pathophysiology	NOUN
cuesj-1446	17	62	of	of	ADP
cuesj-1446	17	63	bph	bph	NOUN
cuesj-1446	17	64	is	be	AUX
cuesj-1446	17	65	now	now	ADV
cuesj-1446	17	66	becoming	become	VERB
cuesj-1446	17	67	evident	evident	ADJ
cuesj-1446	17	68	and	and	CCONJ
cuesj-1446	17	69	is	be	AUX
cuesj-1446	17	70	regarded	regard	VERB
cuesj-1446	17	71	as	as	ADP
cuesj-1446	17	72	a	a	DET
cuesj-1446	17	73	crucial	crucial	ADJ
cuesj-1446	17	74	element	element	NOUN
cuesj-1446	17	75	in	in	ADP
cuesj-1446	17	76	the	the	DET
cuesj-1446	17	77	onset	onset	NOUN
cuesj-1446	17	78	and	and	CCONJ
cuesj-1446	17	79	progression	progression	NOUN
cuesj-1446	17	80	of	of	ADP
cuesj-1446	17	81	bph.[3	bph.[3	PROPN
cuesj-1446	17	82	]	]	PUNCT
cuesj-1446	17	83	following	follow	VERB
cuesj-1446	17	84	lifestyle	lifestyle	NOUN
cuesj-1446	17	85	adjustments	adjustment	NOUN
cuesj-1446	17	86	,	,	PUNCT
cuesj-1446	17	87	pharmacotherapy	pharmacotherapy	NOUN
cuesj-1446	17	88	is	be	AUX
cuesj-1446	17	89	typically	typically	ADV
cuesj-1446	17	90	the	the	DET
cuesj-1446	17	91	primary	primary	ADJ
cuesj-1446	17	92	approach	approach	NOUN
cuesj-1446	17	93	for	for	ADP
cuesj-1446	17	94	managing	manage	VERB
cuesj-1446	17	95	symptomatic	symptomatic	ADJ
cuesj-1446	17	96	bph.[4	bph.[4	PROPN
cuesj-1446	17	97	]	]	X
cuesj-1446	17	98	the	the	DET
cuesj-1446	17	99	gold	gold	ADJ
cuesj-1446	17	100	standard	standard	NOUN
cuesj-1446	17	101	for	for	ADP
cuesj-1446	17	102	treatment	treatment	NOUN
cuesj-1446	17	103	consists	consist	VERB
cuesj-1446	17	104	of	of	ADP
cuesj-1446	17	105	two	two	NUM
cuesj-1446	17	106	classes	class	NOUN
cuesj-1446	17	107	of	of	ADP
cuesj-1446	17	108	drugs	drug	NOUN
cuesj-1446	17	109	:	:	PUNCT
cuesj-1446	17	110	alpha	alpha	NOUN
cuesj-1446	17	111	-	-	PUNCT
cuesj-1446	17	112	adrenergic	adrenergic	ADJ
cuesj-1446	17	113	blockers	blocker	NOUN
cuesj-1446	17	114	and	and	CCONJ
cuesj-1446	17	115	5	5	NUM
cuesj-1446	17	116	-	-	PUNCT
cuesj-1446	17	117	alpha	alpha	NOUN
cuesj-1446	17	118	-	-	PUNCT
cuesj-1446	17	119	reductase	reductase	NOUN
cuesj-1446	17	120	inhibitors.[5	inhibitors.[5	X
cuesj-1446	17	121	]	]	PUNCT
cuesj-1446	17	122	as	as	ADP
cuesj-1446	17	123	a	a	DET
cuesj-1446	17	124	result	result	NOUN
cuesj-1446	17	125	,	,	PUNCT
cuesj-1446	17	126	there	there	PRON
cuesj-1446	17	127	is	be	VERB
cuesj-1446	17	128	growing	grow	VERB
cuesj-1446	17	129	interest	interest	NOUN
cuesj-1446	17	130	in	in	ADP
cuesj-1446	17	131	developing	develop	VERB
cuesj-1446	17	132	safer	safe	ADJ
cuesj-1446	17	133	alternatives	alternative	NOUN
cuesj-1446	17	134	to	to	ADP
cuesj-1446	17	135	the	the	DET
cuesj-1446	17	136	current	current	ADJ
cuesj-1446	17	137	bph	bph	NOUN
cuesj-1446	17	138	medications.[5,6	medications.[5,6	NOUN
cuesj-1446	17	139	]	]	X
cuesj-1446	17	140	sodium	sodium	NOUN
cuesj-1446	17	141	-	-	PUNCT
cuesj-1446	17	142	glucose	glucose	NOUN
cuesj-1446	17	143	cotransporter-2	cotransporter-2	NUM
cuesj-1446	17	144	(	(	PUNCT
cuesj-1446	17	145	sglt2	sglt2	NOUN
cuesj-1446	17	146	)	)	PUNCT
cuesj-1446	17	147	inhibitors	inhibitor	NOUN
cuesj-1446	17	148	have	have	AUX
cuesj-1446	17	149	been	be	AUX
cuesj-1446	17	150	authorized	authorize	VERB
cuesj-1446	17	151	for	for	ADP
cuesj-1446	17	152	the	the	DET
cuesj-1446	17	153	management	management	NOUN
cuesj-1446	17	154	of	of	ADP
cuesj-1446	17	155	type	type	NOUN
cuesj-1446	17	156	2	2	NUM
cuesj-1446	17	157	diabetes	diabete	NOUN
cuesj-1446	17	158	mellitus.[7	mellitus.[7	ADP
cuesj-1446	17	159	]	]	X
cuesj-1446	17	160	these	these	DET
cuesj-1446	17	161	drugs	drug	NOUN
cuesj-1446	17	162	lower	low	ADJ
cuesj-1446	17	163	blood	blood	NOUN
cuesj-1446	17	164	sugar	sugar	NOUN
cuesj-1446	17	165	levels	level	NOUN
cuesj-1446	17	166	by	by	ADP
cuesj-1446	17	167	blocking	block	VERB
cuesj-1446	17	168	the	the	DET
cuesj-1446	17	169	action	action	NOUN
cuesj-1446	17	170	of	of	ADP
cuesj-1446	17	171	the	the	DET
cuesj-1446	17	172	kidneys	kidney	NOUN
cuesj-1446	17	173	’	'	PUNCT
cuesj-1446	17	174	tubules.[8	tubules.[8	NOUN
cuesj-1446	17	175	]	]	PUNCT
cuesj-1446	17	176	in	in	ADP
cuesj-1446	17	177	addition	addition	NOUN
cuesj-1446	17	178	to	to	ADP
cuesj-1446	17	179	their	their	PRON
cuesj-1446	17	180	main	main	ADJ
cuesj-1446	17	181	effects	effect	NOUN
cuesj-1446	17	182	,	,	PUNCT
cuesj-1446	17	183	they	they	PRON
cuesj-1446	17	184	exhibited	exhibit	VERB
cuesj-1446	17	185	significant	significant	ADJ
cuesj-1446	17	186	anti	anti	ADJ
cuesj-1446	17	187	-	-	ADJ
cuesj-1446	17	188	inflammatory	inflammatory	ADJ
cuesj-1446	17	189	effects	effect	NOUN
cuesj-1446	17	190	proved	prove	VERB
cuesj-1446	17	191	by	by	ADP
cuesj-1446	17	192	the	the	DET
cuesj-1446	17	193	reduction	reduction	NOUN
cuesj-1446	17	194	in	in	ADP
cuesj-1446	17	195	cardiovascular	cardiovascular	ADJ
cuesj-1446	17	196	complications,[9	complications,[9	NOUN
cuesj-1446	17	197	]	]	PUNCT
cuesj-1446	17	198	heart	heart	NOUN
cuesj-1446	17	199	failure	failure	NOUN
cuesj-1446	17	200	with	with	ADP
cuesj-1446	17	201	low	low	ADJ
cuesj-1446	17	202	ejection	ejection	NOUN
cuesj-1446	17	203	fraction,[10	fraction,[10	NUM
cuesj-1446	17	204	]	]	X
cuesj-1446	17	205	non	non	ADJ
cuesj-1446	17	206	-	-	ADJ
cuesj-1446	17	207	alcoholic	alcoholic	ADJ
cuesj-1446	17	208	hepatic	hepatic	NOUN
cuesj-1446	17	209	steatosis,[11	steatosis,[11	PROPN
cuesj-1446	17	210	]	]	PUNCT
cuesj-1446	17	211	and	and	CCONJ
cuesj-1446	17	212	persistent	persistent	ADJ
cuesj-1446	17	213	kidney	kidney	NOUN
cuesj-1446	17	214	problems.[12	problems.[12	NOUN
cuesj-1446	17	215	]	]	PUNCT
cuesj-1446	17	216	furthermore	furthermore	ADV
cuesj-1446	17	217	,	,	PUNCT
cuesj-1446	17	218	these	these	DET
cuesj-1446	17	219	drugs	drug	NOUN
cuesj-1446	17	220	demonstrated	demonstrate	VERB
cuesj-1446	17	221	advantageous	advantageous	ADJ
cuesj-1446	17	222	anti	anti	ADJ
cuesj-1446	17	223	-	-	ADJ
cuesj-1446	17	224	proliferative	proliferative	ADJ
cuesj-1446	17	225	properties	property	NOUN
cuesj-1446	17	226	implicated	implicate	VERB
cuesj-1446	17	227	in	in	ADP
cuesj-1446	17	228	reducing	reduce	VERB
cuesj-1446	17	229	the	the	DET
cuesj-1446	17	230	risk	risk	NOUN
cuesj-1446	17	231	of	of	ADP
cuesj-1446	17	232	cancers.[13	cancers.[13	PROPN
cuesj-1446	17	233	]	]	PUNCT
cuesj-1446	17	234	studies	study	NOUN
cuesj-1446	17	235	highlighted	highlight	VERB
cuesj-1446	17	236	an	an	DET
cuesj-1446	17	237	association	association	NOUN
cuesj-1446	17	238	between	between	ADP
cuesj-1446	17	239	molecular	molecular	ADJ
cuesj-1446	17	240	components	component	NOUN
cuesj-1446	17	241	of	of	ADP
cuesj-1446	17	242	diabetes	diabetes	NOUN
cuesj-1446	17	243	and	and	CCONJ
cuesj-1446	17	244	bph,[14	bph,[14	PROPN
cuesj-1446	17	245	]	]	PUNCT
cuesj-1446	17	246	which	which	DET
cuesj-1446	17	247	corresponding	correspond	VERB
cuesj-1446	17	248	author	author	NOUN
cuesj-1446	17	249	:	:	PUNCT
cuesj-1446	17	250	balen	balen	PROPN
cuesj-1446	17	251	m.	m.	PROPN
cuesj-1446	17	252	khudhur	khudhur	PROPN
cuesj-1446	17	253	,	,	PUNCT
cuesj-1446	17	254	department	department	PROPN
cuesj-1446	17	255	of	of	ADP
cuesj-1446	17	256	pharmacology	pharmacology	NOUN
cuesj-1446	17	257	,	,	PUNCT
cuesj-1446	17	258	medical	medical	ADJ
cuesj-1446	17	259	physics	physics	NOUN
cuesj-1446	17	260	and	and	CCONJ
cuesj-1446	17	261	biochemistry	biochemistry	NOUN
cuesj-1446	17	262	,	,	PUNCT
cuesj-1446	17	263	college	college	NOUN
cuesj-1446	17	264	of	of	ADP
cuesj-1446	17	265	medicine	medicine	NOUN
cuesj-1446	17	266	,	,	PUNCT
cuesj-1446	17	267	hawler	hawler	PROPN
cuesj-1446	17	268	medical	medical	PROPN
cuesj-1446	17	269	university	university	PROPN
cuesj-1446	17	270	,	,	PUNCT
cuesj-1446	17	271	erbil	erbil	PROPN
cuesj-1446	17	272	,	,	PUNCT
cuesj-1446	17	273	iraq	iraq	PROPN
cuesj-1446	17	274	.	.	PUNCT
cuesj-1446	18	1	e	e	X
cuesj-1446	18	2	-	-	NOUN
cuesj-1446	18	3	mail	mail	NOUN
cuesj-1446	18	4	:	:	PUNCT
cuesj-1446	18	5	balen.khudhur@med.hmu.edu.krd	balen.khudhur@med.hmu.edu.krd	NOUN
cuesj-1446	18	6	received	receive	VERB
cuesj-1446	18	7	:	:	PUNCT
cuesj-1446	18	8	april	april	PROPN
cuesj-1446	18	9	04	04	NUM
cuesj-1446	18	10	,	,	PUNCT
cuesj-1446	18	11	2025	2025	NUM
cuesj-1446	18	12	accepted	accept	VERB
cuesj-1446	18	13	:	:	PUNCT
cuesj-1446	18	14	may	may	AUX
cuesj-1446	18	15	15	15	NUM
cuesj-1446	18	16	,	,	PUNCT
cuesj-1446	18	17	2025	2025	NUM
cuesj-1446	18	18	published	publish	VERB
cuesj-1446	18	19	:	:	PUNCT
cuesj-1446	18	20	july	july	PROPN
cuesj-1446	18	21	1	1	NUM
cuesj-1446	18	22	,	,	PUNCT
cuesj-1446	18	23	2025	2025	NUM
cuesj-1446	18	24	doi	doi	NOUN
cuesj-1446	18	25	:	:	PUNCT
cuesj-1446	18	26	10.24086	10.24086	NUM
cuesj-1446	18	27	/	/	SYM
cuesj-1446	18	28	cuesj.v9n2y2025.pp1	cuesj.v9n2y2025.pp1	PRON
cuesj-1446	18	29	-	-	SYM
cuesj-1446	18	30	6	6	NUM
cuesj-1446	18	31	copyright	copyright	NOUN
cuesj-1446	18	32	©	©	PROPN
cuesj-1446	18	33	2025	2025	NUM
cuesj-1446	18	34	balen	balen	PROPN
cuesj-1446	18	35	m.	m.	NOUN
cuesj-1446	18	36	khudhur	khudhur	PROPN
cuesj-1446	18	37	,	,	PUNCT
cuesj-1446	18	38	nidhal	nidhal	PROPN
cuesj-1446	18	39	a.m.	a.m.	PROPN
cuesj-1446	18	40	ali	ali	PROPN
cuesj-1446	18	41	.	.	PUNCT
cuesj-1446	19	1	this	this	PRON
cuesj-1446	19	2	is	be	AUX
cuesj-1446	19	3	an	an	DET
cuesj-1446	19	4	open	open	ADJ
cuesj-1446	19	5	-	-	PUNCT
cuesj-1446	19	6	access	access	NOUN
cuesj-1446	19	7	article	article	NOUN
cuesj-1446	19	8	distributed	distribute	VERB
cuesj-1446	19	9	under	under	ADP
cuesj-1446	19	10	the	the	DET
cuesj-1446	19	11	creative	creative	ADJ
cuesj-1446	19	12	commons	common	NOUN
cuesj-1446	19	13	attribution	attribution	NOUN
cuesj-1446	19	14	license	license	NOUN
cuesj-1446	19	15	.	.	PUNCT
cuesj-1446	20	1	cihan	cihan	VERB
cuesj-1446	20	2	university	university	NOUN
cuesj-1446	20	3	-	-	PUNCT
cuesj-1446	20	4	erbil	erbil	PROPN
cuesj-1446	20	5	scientific	scientific	ADJ
cuesj-1446	20	6	journal	journal	NOUN
cuesj-1446	20	7	(	(	PUNCT
cuesj-1446	20	8	cuesj	cuesj	PROPN
cuesj-1446	20	9	)	)	PUNCT
cuesj-1446	20	10	khudhur	khudhur	PROPN
cuesj-1446	20	11	and	and	CCONJ
cuesj-1446	20	12	ali	ali	PROPN
cuesj-1446	20	13	:	:	PUNCT
cuesj-1446	20	14	impact	impact	NOUN
cuesj-1446	20	15	of	of	ADP
cuesj-1446	20	16	sglt2	sglt2	ADJ
cuesj-1446	20	17	inhibitors	inhibitor	NOUN
cuesj-1446	20	18	on	on	ADP
cuesj-1446	20	19	induced	induced	ADJ
cuesj-1446	20	20	benign	benign	ADJ
cuesj-1446	20	21	prostatic	prostatic	ADJ
cuesj-1446	20	22	hyperplasia	hyperplasia	NOUN
cuesj-1446	20	23	in	in	ADP
cuesj-1446	20	24	rats	rat	NOUN
cuesj-1446	20	25	2	2	NUM
cuesj-1446	20	26	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1446	20	27	cuesj	cuesj	NOUN
cuesj-1446	20	28	2025	2025	NUM
cuesj-1446	20	29	,	,	PUNCT
cuesj-1446	20	30	9	9	NUM
cuesj-1446	20	31	(	(	PUNCT
cuesj-1446	20	32	2	2	NUM
cuesj-1446	20	33	):	):	PUNCT
cuesj-1446	20	34	1	1	NUM
cuesj-1446	20	35	-	-	SYM
cuesj-1446	20	36	6	6	NUM
cuesj-1446	20	37	encouraged	encourage	VERB
cuesj-1446	20	38	investigating	investigate	VERB
cuesj-1446	20	39	the	the	DET
cuesj-1446	20	40	impact	impact	NOUN
cuesj-1446	20	41	of	of	ADP
cuesj-1446	20	42	sglt2	sglt2	ADJ
cuesj-1446	20	43	inhibitors	inhibitor	NOUN
cuesj-1446	20	44	in	in	ADP
cuesj-1446	20	45	the	the	DET
cuesj-1446	20	46	management	management	NOUN
cuesj-1446	20	47	of	of	ADP
cuesj-1446	20	48	bph	bph	NOUN
cuesj-1446	20	49	.	.	PUNCT
cuesj-1446	21	1	accordingly	accordingly	ADV
cuesj-1446	21	2	,	,	PUNCT
cuesj-1446	21	3	this	this	DET
cuesj-1446	21	4	study	study	NOUN
cuesj-1446	21	5	was	be	AUX
cuesj-1446	21	6	designed	design	VERB
cuesj-1446	21	7	to	to	PART
cuesj-1446	21	8	investigate	investigate	VERB
cuesj-1446	21	9	the	the	DET
cuesj-1446	21	10	potential	potential	ADJ
cuesj-1446	21	11	effects	effect	NOUN
cuesj-1446	21	12	of	of	ADP
cuesj-1446	21	13	sglt2	sglt2	ADJ
cuesj-1446	21	14	inhibitors	inhibitor	NOUN
cuesj-1446	21	15	on	on	ADP
cuesj-1446	21	16	the	the	DET
cuesj-1446	21	17	progression	progression	NOUN
cuesj-1446	21	18	of	of	ADP
cuesj-1446	21	19	bph	bph	NOUN
cuesj-1446	21	20	in	in	ADP
cuesj-1446	21	21	rats	rat	NOUN
cuesj-1446	21	22	.	.	PUNCT
cuesj-1446	22	1	materials	material	NOUN
cuesj-1446	22	2	and	and	CCONJ
cuesj-1446	22	3	methods	method	NOUN
cuesj-1446	22	4	a	a	DET
cuesj-1446	22	5	total	total	NOUN
cuesj-1446	22	6	of	of	ADP
cuesj-1446	22	7	30	30	NUM
cuesj-1446	22	8	adult	adult	NOUN
cuesj-1446	22	9	male	male	NOUN
cuesj-1446	22	10	albino	albino	NOUN
cuesj-1446	22	11	rats	rat	NOUN
cuesj-1446	22	12	aged	aged	ADJ
cuesj-1446	22	13	9–12	9–12	NOUN
cuesj-1446	22	14	weeks	week	NOUN
cuesj-1446	22	15	were	be	AUX
cuesj-1446	22	16	used	use	VERB
cuesj-1446	22	17	in	in	ADP
cuesj-1446	22	18	this	this	DET
cuesj-1446	22	19	study	study	NOUN
cuesj-1446	22	20	.	.	PUNCT
cuesj-1446	23	1	the	the	DET
cuesj-1446	23	2	rats	rat	NOUN
cuesj-1446	23	3	were	be	AUX
cuesj-1446	23	4	maintained	maintain	VERB
cuesj-1446	23	5	under	under	ADP
cuesj-1446	23	6	hygienic	hygienic	ADJ
cuesj-1446	23	7	conditions	condition	NOUN
cuesj-1446	23	8	in	in	ADP
cuesj-1446	23	9	the	the	DET
cuesj-1446	23	10	animal	animal	NOUN
cuesj-1446	23	11	house	house	NOUN
cuesj-1446	23	12	of	of	ADP
cuesj-1446	23	13	(	(	PUNCT
cuesj-1446	23	14	the	the	DET
cuesj-1446	23	15	animal	animal	NOUN
cuesj-1446	23	16	house	house	NOUN
cuesj-1446	23	17	of	of	ADP
cuesj-1446	23	18	hawler	hawler	PROPN
cuesj-1446	23	19	medical	medical	PROPN
cuesj-1446	23	20	university	university	PROPN
cuesj-1446	23	21	,	,	PUNCT
cuesj-1446	23	22	college	college	NOUN
cuesj-1446	23	23	of	of	ADP
cuesj-1446	23	24	pharmacy	pharmacy	NOUN
cuesj-1446	23	25	)	)	PUNCT
cuesj-1446	23	26	.	.	PUNCT
cuesj-1446	24	1	the	the	DET
cuesj-1446	24	2	rats	rat	NOUN
cuesj-1446	24	3	were	be	AUX
cuesj-1446	24	4	provided	provide	VERB
cuesj-1446	24	5	with	with	ADP
cuesj-1446	24	6	food	food	NOUN
cuesj-1446	24	7	and	and	CCONJ
cuesj-1446	24	8	water	water	NOUN
cuesj-1446	24	9	freely	freely	ADV
cuesj-1446	24	10	.	.	PUNCT
cuesj-1446	25	1	after	after	ADP
cuesj-1446	25	2	an	an	DET
cuesj-1446	25	3	acclimatization	acclimatization	NOUN
cuesj-1446	25	4	period	period	NOUN
cuesj-1446	25	5	of	of	ADP
cuesj-1446	25	6	2	2	NUM
cuesj-1446	25	7	weeks	week	NOUN
cuesj-1446	25	8	,	,	PUNCT
cuesj-1446	25	9	the	the	DET
cuesj-1446	25	10	rats	rat	NOUN
cuesj-1446	25	11	were	be	AUX
cuesj-1446	25	12	randomly	randomly	ADV
cuesj-1446	25	13	allocated	allocate	VERB
cuesj-1446	25	14	into	into	ADP
cuesj-1446	25	15	five	five	NUM
cuesj-1446	25	16	equal	equal	ADJ
cuesj-1446	25	17	groups	group	NOUN
cuesj-1446	25	18	(	(	PUNCT
cuesj-1446	25	19	six	six	NUM
cuesj-1446	25	20	rats	rat	NOUN
cuesj-1446	25	21	in	in	ADP
cuesj-1446	25	22	each	each	DET
cuesj-1446	25	23	group	group	NOUN
cuesj-1446	25	24	)	)	PUNCT
cuesj-1446	25	25	as	as	SCONJ
cuesj-1446	25	26	follows	follow	VERB
cuesj-1446	25	27	:	:	PUNCT
cuesj-1446	25	28	•	•	NUM
cuesj-1446	25	29	group	group	NOUN
cuesj-1446	25	30	cn	cn	NOUN
cuesj-1446	25	31	:	:	PUNCT
cuesj-1446	25	32	control	control	VERB
cuesj-1446	25	33	negative	negative	ADJ
cuesj-1446	25	34	group	group	NOUN
cuesj-1446	25	35	was	be	AUX
cuesj-1446	25	36	given	give	VERB
cuesj-1446	25	37	a	a	DET
cuesj-1446	25	38	placebo	placebo	NOUN
cuesj-1446	25	39	.	.	PUNCT
cuesj-1446	26	1	•	•	NUM
cuesj-1446	26	2	group	group	PROPN
cuesj-1446	26	3	t	t	PROPN
cuesj-1446	26	4	-	-	PUNCT
cuesj-1446	26	5	cp	cp	PROPN
cuesj-1446	26	6	:	:	PUNCT
cuesj-1446	26	7	bph	bph	NOUN
cuesj-1446	26	8	-	-	PUNCT
cuesj-1446	26	9	induced	induce	VERB
cuesj-1446	26	10	control	control	NOUN
cuesj-1446	26	11	positive	positive	ADJ
cuesj-1446	26	12	group	group	NOUN
cuesj-1446	26	13	testosterone	testosterone	NOUN
cuesj-1446	26	14	(	(	PUNCT
cuesj-1446	26	15	3	3	NUM
cuesj-1446	26	16	mg	mg	PROPN
cuesj-1446	26	17	/	/	SYM
cuesj-1446	26	18	kg	kg	NOUN
cuesj-1446	26	19	)	)	PUNCT
cuesj-1446	26	20	•	•	NUM
cuesj-1446	26	21	group	group	NOUN
cuesj-1446	26	22	t	t	PROPN
cuesj-1446	26	23	-	-	PUNCT
cuesj-1446	26	24	ertu	ertu	NOUN
cuesj-1446	26	25	:	:	PUNCT
cuesj-1446	26	26	bph	bph	NOUN
cuesj-1446	26	27	-	-	PUNCT
cuesj-1446	26	28	induced	induce	VERB
cuesj-1446	26	29	group	group	NOUN
cuesj-1446	26	30	,	,	PUNCT
cuesj-1446	26	31	administered	administer	VERB
cuesj-1446	26	32	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	26	33	(	(	PUNCT
cuesj-1446	26	34	10	10	NUM
cuesj-1446	26	35	mg	mg	NUM
cuesj-1446	26	36	/	/	SYM
cuesj-1446	26	37	kg	kg	NOUN
cuesj-1446	26	38	)	)	PUNCT
cuesj-1446	26	39	•	•	NUM
cuesj-1446	26	40	group	group	NOUN
cuesj-1446	26	41	t	t	PROPN
cuesj-1446	26	42	-	-	PUNCT
cuesj-1446	26	43	empa	empa	NOUN
cuesj-1446	26	44	:	:	PUNCT
cuesj-1446	26	45	bph	bph	NOUN
cuesj-1446	26	46	-	-	PUNCT
cuesj-1446	26	47	induced	induce	VERB
cuesj-1446	26	48	group	group	NOUN
cuesj-1446	26	49	,	,	PUNCT
cuesj-1446	26	50	administered	administer	VERB
cuesj-1446	26	51	empagliflozin	empagliflozin	PROPN
cuesj-1446	26	52	(	(	PUNCT
cuesj-1446	26	53	10	10	NUM
cuesj-1446	26	54	mg	mg	NUM
cuesj-1446	26	55	/	/	SYM
cuesj-1446	26	56	kg	kg	NOUN
cuesj-1446	26	57	)	)	PUNCT
cuesj-1446	26	58	•	•	NUM
cuesj-1446	26	59	group	group	NOUN
cuesj-1446	26	60	t	t	PROPN
cuesj-1446	26	61	-	-	PUNCT
cuesj-1446	26	62	fin	fin	NOUN
cuesj-1446	26	63	:	:	PUNCT
cuesj-1446	26	64	bph	bph	NOUN
cuesj-1446	26	65	-	-	PUNCT
cuesj-1446	26	66	induced	induce	VERB
cuesj-1446	26	67	group	group	NOUN
cuesj-1446	26	68	,	,	PUNCT
cuesj-1446	26	69	administered	administer	VERB
cuesj-1446	26	70	finasteride	finasteride	ADV
cuesj-1446	26	71	(	(	PUNCT
cuesj-1446	26	72	0.44	0.44	NUM
cuesj-1446	26	73	mg	mg	PROPN
cuesj-1446	26	74	/	/	SYM
cuesj-1446	26	75	kg	kg	PROPN
cuesj-1446	26	76	)	)	PUNCT
cuesj-1446	26	77	.	.	PUNCT
cuesj-1446	27	1	bph	bph	NOUN
cuesj-1446	27	2	was	be	AUX
cuesj-1446	27	3	induced	induce	VERB
cuesj-1446	27	4	by	by	ADP
cuesj-1446	27	5	subcutaneous	subcutaneous	ADJ
cuesj-1446	27	6	(	(	PUNCT
cuesj-1446	27	7	sc	sc	PROPN
cuesj-1446	27	8	)	)	PUNCT
cuesj-1446	27	9	administration	administration	NOUN
cuesj-1446	27	10	of	of	ADP
cuesj-1446	27	11	testosterone	testosterone	NOUN
cuesj-1446	27	12	enanthate	enanthate	NOUN
cuesj-1446	27	13	(	(	PUNCT
cuesj-1446	27	14	panpharma	panpharma	PROPN
cuesj-1446	27	15	,	,	PUNCT
cuesj-1446	27	16	germany	germany	PROPN
cuesj-1446	27	17	®	®	PROPN
cuesj-1446	27	18	)	)	PUNCT
cuesj-1446	27	19	at	at	ADP
cuesj-1446	27	20	a	a	DET
cuesj-1446	27	21	dose	dose	NOUN
cuesj-1446	27	22	rate	rate	NOUN
cuesj-1446	27	23	of	of	ADP
cuesj-1446	27	24	3	3	NUM
cuesj-1446	27	25	mg	mg	PROPN
cuesj-1446	27	26	/	/	SYM
cuesj-1446	27	27	kg	kg	PROPN
cuesj-1446	27	28	for	for	ADP
cuesj-1446	27	29	28	28	NUM
cuesj-1446	27	30	days	day	NOUN
cuesj-1446	27	31	,	,	PUNCT
cuesj-1446	27	32	according	accord	VERB
cuesj-1446	27	33	to	to	ADP
cuesj-1446	27	34	el	el	PROPN
cuesj-1446	27	35	-	-	PUNCT
cuesj-1446	27	36	shafei	shafei	PROPN
cuesj-1446	27	37	et	et	PROPN
cuesj-1446	27	38	al.[15	al.[15	PROPN
cuesj-1446	27	39	]	]	PUNCT
cuesj-1446	27	40	the	the	DET
cuesj-1446	27	41	drugs	drug	NOUN
cuesj-1446	27	42	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	27	43	,	,	PUNCT
cuesj-1446	27	44	empagliflozin	empagliflozin	PROPN
cuesj-1446	27	45	(	(	PUNCT
cuesj-1446	27	46	sami	sami	PROPN
cuesj-1446	27	47	pharmaceuticals	pharmaceuticals	PROPN
cuesj-1446	27	48	,	,	PUNCT
cuesj-1446	27	49	pakistan	pakistan	PROPN
cuesj-1446	27	50	®	®	PROPN
cuesj-1446	27	51	)	)	PUNCT
cuesj-1446	27	52	and	and	CCONJ
cuesj-1446	27	53	finasteride	finasteride	ADJ
cuesj-1446	27	54	(	(	PUNCT
cuesj-1446	27	55	accord	accord	NOUN
cuesj-1446	27	56	healthcare	healthcare	PROPN
cuesj-1446	27	57	,	,	PUNCT
cuesj-1446	27	58	uk	uk	PROPN
cuesj-1446	27	59	®	®	NOUN
cuesj-1446	27	60	)	)	PUNCT
cuesj-1446	27	61	were	be	AUX
cuesj-1446	27	62	given	give	VERB
cuesj-1446	27	63	daily	daily	ADV
cuesj-1446	27	64	at	at	ADP
cuesj-1446	27	65	a	a	DET
cuesj-1446	27	66	dose	dose	NOUN
cuesj-1446	27	67	rate	rate	NOUN
cuesj-1446	27	68	of	of	ADP
cuesj-1446	27	69	10	10	NUM
cuesj-1446	27	70	mg	mg	NUM
cuesj-1446	27	71	/	/	SYM
cuesj-1446	27	72	kg	kg	NOUN
cuesj-1446	27	73	for	for	ADP
cuesj-1446	27	74	both	both	DET
cuesj-1446	27	75	ertugliflozin[16	ertugliflozin[16	NOUN
cuesj-1446	27	76	]	]	PUNCT
cuesj-1446	27	77	and	and	CCONJ
cuesj-1446	27	78	empagliflozin	empagliflozin	PROPN
cuesj-1446	27	79	according	accord	VERB
cuesj-1446	27	80	to	to	ADP
cuesj-1446	27	81	malínská	malínská	PROPN
cuesj-1446	27	82	et	et	PROPN
cuesj-1446	27	83	al	al	PROPN
cuesj-1446	27	84	.	.	PROPN
cuesj-1446	27	85	,[17	,[17	PROPN
cuesj-1446	27	86	]	]	PUNCT
cuesj-1446	27	87	whereas	whereas	SCONJ
cuesj-1446	27	88	finasteride	finasteride	ADJ
cuesj-1446	27	89	was	be	AUX
cuesj-1446	27	90	given	give	VERB
cuesj-1446	27	91	at	at	ADP
cuesj-1446	27	92	0.44	0.44	NUM
cuesj-1446	27	93	mg	mg	PROPN
cuesj-1446	27	94	/	/	SYM
cuesj-1446	27	95	kg	kg	NOUN
cuesj-1446	27	96	according	accord	VERB
cuesj-1446	27	97	to	to	ADP
cuesj-1446	27	98	jawad	jawad	PROPN
cuesj-1446	27	99	and	and	CCONJ
cuesj-1446	27	100	jasim.[18	jasim.[18	PROPN
cuesj-1446	27	101	]	]	PUNCT
cuesj-1446	27	102	testosterone	testosterone	NOUN
cuesj-1446	27	103	enanthate	enanthate	NOUN
cuesj-1446	27	104	ampoule	ampoule	NOUN
cuesj-1446	27	105	was	be	AUX
cuesj-1446	27	106	diluted	dilute	VERB
cuesj-1446	27	107	in	in	ADP
cuesj-1446	27	108	olive	olive	ADJ
cuesj-1446	27	109	oil	oil	NOUN
cuesj-1446	27	110	,	,	PUNCT
cuesj-1446	27	111	whereas	whereas	SCONJ
cuesj-1446	27	112	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	27	113	,	,	PUNCT
cuesj-1446	27	114	empagliflozin	empagliflozin	PROPN
cuesj-1446	27	115	,	,	PUNCT
cuesj-1446	27	116	and	and	CCONJ
cuesj-1446	27	117	finasteride	finasteride	ADJ
cuesj-1446	27	118	were	be	AUX
cuesj-1446	27	119	dissolved	dissolve	VERB
cuesj-1446	27	120	in	in	ADP
cuesj-1446	27	121	distilled	distil	VERB
cuesj-1446	27	122	water	water	NOUN
cuesj-1446	27	123	and	and	CCONJ
cuesj-1446	27	124	given	give	VERB
cuesj-1446	27	125	daily	daily	ADV
cuesj-1446	27	126	by	by	ADP
cuesj-1446	27	127	oral	oral	ADJ
cuesj-1446	27	128	gavage	gavage	NOUN
cuesj-1446	27	129	to	to	ADP
cuesj-1446	27	130	their	their	PRON
cuesj-1446	27	131	allocated	allocate	VERB
cuesj-1446	27	132	experimental	experimental	ADJ
cuesj-1446	27	133	groups	group	NOUN
cuesj-1446	27	134	for	for	ADP
cuesj-1446	27	135	8	8	NUM
cuesj-1446	27	136	weeks	week	NOUN
cuesj-1446	27	137	after	after	ADP
cuesj-1446	27	138	28	28	NUM
cuesj-1446	27	139	days	day	NOUN
cuesj-1446	27	140	of	of	ADP
cuesj-1446	27	141	inducing	induce	VERB
cuesj-1446	27	142	bph	bph	NOUN
cuesj-1446	27	143	.	.	PUNCT
cuesj-1446	28	1	the	the	DET
cuesj-1446	28	2	bph	bph	NOUN
cuesj-1446	28	3	-	-	PUNCT
cuesj-1446	28	4	inducing	induce	VERB
cuesj-1446	28	5	agent	agent	NOUN
cuesj-1446	28	6	,	,	PUNCT
cuesj-1446	28	7	testosterone	testosterone	NOUN
cuesj-1446	28	8	enanthate	enanthate	NOUN
cuesj-1446	28	9	,	,	PUNCT
cuesj-1446	28	10	was	be	AUX
cuesj-1446	28	11	given	give	VERB
cuesj-1446	28	12	daily	daily	ADV
cuesj-1446	28	13	to	to	ADP
cuesj-1446	28	14	the	the	DET
cuesj-1446	28	15	positive	positive	ADJ
cuesj-1446	28	16	control	control	NOUN
cuesj-1446	28	17	group	group	NOUN
cuesj-1446	28	18	as	as	ADV
cuesj-1446	28	19	well	well	ADV
cuesj-1446	28	20	as	as	ADP
cuesj-1446	28	21	to	to	ADP
cuesj-1446	28	22	the	the	DET
cuesj-1446	28	23	treatment	treatment	NOUN
cuesj-1446	28	24	groups	group	NOUN
cuesj-1446	28	25	for	for	ADP
cuesj-1446	28	26	the	the	DET
cuesj-1446	28	27	whole	whole	ADJ
cuesj-1446	28	28	period	period	NOUN
cuesj-1446	28	29	of	of	ADP
cuesj-1446	28	30	the	the	DET
cuesj-1446	28	31	experimental	experimental	ADJ
cuesj-1446	28	32	protocol	protocol	NOUN
cuesj-1446	28	33	.	.	PUNCT
cuesj-1446	29	1	the	the	DET
cuesj-1446	29	2	cn	cn	PROPN
cuesj-1446	29	3	group	group	NOUN
cuesj-1446	29	4	was	be	AUX
cuesj-1446	29	5	given	give	VERB
cuesj-1446	29	6	an	an	DET
cuesj-1446	29	7	sc	sc	NOUN
cuesj-1446	29	8	injection	injection	NOUN
cuesj-1446	29	9	of	of	ADP
cuesj-1446	29	10	olive	olive	ADJ
cuesj-1446	29	11	oil	oil	NOUN
cuesj-1446	29	12	and	and	CCONJ
cuesj-1446	29	13	distilled	distil	VERB
cuesj-1446	29	14	water	water	NOUN
cuesj-1446	29	15	orally	orally	ADV
cuesj-1446	29	16	as	as	ADP
cuesj-1446	29	17	a	a	DET
cuesj-1446	29	18	placebo	placebo	NOUN
cuesj-1446	29	19	.	.	PUNCT
cuesj-1446	30	1	the	the	DET
cuesj-1446	30	2	body	body	NOUN
cuesj-1446	30	3	weight	weight	NOUN
cuesj-1446	30	4	of	of	ADP
cuesj-1446	30	5	each	each	DET
cuesj-1446	30	6	rat	rat	NOUN
cuesj-1446	30	7	in	in	ADP
cuesj-1446	30	8	different	different	ADJ
cuesj-1446	30	9	groups	group	NOUN
cuesj-1446	30	10	was	be	AUX
cuesj-1446	30	11	recorded	record	VERB
cuesj-1446	30	12	weekly	weekly	ADV
cuesj-1446	30	13	,	,	PUNCT
cuesj-1446	30	14	commencing	commence	VERB
cuesj-1446	30	15	the	the	DET
cuesj-1446	30	16	experimental	experimental	ADJ
cuesj-1446	30	17	study	study	NOUN
cuesj-1446	30	18	.	.	PUNCT
cuesj-1446	31	1	after	after	ADP
cuesj-1446	31	2	8	8	NUM
cuesj-1446	31	3	weeks	week	NOUN
cuesj-1446	31	4	of	of	ADP
cuesj-1446	31	5	the	the	DET
cuesj-1446	31	6	application	application	NOUN
cuesj-1446	31	7	of	of	ADP
cuesj-1446	31	8	the	the	DET
cuesj-1446	31	9	treatment	treatment	NOUN
cuesj-1446	31	10	protocol	protocol	NOUN
cuesj-1446	31	11	,	,	PUNCT
cuesj-1446	31	12	the	the	DET
cuesj-1446	31	13	rats	rat	NOUN
cuesj-1446	31	14	were	be	AUX
cuesj-1446	31	15	euthanized	euthanize	VERB
cuesj-1446	31	16	by	by	ADP
cuesj-1446	31	17	intraperitoneal	intraperitoneal	ADJ
cuesj-1446	31	18	administration	administration	NOUN
cuesj-1446	31	19	of	of	ADP
cuesj-1446	31	20	ketamine	ketamine	PROPN
cuesj-1446	31	21	(	(	PUNCT
cuesj-1446	31	22	90	90	NUM
cuesj-1446	31	23	mg	mg	NUM
cuesj-1446	31	24	/	/	SYM
cuesj-1446	31	25	kg	kg	NOUN
cuesj-1446	31	26	)	)	PUNCT
cuesj-1446	31	27	and	and	CCONJ
cuesj-1446	31	28	xylazine	xylazine	NOUN
cuesj-1446	31	29	(	(	PUNCT
cuesj-1446	31	30	40	40	NUM
cuesj-1446	31	31	mg	mg	PROPN
cuesj-1446	31	32	/	/	SYM
cuesj-1446	31	33	kg	kg	PROPN
cuesj-1446	31	34	)	)	PUNCT
cuesj-1446	31	35	according	accord	VERB
cuesj-1446	31	36	to	to	ADP
cuesj-1446	31	37	abdulla	abdulla	PROPN
cuesj-1446	31	38	and	and	CCONJ
cuesj-1446	31	39	al	al	PROPN
cuesj-1446	31	40	-	-	PUNCT
cuesj-1446	31	41	okaily,[19	okaily,[19	PROPN
cuesj-1446	31	42	]	]	PUNCT
cuesj-1446	31	43	blood	blood	NOUN
cuesj-1446	31	44	samples	sample	NOUN
cuesj-1446	31	45	were	be	AUX
cuesj-1446	31	46	withdrawn	withdraw	VERB
cuesj-1446	31	47	by	by	ADP
cuesj-1446	31	48	cardiac	cardiac	ADJ
cuesj-1446	31	49	puncture	puncture	NOUN
cuesj-1446	31	50	from	from	ADP
cuesj-1446	31	51	each	each	DET
cuesj-1446	31	52	rat	rat	NOUN
cuesj-1446	31	53	,	,	PUNCT
cuesj-1446	31	54	and	and	CCONJ
cuesj-1446	31	55	their	their	PRON
cuesj-1446	31	56	serum	serum	NOUN
cuesj-1446	31	57	was	be	AUX
cuesj-1446	31	58	used	use	VERB
cuesj-1446	31	59	for	for	ADP
cuesj-1446	31	60	investigations	investigation	NOUN
cuesj-1446	31	61	of	of	ADP
cuesj-1446	31	62	testosterone	testosterone	NOUN
cuesj-1446	31	63	levels	level	NOUN
cuesj-1446	31	64	(	(	PUNCT
cuesj-1446	31	65	rats	rat	NOUN
cuesj-1446	31	66	kit	kit	NOUN
cuesj-1446	31	67	for	for	ADP
cuesj-1446	31	68	enzymelinked	enzymelinke	VERB
cuesj-1446	31	69	immunosorbent	immunosorbent	NOUN
cuesj-1446	31	70	assay	assay	ADV
cuesj-1446	31	71	;	;	PUNCT
cuesj-1446	31	72	sunlong	sunlong	PROPN
cuesj-1446	31	73	biotech	biotech	PROPN
cuesj-1446	31	74	,	,	PUNCT
cuesj-1446	31	75	china	china	PROPN
cuesj-1446	31	76	;	;	PUNCT
cuesj-1446	31	77	catalog	catalog	NOUN
cuesj-1446	31	78	no	no	NOUN
cuesj-1446	31	79	.	.	PUNCT
cuesj-1446	31	80	sl0668ra	sl0668ra	VERB
cuesj-1446	31	81	)	)	PUNCT
cuesj-1446	31	82	was	be	AUX
cuesj-1446	31	83	used	use	VERB
cuesj-1446	31	84	for	for	ADP
cuesj-1446	31	85	serum	serum	NOUN
cuesj-1446	31	86	testosterone	testosterone	NOUN
cuesj-1446	31	87	levels	level	NOUN
cuesj-1446	31	88	determination	determination	NOUN
cuesj-1446	31	89	(	(	PUNCT
cuesj-1446	31	90	sensitivity	sensitivity	NOUN
cuesj-1446	31	91	of	of	ADP
cuesj-1446	31	92	the	the	DET
cuesj-1446	31	93	method	method	NOUN
cuesj-1446	31	94	was	be	AUX
cuesj-1446	31	95	0.01	0.01	NUM
cuesj-1446	31	96	ng	ng	PROPN
cuesj-1446	31	97	/	/	SYM
cuesj-1446	31	98	ml	ml	PROPN
cuesj-1446	31	99	with	with	ADP
cuesj-1446	31	100	intra	intra	ADJ
cuesj-1446	31	101	-	-	ADJ
cuesj-1446	31	102	and	and	CCONJ
cuesj-1446	31	103	inter	inter	ADJ
cuesj-1446	31	104	-	-	ADJ
cuesj-1446	31	105	assay	assay	ADJ
cuesj-1446	31	106	variability	variability	NOUN
cuesj-1446	31	107	of	of	ADP
cuesj-1446	31	108	<	<	X
cuesj-1446	31	109	10	10	NUM
cuesj-1446	31	110	%	%	NOUN
cuesj-1446	31	111	and	and	CCONJ
cuesj-1446	31	112	<	<	X
cuesj-1446	31	113	12	12	NUM
cuesj-1446	31	114	%	%	NOUN
cuesj-1446	31	115	respectively	respectively	ADV
cuesj-1446	31	116	)	)	PUNCT
cuesj-1446	31	117	,	,	PUNCT
cuesj-1446	31	118	and	and	CCONJ
cuesj-1446	31	119	their	their	PRON
cuesj-1446	31	120	prostates	prostate	NOUN
cuesj-1446	31	121	were	be	AUX
cuesj-1446	31	122	carefully	carefully	ADV
cuesj-1446	31	123	isolated	isolate	VERB
cuesj-1446	31	124	and	and	CCONJ
cuesj-1446	31	125	weighed	weigh	VERB
cuesj-1446	31	126	to	to	PART
cuesj-1446	31	127	assess	assess	VERB
cuesj-1446	31	128	for	for	ADP
cuesj-1446	31	129	hypertrophy	hypertrophy	NOUN
cuesj-1446	31	130	.	.	PUNCT
cuesj-1446	32	1	the	the	DET
cuesj-1446	32	2	prostate	prostate	NOUN
cuesj-1446	32	3	index	index	NOUN
cuesj-1446	32	4	(	(	PUNCT
cuesj-1446	32	5	pi	pi	NOUN
cuesj-1446	32	6	)	)	PUNCT
cuesj-1446	32	7	was	be	AUX
cuesj-1446	32	8	obtained	obtain	VERB
cuesj-1446	32	9	by	by	ADP
cuesj-1446	32	10	equation	equation	NOUN
cuesj-1446	32	11	(	(	PUNCT
cuesj-1446	32	12	1):[20	1):[20	PART
cuesj-1446	32	13	]	]	X
cuesj-1446	32	14	=	=	PUNCT
cuesj-1446	32	15	×	×	NOUN
cuesj-1446	32	16	   	   	SPACE
cuesj-1446	32	17	(	(	PUNCT
cuesj-1446	32	18	)	)	PUNCT
cuesj-1446	32	19	100	100	NUM
cuesj-1446	32	20	   	   	SPACE
cuesj-1446	32	21	(	(	PUNCT
cuesj-1446	32	22	)	)	PUNCT
cuesj-1446	32	23	prostateweight	prostateweight	NOUN
cuesj-1446	32	24	pw	pw	PROPN
cuesj-1446	33	1	pi	pi	NOUN
cuesj-1446	33	2	body	body	NOUN
cuesj-1446	33	3	weight	weight	NOUN
cuesj-1446	33	4	bw	bw	NOUN
cuesj-1446	33	5	(	(	PUNCT
cuesj-1446	33	6	1	1	X
cuesj-1446	33	7	)	)	PUNCT
cuesj-1446	33	8	the	the	DET
cuesj-1446	33	9	percent	percent	NOUN
cuesj-1446	33	10	inhibition	inhibition	NOUN
cuesj-1446	33	11	of	of	ADP
cuesj-1446	33	12	hyperplasia	hyperplasia	NOUN
cuesj-1446	33	13	(	(	PUNCT
cuesj-1446	33	14	pih	pih	PROPN
cuesj-1446	33	15	)	)	PUNCT
cuesj-1446	33	16	was	be	AUX
cuesj-1446	33	17	calculated	calculate	VERB
cuesj-1446	33	18	from	from	ADP
cuesj-1446	33	19	the	the	DET
cuesj-1446	33	20	relative	relative	ADJ
cuesj-1446	33	21	prostate	prostate	NOUN
cuesj-1446	33	22	weight	weight	NOUN
cuesj-1446	33	23	,	,	PUNCT
cuesj-1446	33	24	as	as	SCONJ
cuesj-1446	33	25	shown	show	VERB
cuesj-1446	33	26	in	in	ADP
cuesj-1446	33	27	equation	equation	NOUN
cuesj-1446	33	28	(	(	PUNCT
cuesj-1446	33	29	2):[21	2):[21	X
cuesj-1446	33	30	]	]	X
cuesj-1446	33	31			VERB
cuesj-1446	33	32			PRON
cuesj-1446	33	33			PUNCT
cuesj-1446	34	1			ADJ
cuesj-1446	34	2			ADJ
cuesj-1446	34	3			NOUN
cuesj-1446	34	4			VERB
cuesj-1446	34	5			ADJ
cuesj-1446	34	6			NOUN
cuesj-1446	34	7			VERB
cuesj-1446	34	8			ADJ
cuesj-1446	34	9			NOUN
cuesj-1446	34	10			VERB
cuesj-1446	34	11			ADJ
cuesj-1446	34	12			X
cuesj-1446	34	13			VERB
cuesj-1446	34	14			ADP
cuesj-1446	34	15			NOUN
cuesj-1446	34	16			NOUN
cuesj-1446	34	17	      	      	SPACE
cuesj-1446	34	18	]	]	PUNCT
cuesj-1446	34	19	           	           	SPACE
cuesj-1446	34	20	treated	treat	VERB
cuesj-1446	34	21	group	group	NOUN
cuesj-1446	34	22	normalcontrol	normalcontrol	PROPN
cuesj-1446	34	23	group	group	PROPN
cuesj-1446	34	24	pih	pih	PROPN
cuesj-1446	34	25	positivecontrol	positivecontrol	PROPN
cuesj-1446	34	26	group	group	PROPN
cuesj-1446	34	27	normalcontrol	normalcontrol	PROPN
cuesj-1446	34	28	group	group	PROPN
cuesj-1446	34	29	−	−	PROPN
cuesj-1446	34	30	=	=	NOUN
cuesj-1446	34	31	100	100	NUM
cuesj-1446	34	32	−	−	PROPN
cuesj-1446	34	33	×100	×100	NOUN
cuesj-1446	34	34	−	−	PROPN
cuesj-1446	35	1	(	(	PUNCT
cuesj-1446	35	2	2	2	X
cuesj-1446	35	3	)	)	PUNCT
cuesj-1446	35	4	the	the	DET
cuesj-1446	35	5	prostates	prostate	NOUN
cuesj-1446	35	6	were	be	AUX
cuesj-1446	35	7	dissected	dissect	VERB
cuesj-1446	35	8	out	out	ADP
cuesj-1446	35	9	,	,	PUNCT
cuesj-1446	35	10	and	and	CCONJ
cuesj-1446	35	11	a	a	DET
cuesj-1446	35	12	tissue	tissue	NOUN
cuesj-1446	35	13	sample	sample	NOUN
cuesj-1446	35	14	was	be	AUX
cuesj-1446	35	15	obtained	obtain	VERB
cuesj-1446	35	16	,	,	PUNCT
cuesj-1446	35	17	fixed	fix	VERB
cuesj-1446	35	18	in	in	ADP
cuesj-1446	35	19	formalin	formalin	NOUN
cuesj-1446	35	20	for	for	ADP
cuesj-1446	35	21	histopathological	histopathological	ADJ
cuesj-1446	35	22	examination	examination	NOUN
cuesj-1446	35	23	of	of	ADP
cuesj-1446	35	24	prostate	prostate	NOUN
cuesj-1446	35	25	tissue	tissue	NOUN
cuesj-1446	35	26	.	.	PUNCT
cuesj-1446	36	1	the	the	DET
cuesj-1446	36	2	study	study	NOUN
cuesj-1446	36	3	was	be	AUX
cuesj-1446	36	4	approved	approve	VERB
cuesj-1446	36	5	by	by	ADP
cuesj-1446	36	6	the	the	DET
cuesj-1446	36	7	ethical	ethical	ADJ
cuesj-1446	36	8	committee	committee	NOUN
cuesj-1446	36	9	of	of	ADP
cuesj-1446	36	10	the	the	DET
cuesj-1446	36	11	hawler	hawler	PROPN
cuesj-1446	36	12	medical	medical	PROPN
cuesj-1446	36	13	university	university	PROPN
cuesj-1446	36	14	,	,	PUNCT
cuesj-1446	36	15	college	college	NOUN
cuesj-1446	36	16	of	of	ADP
cuesj-1446	36	17	medicine	medicine	NOUN
cuesj-1446	36	18	(	(	PUNCT
cuesj-1446	36	19	meeting	meet	VERB
cuesj-1446	36	20	code	code	NOUN
cuesj-1446	36	21	:	:	PUNCT
cuesj-1446	36	22	2	2	NUM
cuesj-1446	36	23	;	;	PUNCT
cuesj-1446	36	24	paper	paper	NOUN
cuesj-1446	36	25	code	code	NOUN
cuesj-1446	36	26	:	:	PUNCT
cuesj-1446	36	27	12	12	NUM
cuesj-1446	36	28	;	;	PUNCT
cuesj-1446	36	29	date	date	NOUN
cuesj-1446	36	30	:	:	PUNCT
cuesj-1446	36	31	14/11/2024	14/11/2024	NUM
cuesj-1446	36	32	)	)	PUNCT
cuesj-1446	36	33	.	.	PUNCT
cuesj-1446	37	1	statistical	statistical	ADJ
cuesj-1446	37	2	analysis	analysis	NOUN
cuesj-1446	37	3	of	of	ADP
cuesj-1446	37	4	data	datum	NOUN
cuesj-1446	37	5	was	be	AUX
cuesj-1446	37	6	performed	perform	VERB
cuesj-1446	37	7	using	use	VERB
cuesj-1446	37	8	statistical	statistical	ADJ
cuesj-1446	37	9	package	package	NOUN
cuesj-1446	37	10	for	for	ADP
cuesj-1446	37	11	the	the	DET
cuesj-1446	37	12	social	social	ADJ
cuesj-1446	37	13	sciences	science	NOUN
cuesj-1446	37	14	(	(	PUNCT
cuesj-1446	37	15	version	version	NOUN
cuesj-1446	37	16	30	30	NUM
cuesj-1446	37	17	)	)	PUNCT
cuesj-1446	37	18	,	,	PUNCT
cuesj-1446	37	19	and	and	CCONJ
cuesj-1446	37	20	the	the	DET
cuesj-1446	37	21	data	datum	NOUN
cuesj-1446	37	22	are	be	AUX
cuesj-1446	37	23	expressed	express	VERB
cuesj-1446	37	24	as	as	ADP
cuesj-1446	37	25	mean	mean	NOUN
cuesj-1446	37	26	±	±	NUM
cuesj-1446	37	27	standard	standard	ADJ
cuesj-1446	37	28	error	error	NOUN
cuesj-1446	37	29	of	of	ADP
cuesj-1446	37	30	the	the	DET
cuesj-1446	37	31	mean	mean	NOUN
cuesj-1446	37	32	.	.	PUNCT
cuesj-1446	38	1	oneway	oneway	ADJ
cuesj-1446	38	2	analysis	analysis	NOUN
cuesj-1446	38	3	of	of	ADP
cuesj-1446	38	4	variance	variance	NOUN
cuesj-1446	38	5	was	be	AUX
cuesj-1446	38	6	used	use	VERB
cuesj-1446	38	7	to	to	PART
cuesj-1446	38	8	compare	compare	VERB
cuesj-1446	38	9	the	the	DET
cuesj-1446	38	10	statistical	statistical	ADJ
cuesj-1446	38	11	differences	difference	NOUN
cuesj-1446	38	12	between	between	ADP
cuesj-1446	38	13	the	the	DET
cuesj-1446	38	14	groups	group	NOUN
cuesj-1446	38	15	.	.	PUNCT
cuesj-1446	39	1	differences	difference	NOUN
cuesj-1446	39	2	are	be	AUX
cuesj-1446	39	3	considered	consider	VERB
cuesj-1446	39	4	significant	significant	ADJ
cuesj-1446	39	5	at	at	ADP
cuesj-1446	39	6	the	the	DET
cuesj-1446	39	7	level	level	NOUN
cuesj-1446	39	8	of	of	ADP
cuesj-1446	39	9	p	p	NOUN
cuesj-1446	39	10	≤	≤	NUM
cuesj-1446	39	11	0.05	0.05	NUM
cuesj-1446	39	12	.	.	PUNCT
cuesj-1446	40	1	results	result	VERB
cuesj-1446	40	2	the	the	DET
cuesj-1446	40	3	mean	mean	ADJ
cuesj-1446	40	4	body	body	NOUN
cuesj-1446	40	5	weight	weight	NOUN
cuesj-1446	40	6	,	,	PUNCT
cuesj-1446	40	7	prostate	prostate	NOUN
cuesj-1446	40	8	weight	weight	NOUN
cuesj-1446	40	9	(	(	PUNCT
cuesj-1446	40	10	pw	pw	NOUN
cuesj-1446	40	11	)	)	PUNCT
cuesj-1446	40	12	,	,	PUNCT
cuesj-1446	40	13	and	and	CCONJ
cuesj-1446	40	14	prostate	prostate	NOUN
cuesj-1446	40	15	index	index	NOUN
cuesj-1446	40	16	(	(	PUNCT
cuesj-1446	40	17	pi	pi	NOUN
cuesj-1446	40	18	)	)	PUNCT
cuesj-1446	40	19	across	across	ADP
cuesj-1446	40	20	study	study	NOUN
cuesj-1446	40	21	groups	group	NOUN
cuesj-1446	40	22	are	be	AUX
cuesj-1446	40	23	presented	present	VERB
cuesj-1446	40	24	in	in	ADP
cuesj-1446	40	25	table	table	NOUN
cuesj-1446	40	26	1	1	NUM
cuesj-1446	40	27	.	.	PUNCT
cuesj-1446	41	1	the	the	DET
cuesj-1446	41	2	average	average	ADJ
cuesj-1446	41	3	body	body	NOUN
cuesj-1446	41	4	weight	weight	NOUN
cuesj-1446	41	5	of	of	ADP
cuesj-1446	41	6	the	the	DET
cuesj-1446	41	7	rats	rat	NOUN
cuesj-1446	41	8	did	do	AUX
cuesj-1446	41	9	not	not	PART
cuesj-1446	41	10	exhibit	exhibit	VERB
cuesj-1446	41	11	statistical	statistical	ADJ
cuesj-1446	41	12	significance	significance	NOUN
cuesj-1446	41	13	(	(	PUNCT
cuesj-1446	41	14	p	p	X
cuesj-1446	41	15	>	>	X
cuesj-1446	41	16	0.05	0.05	NUM
cuesj-1446	41	17	)	)	PUNCT
cuesj-1446	41	18	across	across	ADP
cuesj-1446	41	19	all	all	DET
cuesj-1446	41	20	experimental	experimental	ADJ
cuesj-1446	41	21	groups	group	NOUN
cuesj-1446	41	22	[	[	X
cuesj-1446	41	23	table	table	NOUN
cuesj-1446	41	24	1	1	NUM
cuesj-1446	41	25	]	]	PUNCT
cuesj-1446	41	26	.	.	PUNCT
cuesj-1446	42	1	figure	figure	NOUN
cuesj-1446	42	2	1	1	NUM
cuesj-1446	42	3	illustrates	illustrate	VERB
cuesj-1446	42	4	the	the	DET
cuesj-1446	42	5	impact	impact	NOUN
cuesj-1446	42	6	of	of	ADP
cuesj-1446	42	7	administering	administer	VERB
cuesj-1446	42	8	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	42	9	,	,	PUNCT
cuesj-1446	42	10	empagliflozin	empagliflozin	PROPN
cuesj-1446	42	11	,	,	PUNCT
cuesj-1446	42	12	and	and	CCONJ
cuesj-1446	42	13	finasteride	finasteride	ADV
cuesj-1446	42	14	over	over	ADP
cuesj-1446	42	15	an	an	DET
cuesj-1446	42	16	8	8	NUM
cuesj-1446	42	17	-	-	PUNCT
cuesj-1446	42	18	week	week	NOUN
cuesj-1446	42	19	period	period	NOUN
cuesj-1446	42	20	on	on	ADP
cuesj-1446	42	21	the	the	DET
cuesj-1446	42	22	mean	mean	NOUN
cuesj-1446	42	23	pw	pw	NOUN
cuesj-1446	42	24	and	and	CCONJ
cuesj-1446	42	25	pi	pi	NOUN
cuesj-1446	42	26	across	across	ADP
cuesj-1446	42	27	various	various	ADJ
cuesj-1446	42	28	experimental	experimental	ADJ
cuesj-1446	42	29	groups	group	NOUN
cuesj-1446	42	30	.	.	PUNCT
cuesj-1446	43	1	the	the	DET
cuesj-1446	43	2	testosterone	testosterone	NOUN
cuesj-1446	43	3	-	-	PUNCT
cuesj-1446	43	4	induced	induce	VERB
cuesj-1446	43	5	bph	bph	NOUN
cuesj-1446	43	6	(	(	PUNCT
cuesj-1446	43	7	t	t	PROPN
cuesj-1446	43	8	-	-	PUNCT
cuesj-1446	43	9	cp	cp	NOUN
cuesj-1446	43	10	)	)	PUNCT
cuesj-1446	43	11	group	group	NOUN
cuesj-1446	43	12	had	have	VERB
cuesj-1446	43	13	significantly	significantly	ADV
cuesj-1446	43	14	(	(	PUNCT
cuesj-1446	43	15	p	p	X
cuesj-1446	43	16	<	<	X
cuesj-1446	43	17	0.05	0.05	NUM
cuesj-1446	43	18	)	)	PUNCT
cuesj-1446	43	19	higher	high	ADJ
cuesj-1446	43	20	mean	mean	VERB
cuesj-1446	43	21	pw	pw	NOUN
cuesj-1446	44	1	and	and	CCONJ
cuesj-1446	44	2	pi	pi	NOUN
cuesj-1446	45	1	[	[	X
cuesj-1446	45	2	figure	figure	NOUN
cuesj-1446	45	3	1	1	NUM
cuesj-1446	45	4	]	]	PUNCT
cuesj-1446	45	5	compared	compare	VERB
cuesj-1446	45	6	to	to	ADP
cuesj-1446	45	7	the	the	DET
cuesj-1446	45	8	cn	cn	PROPN
cuesj-1446	45	9	-	-	ADJ
cuesj-1446	45	10	placebo	placebo	NOUN
cuesj-1446	45	11	group	group	NOUN
cuesj-1446	45	12	.	.	PUNCT
cuesj-1446	46	1	in	in	ADP
cuesj-1446	46	2	contrast	contrast	NOUN
cuesj-1446	46	3	,	,	PUNCT
cuesj-1446	46	4	the	the	DET
cuesj-1446	46	5	mean	mean	ADJ
cuesj-1446	46	6	pi	pi	NOUN
cuesj-1446	46	7	of	of	ADP
cuesj-1446	46	8	the	the	DET
cuesj-1446	46	9	bph	bph	NOUN
cuesj-1446	46	10	-	-	PUNCT
cuesj-1446	46	11	induced	induce	VERB
cuesj-1446	46	12	group	group	NOUN
cuesj-1446	46	13	treated	treat	VERB
cuesj-1446	46	14	with	with	ADP
cuesj-1446	46	15	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	46	16	(	(	PUNCT
cuesj-1446	46	17	t	t	NOUN
cuesj-1446	46	18	-	-	PUNCT
cuesj-1446	46	19	ertu	ertu	NOUN
cuesj-1446	46	20	)	)	PUNCT
cuesj-1446	46	21	,	,	PUNCT
cuesj-1446	46	22	the	the	DET
cuesj-1446	46	23	bph	bph	NOUN
cuesj-1446	46	24	-	-	PUNCT
cuesj-1446	46	25	induced	induce	VERB
cuesj-1446	46	26	group	group	NOUN
cuesj-1446	46	27	treated	treat	VERB
cuesj-1446	46	28	with	with	ADP
cuesj-1446	46	29	empagliflozin	empagliflozin	PROPN
cuesj-1446	46	30	(	(	PUNCT
cuesj-1446	46	31	t	t	NOUN
cuesj-1446	46	32	-	-	PUNCT
cuesj-1446	46	33	empa	empa	NOUN
cuesj-1446	46	34	)	)	PUNCT
cuesj-1446	46	35	and	and	CCONJ
cuesj-1446	46	36	finasteride	finasteride	ADJ
cuesj-1446	46	37	group	group	NOUN
cuesj-1446	46	38	(	(	PUNCT
cuesj-1446	46	39	t	t	NOUN
cuesj-1446	46	40	-	-	PUNCT
cuesj-1446	46	41	fin	fin	NOUN
cuesj-1446	46	42	)	)	PUNCT
cuesj-1446	46	43	were	be	AUX
cuesj-1446	46	44	non	non	ADJ
cuesj-1446	46	45	-	-	ADJ
cuesj-1446	46	46	significantly	significantly	ADV
cuesj-1446	46	47	(	(	PUNCT
cuesj-1446	46	48	p	p	X
cuesj-1446	46	49	>	>	X
cuesj-1446	46	50	0.05	0.05	NUM
cuesj-1446	46	51	)	)	PUNCT
cuesj-1446	46	52	different	different	ADJ
cuesj-1446	46	53	than	than	ADP
cuesj-1446	46	54	those	those	PRON
cuesj-1446	46	55	of	of	ADP
cuesj-1446	46	56	cn	cn	PROPN
cuesj-1446	46	57	-	-	ADJ
cuesj-1446	46	58	placebo	placebo	NOUN
cuesj-1446	46	59	group	group	NOUN
cuesj-1446	46	60	.	.	PUNCT
cuesj-1446	47	1	rats	rat	NOUN
cuesj-1446	47	2	in	in	ADP
cuesj-1446	47	3	the	the	DET
cuesj-1446	47	4	bph	bph	NOUN
cuesj-1446	47	5	-	-	PUNCT
cuesj-1446	47	6	induced	induce	VERB
cuesj-1446	47	7	group	group	NOUN
cuesj-1446	47	8	treated	treat	VERB
cuesj-1446	47	9	with	with	ADP
cuesj-1446	47	10	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	47	11	(	(	PUNCT
cuesj-1446	47	12	t	t	NOUN
cuesj-1446	47	13	-	-	PUNCT
cuesj-1446	47	14	ertu	ertu	NOUN
cuesj-1446	47	15	)	)	PUNCT
cuesj-1446	47	16	,	,	PUNCT
cuesj-1446	47	17	empagliflozin	empagliflozin	PROPN
cuesj-1446	47	18	(	(	PUNCT
cuesj-1446	47	19	t	t	NOUN
cuesj-1446	47	20	-	-	PUNCT
cuesj-1446	47	21	empa	empa	NOUN
cuesj-1446	47	22	)	)	PUNCT
cuesj-1446	47	23	,	,	PUNCT
cuesj-1446	47	24	and	and	CCONJ
cuesj-1446	47	25	finasteride	finasteride	ADJ
cuesj-1446	47	26	(	(	PUNCT
cuesj-1446	47	27	t	t	NOUN
cuesj-1446	47	28	-	-	PUNCT
cuesj-1446	47	29	fin	fin	NOUN
cuesj-1446	47	30	)	)	PUNCT
cuesj-1446	47	31	exhibited	exhibit	VERB
cuesj-1446	47	32	a	a	DET
cuesj-1446	47	33	significantly	significantly	ADV
cuesj-1446	47	34	reduced	reduce	VERB
cuesj-1446	47	35	(	(	PUNCT
cuesj-1446	47	36	p	p	X
cuesj-1446	47	37	<	<	X
cuesj-1446	47	38	0.05	0.05	NUM
cuesj-1446	47	39	)	)	PUNCT
cuesj-1446	47	40	mean	mean	NOUN
cuesj-1446	47	41	pw	pw	NOUN
cuesj-1446	47	42	and	and	CCONJ
cuesj-1446	47	43	pi	pi	NOUN
cuesj-1446	47	44	compared	compare	VERB
cuesj-1446	47	45	to	to	ADP
cuesj-1446	47	46	the	the	DET
cuesj-1446	47	47	testosterone	testosterone	NOUN
cuesj-1446	47	48	-	-	PUNCT
cuesj-1446	47	49	induced	induce	VERB
cuesj-1446	47	50	bph	bph	NOUN
cuesj-1446	47	51	(	(	PUNCT
cuesj-1446	47	52	t	t	PROPN
cuesj-1446	47	53	-	-	PUNCT
cuesj-1446	47	54	cp	cp	PROPN
cuesj-1446	47	55	)	)	PUNCT
cuesj-1446	47	56	group	group	NOUN
cuesj-1446	47	57	,	,	PUNCT
cuesj-1446	47	58	as	as	SCONJ
cuesj-1446	47	59	illustrated	illustrate	VERB
cuesj-1446	47	60	in	in	ADP
cuesj-1446	47	61	table	table	NOUN
cuesj-1446	47	62	1	1	NUM
cuesj-1446	47	63	.	.	PUNCT
cuesj-1446	48	1	the	the	DET
cuesj-1446	48	2	mean	mean	ADJ
cuesj-1446	48	3	serum	serum	NOUN
cuesj-1446	48	4	testosterone	testosterone	NOUN
cuesj-1446	48	5	levels	level	NOUN
cuesj-1446	48	6	are	be	AUX
cuesj-1446	48	7	displayed	display	VERB
cuesj-1446	48	8	in	in	ADP
cuesj-1446	48	9	table	table	NOUN
cuesj-1446	48	10	2	2	NUM
cuesj-1446	48	11	.	.	PUNCT
cuesj-1446	49	1	statistical	statistical	ADJ
cuesj-1446	49	2	analysis	analysis	NOUN
cuesj-1446	49	3	indicated	indicate	VERB
cuesj-1446	49	4	a	a	DET
cuesj-1446	49	5	significant	significant	ADJ
cuesj-1446	49	6	(	(	PUNCT
cuesj-1446	49	7	p	p	X
cuesj-1446	49	8	<	<	X
cuesj-1446	49	9	0.05	0.05	NUM
cuesj-1446	49	10	)	)	PUNCT
cuesj-1446	49	11	elevation	elevation	NOUN
cuesj-1446	49	12	in	in	ADP
cuesj-1446	49	13	mean	mean	PROPN
cuesj-1446	49	14	serum	serum	NOUN
cuesj-1446	49	15	testosterone	testosterone	NOUN
cuesj-1446	49	16	levels	level	NOUN
cuesj-1446	49	17	in	in	ADP
cuesj-1446	49	18	the	the	DET
cuesj-1446	49	19	bph	bph	NOUN
cuesj-1446	49	20	-	-	PUNCT
cuesj-1446	49	21	induced	induce	VERB
cuesj-1446	49	22	positive	positive	ADJ
cuesj-1446	49	23	control	control	NOUN
cuesj-1446	49	24	group	group	NOUN
cuesj-1446	49	25	compared	compare	VERB
cuesj-1446	49	26	to	to	ADP
cuesj-1446	49	27	the	the	DET
cuesj-1446	49	28	cn	cn	PROPN
cuesj-1446	49	29	,	,	PUNCT
cuesj-1446	49	30	t	t	PROPN
cuesj-1446	49	31	-	-	PUNCT
cuesj-1446	49	32	ertu	ertu	NOUN
cuesj-1446	49	33	,	,	PUNCT
cuesj-1446	49	34	t	t	NOUN
cuesj-1446	49	35	-	-	PUNCT
cuesj-1446	49	36	empa	empa	NOUN
cuesj-1446	49	37	,	,	PUNCT
cuesj-1446	49	38	and	and	CCONJ
cuesj-1446	49	39	t	t	PROPN
cuesj-1446	49	40	-	-	PUNCT
cuesj-1446	49	41	fin	fin	NOUN
cuesj-1446	49	42	groups	group	NOUN
cuesj-1446	49	43	,	,	PUNCT
cuesj-1446	49	44	respectively	respectively	ADV
cuesj-1446	49	45	.	.	PUNCT
cuesj-1446	50	1	the	the	DET
cuesj-1446	50	2	groups	group	NOUN
cuesj-1446	50	3	administered	administer	VERB
cuesj-1446	50	4	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	50	5	,	,	PUNCT
cuesj-1446	50	6	empagliflozin	empagliflozin	PROPN
cuesj-1446	50	7	,	,	PUNCT
cuesj-1446	50	8	and	and	CCONJ
cuesj-1446	50	9	finasteride	finasteride	ADV
cuesj-1446	50	10	exhibited	exhibit	VERB
cuesj-1446	50	11	a	a	DET
cuesj-1446	50	12	nonsignificant	nonsignificant	ADJ
cuesj-1446	50	13	(	(	PUNCT
cuesj-1446	50	14	p	p	X
cuesj-1446	50	15	>	>	X
cuesj-1446	50	16	0.05	0.05	NUM
cuesj-1446	50	17	)	)	PUNCT
cuesj-1446	50	18	difference	difference	NOUN
cuesj-1446	50	19	in	in	ADP
cuesj-1446	50	20	mean	mean	PROPN
cuesj-1446	50	21	serum	serum	NOUN
cuesj-1446	50	22	testosterone	testosterone	NOUN
cuesj-1446	50	23	levels	level	NOUN
cuesj-1446	50	24	as	as	SCONJ
cuesj-1446	50	25	compared	compare	VERB
cuesj-1446	50	26	to	to	ADP
cuesj-1446	50	27	the	the	DET
cuesj-1446	50	28	cn	cn	PROPN
cuesj-1446	50	29	group	group	NOUN
cuesj-1446	50	30	.	.	PUNCT
cuesj-1446	51	1	the	the	DET
cuesj-1446	51	2	histological	histological	ADJ
cuesj-1446	51	3	section	section	NOUN
cuesj-1446	52	1	[	[	X
cuesj-1446	52	2	figure	figure	NOUN
cuesj-1446	52	3	2a	2a	NUM
cuesj-1446	52	4	and	and	CCONJ
cuesj-1446	52	5	b	b	X
cuesj-1446	52	6	]	]	X
cuesj-1446	52	7	depicts	depict	VERB
cuesj-1446	52	8	an	an	DET
cuesj-1446	52	9	image	image	NOUN
cuesj-1446	52	10	of	of	ADP
cuesj-1446	52	11	the	the	DET
cuesj-1446	52	12	prostate	prostate	NOUN
cuesj-1446	52	13	gland	gland	NOUN
cuesj-1446	52	14	from	from	ADP
cuesj-1446	52	15	the	the	DET
cuesj-1446	52	16	cp	cp	PROPN
cuesj-1446	52	17	group	group	NOUN
cuesj-1446	52	18	with	with	ADP
cuesj-1446	52	19	hormonal	hormonal	NOUN
cuesj-1446	52	20	-	-	PUNCT
cuesj-1446	52	21	induced	induce	VERB
cuesj-1446	52	22	hyperplasia	hyperplasia	NOUN
cuesj-1446	52	23	of	of	ADP
cuesj-1446	52	24	the	the	DET
cuesj-1446	52	25	prostate	prostate	NOUN
cuesj-1446	52	26	,	,	PUNCT
cuesj-1446	52	27	demonstrating	demonstrate	VERB
cuesj-1446	52	28	pronounced	pronounced	ADJ
cuesj-1446	52	29	bph	bph	NOUN
cuesj-1446	52	30	features	feature	NOUN
cuesj-1446	52	31	,	,	PUNCT
cuesj-1446	52	32	including	include	VERB
cuesj-1446	52	33	significant	significant	ADJ
cuesj-1446	52	34	hyperplasia	hyperplasia	NOUN
cuesj-1446	52	35	of	of	ADP
cuesj-1446	52	36	the	the	DET
cuesj-1446	52	37	epithelial	epithelial	ADJ
cuesj-1446	52	38	lining	lining	NOUN
cuesj-1446	52	39	,	,	PUNCT
cuesj-1446	52	40	irregular	irregular	ADJ
cuesj-1446	52	41	micropapillary	micropapillary	ADJ
cuesj-1446	52	42	projections	projection	NOUN
cuesj-1446	52	43	within	within	ADP
cuesj-1446	52	44	the	the	DET
cuesj-1446	52	45	gland	gland	NOUN
cuesj-1446	52	46	’s	’s	PART
cuesj-1446	52	47	lumen	luman	NOUN
cuesj-1446	52	48	,	,	PUNCT
cuesj-1446	52	49	and	and	CCONJ
cuesj-1446	52	50	notable	notable	ADJ
cuesj-1446	52	51	stromal	stromal	ADJ
cuesj-1446	52	52	expanding	expand	VERB
cuesj-1446	52	53	accompanied	accompany	VERB
cuesj-1446	52	54	by	by	ADP
cuesj-1446	52	55	blood	blood	NOUN
cuesj-1446	52	56	vessels	vessel	NOUN
cuesj-1446	52	57	congestion	congestion	NOUN
cuesj-1446	52	58	.	.	PUNCT
cuesj-1446	53	1	khudhur	khudhur	PROPN
cuesj-1446	53	2	and	and	CCONJ
cuesj-1446	53	3	ali	ali	PROPN
cuesj-1446	53	4	:	:	PUNCT
cuesj-1446	53	5	impact	impact	NOUN
cuesj-1446	53	6	of	of	ADP
cuesj-1446	53	7	sglt2	sglt2	ADJ
cuesj-1446	53	8	inhibitors	inhibitor	NOUN
cuesj-1446	53	9	on	on	ADP
cuesj-1446	53	10	induced	induced	ADJ
cuesj-1446	53	11	benign	benign	ADJ
cuesj-1446	53	12	prostatic	prostatic	ADJ
cuesj-1446	53	13	hyperplasia	hyperplasia	NOUN
cuesj-1446	53	14	in	in	ADP
cuesj-1446	53	15	rats	rat	NOUN
cuesj-1446	53	16	3	3	NUM
cuesj-1446	53	17	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1446	53	18	cuesj	cuesj	NOUN
cuesj-1446	53	19	2025	2025	NUM
cuesj-1446	53	20	,	,	PUNCT
cuesj-1446	53	21	9	9	NUM
cuesj-1446	53	22	(	(	PUNCT
cuesj-1446	53	23	2	2	NUM
cuesj-1446	53	24	):	):	PUNCT
cuesj-1446	53	25	1	1	NUM
cuesj-1446	53	26	-	-	SYM
cuesj-1446	53	27	6	6	NUM
cuesj-1446	53	28	the	the	DET
cuesj-1446	53	29	microscopic	microscopic	ADJ
cuesj-1446	53	30	analysis	analysis	NOUN
cuesj-1446	53	31	of	of	ADP
cuesj-1446	53	32	prostate	prostate	NOUN
cuesj-1446	53	33	tissue	tissue	NOUN
cuesj-1446	53	34	from	from	ADP
cuesj-1446	53	35	the	the	DET
cuesj-1446	53	36	cn	cn	PROPN
cuesj-1446	53	37	group	group	NOUN
cuesj-1446	54	1	[	[	X
cuesj-1446	54	2	figure	figure	NOUN
cuesj-1446	54	3	2c	2c	NOUN
cuesj-1446	54	4	]	]	PUNCT
cuesj-1446	54	5	reveals	reveal	VERB
cuesj-1446	54	6	normal	normal	ADJ
cuesj-1446	54	7	prostatic	prostatic	ADJ
cuesj-1446	54	8	architecture	architecture	NOUN
cuesj-1446	54	9	characterized	characterize	VERB
cuesj-1446	54	10	by	by	ADP
cuesj-1446	54	11	well	well	ADV
cuesj-1446	54	12	-	-	PUNCT
cuesj-1446	54	13	maintained	maintain	VERB
cuesj-1446	54	14	glandular	glandular	ADJ
cuesj-1446	54	15	and	and	CCONJ
cuesj-1446	54	16	stromal	stromal	ADJ
cuesj-1446	54	17	components	component	NOUN
cuesj-1446	54	18	.	.	PUNCT
cuesj-1446	55	1	the	the	DET
cuesj-1446	55	2	cell	cell	NOUN
cuesj-1446	55	3	layers	layer	NOUN
cuesj-1446	55	4	of	of	ADP
cuesj-1446	55	5	the	the	DET
cuesj-1446	55	6	prostatic	prostatic	ADJ
cuesj-1446	55	7	glands	gland	NOUN
cuesj-1446	55	8	are	be	AUX
cuesj-1446	55	9	intact	intact	ADJ
cuesj-1446	55	10	,	,	PUNCT
cuesj-1446	55	11	the	the	DET
cuesj-1446	55	12	lumen	luman	NOUN
cuesj-1446	55	13	includes	include	VERB
cuesj-1446	55	14	a	a	DET
cuesj-1446	55	15	limited	limited	ADJ
cuesj-1446	55	16	number	number	NOUN
cuesj-1446	55	17	of	of	ADP
cuesj-1446	55	18	papillary	papillary	ADJ
cuesj-1446	55	19	folds	fold	NOUN
cuesj-1446	55	20	,	,	PUNCT
cuesj-1446	55	21	and	and	CCONJ
cuesj-1446	55	22	the	the	DET
cuesj-1446	55	23	adjacent	adjacent	ADJ
cuesj-1446	55	24	fibromuscular	fibromuscular	ADJ
cuesj-1446	55	25	stroma	stroma	NOUN
cuesj-1446	55	26	retains	retain	VERB
cuesj-1446	55	27	its	its	PRON
cuesj-1446	55	28	characteristic	characteristic	ADJ
cuesj-1446	55	29	architecture	architecture	NOUN
cuesj-1446	55	30	.	.	PUNCT
cuesj-1446	56	1	no	no	DET
cuesj-1446	56	2	evidence	evidence	NOUN
cuesj-1446	56	3	of	of	ADP
cuesj-1446	56	4	abnormal	abnormal	ADJ
cuesj-1446	56	5	changes	change	NOUN
cuesj-1446	56	6	,	,	PUNCT
cuesj-1446	56	7	including	include	VERB
cuesj-1446	56	8	hyperplasia	hyperplasia	NOUN
cuesj-1446	56	9	,	,	PUNCT
cuesj-1446	56	10	inflammation	inflammation	NOUN
cuesj-1446	56	11	,	,	PUNCT
cuesj-1446	56	12	or	or	CCONJ
cuesj-1446	56	13	fibrosis	fibrosis	NOUN
cuesj-1446	56	14	,	,	PUNCT
cuesj-1446	56	15	is	be	AUX
cuesj-1446	56	16	seen	see	VERB
cuesj-1446	56	17	,	,	PUNCT
cuesj-1446	56	18	suggesting	suggest	VERB
cuesj-1446	56	19	that	that	SCONJ
cuesj-1446	56	20	the	the	DET
cuesj-1446	56	21	tissue	tissue	NOUN
cuesj-1446	56	22	is	be	AUX
cuesj-1446	56	23	in	in	ADP
cuesj-1446	56	24	its	its	PRON
cuesj-1446	56	25	normal	normal	ADJ
cuesj-1446	56	26	physiological	physiological	ADJ
cuesj-1446	56	27	condition	condition	NOUN
cuesj-1446	56	28	.	.	PUNCT
cuesj-1446	57	1	in	in	ADP
cuesj-1446	57	2	the	the	DET
cuesj-1446	57	3	conventional	conventional	ADJ
cuesj-1446	57	4	treatment	treatment	NOUN
cuesj-1446	57	5	,	,	PUNCT
cuesj-1446	57	6	finasteride	finasteride	ADV
cuesj-1446	57	7	-	-	PUNCT
cuesj-1446	57	8	treated	treat	VERB
cuesj-1446	57	9	group	group	NOUN
cuesj-1446	57	10	[	[	X
cuesj-1446	57	11	figure	figure	NOUN
cuesj-1446	57	12	2d	2d	NOUN
cuesj-1446	57	13	]	]	PUNCT
cuesj-1446	57	14	,	,	PUNCT
cuesj-1446	57	15	the	the	DET
cuesj-1446	57	16	severe	severe	ADJ
cuesj-1446	57	17	characteristics	characteristic	NOUN
cuesj-1446	57	18	of	of	ADP
cuesj-1446	57	19	bph	bph	NOUN
cuesj-1446	57	20	were	be	AUX
cuesj-1446	57	21	greatly	greatly	ADV
cuesj-1446	57	22	diminished	diminish	VERB
cuesj-1446	57	23	,	,	PUNCT
cuesj-1446	57	24	evidenced	evidence	VERB
cuesj-1446	57	25	by	by	ADP
cuesj-1446	57	26	a	a	DET
cuesj-1446	57	27	marked	mark	VERB
cuesj-1446	57	28	improvement	improvement	NOUN
cuesj-1446	57	29	in	in	ADP
cuesj-1446	57	30	both	both	CCONJ
cuesj-1446	57	31	epithelial	epithelial	ADJ
cuesj-1446	57	32	and	and	CCONJ
cuesj-1446	57	33	stromal	stromal	ADJ
cuesj-1446	57	34	hyperplasia	hyperplasia	NOUN
cuesj-1446	57	35	,	,	PUNCT
cuesj-1446	57	36	with	with	ADP
cuesj-1446	57	37	histological	histological	ADJ
cuesj-1446	57	38	traits	trait	NOUN
cuesj-1446	57	39	nearing	near	VERB
cuesj-1446	57	40	normality	normality	NOUN
cuesj-1446	57	41	.	.	PUNCT
cuesj-1446	58	1	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	58	2	treatment	treatment	PROPN
cuesj-1446	58	3	resulted	result	VERB
cuesj-1446	58	4	in	in	ADP
cuesj-1446	58	5	a	a	DET
cuesj-1446	58	6	significant	significant	ADJ
cuesj-1446	58	7	decrease	decrease	NOUN
cuesj-1446	58	8	in	in	ADP
cuesj-1446	58	9	bph	bph	NOUN
cuesj-1446	58	10	-	-	PUNCT
cuesj-1446	58	11	related	relate	VERB
cuesj-1446	58	12	histopathological	histopathological	ADJ
cuesj-1446	58	13	alterations	alteration	NOUN
cuesj-1446	58	14	,	,	PUNCT
cuesj-1446	58	15	evidenced	evidence	VERB
cuesj-1446	58	16	by	by	ADP
cuesj-1446	58	17	mild	mild	ADJ
cuesj-1446	58	18	epithelial	epithelial	ADJ
cuesj-1446	58	19	and	and	CCONJ
cuesj-1446	58	20	stromal	stromal	ADJ
cuesj-1446	58	21	hyperplasia	hyperplasia	NOUN
cuesj-1446	58	22	and	and	CCONJ
cuesj-1446	58	23	vascular	vascular	ADJ
cuesj-1446	58	24	congestion	congestion	NOUN
cuesj-1446	59	1	[	[	X
cuesj-1446	59	2	figure	figure	NOUN
cuesj-1446	59	3	2e	2e	NOUN
cuesj-1446	59	4	]	]	PUNCT
cuesj-1446	59	5	.	.	PUNCT
cuesj-1446	60	1	whereas	whereas	SCONJ
cuesj-1446	60	2	,	,	PUNCT
cuesj-1446	60	3	the	the	DET
cuesj-1446	60	4	empagliflozin	empagliflozin	PROPN
cuesj-1446	60	5	treatment	treatment	NOUN
cuesj-1446	60	6	produced	produce	VERB
cuesj-1446	60	7	mild	mild	ADJ
cuesj-1446	60	8	-	-	PUNCT
cuesj-1446	60	9	to	to	ADP
cuesj-1446	60	10	-	-	PUNCT
cuesj-1446	60	11	moderately	moderately	ADV
cuesj-1446	60	12	hyperplastic	hyperplastic	ADJ
cuesj-1446	60	13	epithelial	epithelial	ADJ
cuesj-1446	60	14	cells	cell	NOUN
cuesj-1446	60	15	with	with	ADP
cuesj-1446	60	16	papillary	papillary	ADJ
cuesj-1446	60	17	projections	projection	NOUN
cuesj-1446	60	18	[	[	X
cuesj-1446	60	19	figure	figure	NOUN
cuesj-1446	60	20	2f	2f	NUM
cuesj-1446	60	21	]	]	PUNCT
cuesj-1446	60	22	.	.	PUNCT
cuesj-1446	61	1	discussion	discussion	NOUN
cuesj-1446	61	2	this	this	DET
cuesj-1446	61	3	study	study	NOUN
cuesj-1446	61	4	explored	explore	VERB
cuesj-1446	61	5	the	the	DET
cuesj-1446	61	6	potential	potential	ADJ
cuesj-1446	61	7	effects	effect	NOUN
cuesj-1446	61	8	of	of	ADP
cuesj-1446	61	9	two	two	NUM
cuesj-1446	61	10	sglt2	sglt2	ADJ
cuesj-1446	61	11	inhibitors	inhibitor	NOUN
cuesj-1446	61	12	,	,	PUNCT
cuesj-1446	61	13	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	61	14	,	,	PUNCT
cuesj-1446	61	15	and	and	CCONJ
cuesj-1446	61	16	empagliflozin	empagliflozin	PROPN
cuesj-1446	61	17	,	,	PUNCT
cuesj-1446	61	18	in	in	ADP
cuesj-1446	61	19	counteracting	counteract	VERB
cuesj-1446	61	20	the	the	DET
cuesj-1446	61	21	influence	influence	NOUN
cuesj-1446	61	22	of	of	ADP
cuesj-1446	61	23	testosterone	testosterone	NOUN
cuesj-1446	61	24	in	in	ADP
cuesj-1446	61	25	promoting	promote	VERB
cuesj-1446	61	26	the	the	DET
cuesj-1446	61	27	progression	progression	NOUN
cuesj-1446	61	28	of	of	ADP
cuesj-1446	61	29	bph	bph	NOUN
cuesj-1446	61	30	induced	induce	VERB
cuesj-1446	61	31	in	in	ADP
cuesj-1446	61	32	rats	rat	NOUN
cuesj-1446	61	33	.	.	PUNCT
cuesj-1446	62	1	the	the	DET
cuesj-1446	62	2	non	non	ADJ
cuesj-1446	62	3	-	-	ADJ
cuesj-1446	62	4	significant	significant	ADJ
cuesj-1446	62	5	(	(	PUNCT
cuesj-1446	62	6	p	p	X
cuesj-1446	62	7	>	>	X
cuesj-1446	62	8	0.05	0.05	NUM
cuesj-1446	62	9	)	)	PUNCT
cuesj-1446	62	10	differences	difference	NOUN
cuesj-1446	62	11	in	in	ADP
cuesj-1446	62	12	the	the	DET
cuesj-1446	62	13	mean	mean	ADJ
cuesj-1446	62	14	body	body	NOUN
cuesj-1446	62	15	weight	weight	NOUN
cuesj-1446	62	16	among	among	ADP
cuesj-1446	62	17	the	the	DET
cuesj-1446	62	18	experimental	experimental	ADJ
cuesj-1446	62	19	groups	group	NOUN
cuesj-1446	62	20	align	align	VERB
cuesj-1446	62	21	with	with	ADP
cuesj-1446	62	22	prior	prior	ADJ
cuesj-1446	62	23	research,[22,23	research,[22,23	NOUN
cuesj-1446	62	24	]	]	PUNCT
cuesj-1446	62	25	that	that	PRON
cuesj-1446	62	26	also	also	ADV
cuesj-1446	62	27	observed	observe	VERB
cuesj-1446	62	28	no	no	DET
cuesj-1446	62	29	changes	change	NOUN
cuesj-1446	62	30	in	in	ADP
cuesj-1446	62	31	the	the	DET
cuesj-1446	62	32	body	body	NOUN
cuesj-1446	62	33	weight	weight	NOUN
cuesj-1446	62	34	of	of	ADP
cuesj-1446	62	35	testosterone	testosterone	NOUN
cuesj-1446	62	36	-	-	PUNCT
cuesj-1446	62	37	induced	induce	VERB
cuesj-1446	62	38	bph	bph	NOUN
cuesj-1446	62	39	in	in	ADP
cuesj-1446	62	40	rats	rat	NOUN
cuesj-1446	62	41	under	under	ADP
cuesj-1446	62	42	comparable	comparable	ADJ
cuesj-1446	62	43	experimental	experimental	ADJ
cuesj-1446	62	44	conditions	condition	NOUN
cuesj-1446	62	45	.	.	PUNCT
cuesj-1446	63	1	however	however	ADV
cuesj-1446	63	2	,	,	PUNCT
cuesj-1446	63	3	there	there	PRON
cuesj-1446	63	4	is	be	VERB
cuesj-1446	63	5	conflicting	conflicting	ADJ
cuesj-1446	63	6	evidence	evidence	NOUN
cuesj-1446	63	7	on	on	ADP
cuesj-1446	63	8	the	the	DET
cuesj-1446	63	9	effects	effect	NOUN
cuesj-1446	63	10	of	of	ADP
cuesj-1446	63	11	testosterone	testosterone	NOUN
cuesj-1446	63	12	on	on	ADP
cuesj-1446	63	13	body	body	NOUN
cuesj-1446	63	14	weight	weight	NOUN
cuesj-1446	63	15	related	relate	VERB
cuesj-1446	63	16	to	to	ADP
cuesj-1446	63	17	the	the	DET
cuesj-1446	63	18	dose	dose	NOUN
cuesj-1446	63	19	and	and	CCONJ
cuesj-1446	63	20	duration	duration	NOUN
cuesj-1446	63	21	of	of	ADP
cuesj-1446	63	22	administration.[24	administration.[24	NOUN
cuesj-1446	63	23	]	]	PUNCT
cuesj-1446	63	24	the	the	DET
cuesj-1446	63	25	pw	pw	PROPN
cuesj-1446	63	26	and	and	CCONJ
cuesj-1446	63	27	pi	pi	NOUN
cuesj-1446	63	28	are	be	AUX
cuesj-1446	63	29	frequently	frequently	ADV
cuesj-1446	63	30	used	use	VERB
cuesj-1446	63	31	to	to	PART
cuesj-1446	63	32	determine	determine	VERB
cuesj-1446	63	33	the	the	DET
cuesj-1446	63	34	extent	extent	NOUN
cuesj-1446	63	35	of	of	ADP
cuesj-1446	63	36	bph	bph	NOUN
cuesj-1446	63	37	progression.[20	progression.[20	PROPN
cuesj-1446	63	38	]	]	X
cuesj-1446	63	39	the	the	DET
cuesj-1446	63	40	significant	significant	ADJ
cuesj-1446	63	41	(	(	PUNCT
cuesj-1446	63	42	p	p	X
cuesj-1446	63	43	<	<	X
cuesj-1446	63	44	0.05	0.05	NUM
cuesj-1446	63	45	)	)	PUNCT
cuesj-1446	63	46	increase	increase	NOUN
cuesj-1446	63	47	in	in	ADP
cuesj-1446	63	48	pw	pw	PROPN
cuesj-1446	63	49	and	and	CCONJ
cuesj-1446	63	50	pi	pi	NOUN
cuesj-1446	63	51	of	of	ADP
cuesj-1446	63	52	bph	bph	NOUN
cuesj-1446	63	53	induced	induce	VERB
cuesj-1446	63	54	group	group	NOUN
cuesj-1446	63	55	(	(	PUNCT
cuesj-1446	63	56	t	t	PROPN
cuesj-1446	63	57	-	-	PUNCT
cuesj-1446	63	58	cp	cp	NOUN
cuesj-1446	63	59	)	)	PUNCT
cuesj-1446	63	60	compared	compare	VERB
cuesj-1446	63	61	to	to	ADP
cuesj-1446	63	62	the	the	DET
cuesj-1446	63	63	cn	cn	PROPN
cuesj-1446	63	64	group	group	NOUN
cuesj-1446	63	65	in	in	ADP
cuesj-1446	63	66	the	the	DET
cuesj-1446	63	67	present	present	ADJ
cuesj-1446	63	68	study	study	NOUN
cuesj-1446	63	69	is	be	AUX
cuesj-1446	63	70	the	the	DET
cuesj-1446	63	71	consequence	consequence	NOUN
cuesj-1446	63	72	of	of	ADP
cuesj-1446	63	73	dihydrotestosterone	dihydrotestosterone	NOUN
cuesj-1446	63	74	(	(	PUNCT
cuesj-1446	63	75	dht	dht	NOUN
cuesj-1446	63	76	)	)	PUNCT
cuesj-1446	63	77	activation	activation	NOUN
cuesj-1446	63	78	of	of	ADP
cuesj-1446	63	79	androgenic	androgenic	ADJ
cuesj-1446	63	80	receptors	receptor	NOUN
cuesj-1446	63	81	that	that	PRON
cuesj-1446	63	82	promote	promote	VERB
cuesj-1446	63	83	the	the	DET
cuesj-1446	63	84	proliferation	proliferation	NOUN
cuesj-1446	63	85	of	of	ADP
cuesj-1446	63	86	epithelial	epithelial	ADJ
cuesj-1446	63	87	and	and	CCONJ
cuesj-1446	63	88	stromal	stromal	ADJ
cuesj-1446	63	89	cells	cell	NOUN
cuesj-1446	63	90	of	of	ADP
cuesj-1446	63	91	prostate.[25	prostate.[25	PROPN
cuesj-1446	63	92	]	]	PUNCT
cuesj-1446	63	93	similar	similar	ADJ
cuesj-1446	63	94	observations	observation	NOUN
cuesj-1446	63	95	have	have	AUX
cuesj-1446	63	96	been	be	AUX
cuesj-1446	63	97	reported	report	VERB
cuesj-1446	63	98	by	by	ADP
cuesj-1446	63	99	shanmugasundaram	shanmugasundaram	PROPN
cuesj-1446	63	100	et	et	PROPN
cuesj-1446	63	101	al.[26	al.[26	PROPN
cuesj-1446	63	102	]	]	PUNCT
cuesj-1446	63	103	and	and	CCONJ
cuesj-1446	63	104	alamoudi	alamoudi	ADJ
cuesj-1446	63	105	et	et	PROPN
cuesj-1446	63	106	al.[27	al.[27	PROPN
cuesj-1446	63	107	]	]	PUNCT
cuesj-1446	63	108	moreover	moreover	ADV
cuesj-1446	63	109	,	,	PUNCT
cuesj-1446	63	110	the	the	DET
cuesj-1446	63	111	t	t	PROPN
cuesj-1446	63	112	-	-	PUNCT
cuesj-1446	63	113	cp	cp	PROPN
cuesj-1446	63	114	group	group	NOUN
cuesj-1446	63	115	had	have	VERB
cuesj-1446	63	116	significantly	significantly	ADV
cuesj-1446	63	117	(	(	PUNCT
cuesj-1446	63	118	p	p	X
cuesj-1446	63	119	<	<	X
cuesj-1446	63	120	0.05	0.05	NUM
cuesj-1446	63	121	)	)	PUNCT
cuesj-1446	63	122	higher	high	ADJ
cuesj-1446	63	123	mean	mean	NOUN
cuesj-1446	63	124	serum	serum	NOUN
cuesj-1446	63	125	testosterone	testosterone	NOUN
cuesj-1446	63	126	levels	level	NOUN
cuesj-1446	63	127	than	than	ADP
cuesj-1446	63	128	the	the	DET
cuesj-1446	63	129	cn	cn	PROPN
cuesj-1446	63	130	group	group	NOUN
cuesj-1446	63	131	.	.	PUNCT
cuesj-1446	64	1	these	these	DET
cuesj-1446	64	2	results	result	NOUN
cuesj-1446	64	3	explain	explain	VERB
cuesj-1446	64	4	the	the	DET
cuesj-1446	64	5	significant	significant	ADJ
cuesj-1446	64	6	rise	rise	NOUN
cuesj-1446	64	7	in	in	ADP
cuesj-1446	64	8	both	both	CCONJ
cuesj-1446	64	9	the	the	DET
cuesj-1446	64	10	mean	mean	NOUN
cuesj-1446	64	11	pw	pw	NOUN
cuesj-1446	64	12	and	and	CCONJ
cuesj-1446	64	13	pi	pi	NOUN
cuesj-1446	64	14	of	of	ADP
cuesj-1446	64	15	the	the	DET
cuesj-1446	64	16	t	t	PROPN
cuesj-1446	64	17	-	-	PUNCT
cuesj-1446	64	18	cp	cp	PROPN
cuesj-1446	64	19	group	group	NOUN
cuesj-1446	64	20	relative	relative	ADJ
cuesj-1446	64	21	to	to	ADP
cuesj-1446	64	22	the	the	DET
cuesj-1446	64	23	cn	cn	PROPN
cuesj-1446	64	24	group	group	PROPN
cuesj-1446	64	25	(	(	PUNCT
cuesj-1446	64	26	p	p	X
cuesj-1446	64	27	<	<	X
cuesj-1446	64	28	0.05	0.05	NUM
cuesj-1446	64	29	)	)	PUNCT
cuesj-1446	64	30	in	in	ADP
cuesj-1446	64	31	our	our	PRON
cuesj-1446	64	32	investigation	investigation	NOUN
cuesj-1446	64	33	.	.	PUNCT
cuesj-1446	65	1	research	research	NOUN
cuesj-1446	65	2	has	have	AUX
cuesj-1446	65	3	established	establish	VERB
cuesj-1446	65	4	a	a	DET
cuesj-1446	65	5	significant	significant	ADJ
cuesj-1446	65	6	table	table	NOUN
cuesj-1446	65	7	2	2	NUM
cuesj-1446	65	8	:	:	PUNCT
cuesj-1446	65	9	impact	impact	NOUN
cuesj-1446	65	10	of	of	ADP
cuesj-1446	65	11	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	65	12	,	,	PUNCT
cuesj-1446	65	13	empagliflozin	empagliflozin	PROPN
cuesj-1446	65	14	,	,	PUNCT
cuesj-1446	65	15	and	and	CCONJ
cuesj-1446	65	16	finasteride	finasteride	ADV
cuesj-1446	65	17	on	on	ADP
cuesj-1446	65	18	mean	mean	ADJ
cuesj-1446	65	19	serum	serum	NOUN
cuesj-1446	65	20	testosterone	testosterone	NOUN
cuesj-1446	65	21	levels	level	NOUN
cuesj-1446	65	22	in	in	ADP
cuesj-1446	65	23	testosterone	testosterone	NOUN
cuesj-1446	65	24	-	-	PUNCT
cuesj-1446	65	25	induced	induce	VERB
cuesj-1446	65	26	bph	bph	NOUN
cuesj-1446	65	27	in	in	ADP
cuesj-1446	65	28	rats	rat	NOUN
cuesj-1446	65	29	group	group	NOUN
cuesj-1446	65	30	cn	cn	PROPN
cuesj-1446	65	31	t	t	PROPN
cuesj-1446	65	32	-	-	PUNCT
cuesj-1446	65	33	cp	cp	PROPN
cuesj-1446	65	34	t	t	PROPN
cuesj-1446	65	35	-	-	PUNCT
cuesj-1446	65	36	ertu	ertu	NOUN
cuesj-1446	65	37	t	t	PROPN
cuesj-1446	65	38	-	-	PUNCT
cuesj-1446	65	39	empa	empa	NOUN
cuesj-1446	65	40	t	t	PROPN
cuesj-1446	65	41	-	-	PUNCT
cuesj-1446	65	42	fin	fin	NOUN
cuesj-1446	65	43	mean±sem	mean±sem	NOUN
cuesj-1446	65	44	2.53±0.25acde	2.53±0.25acde	NUM
cuesj-1446	65	45	4.27±0.37b	4.27±0.37b	NUM
cuesj-1446	65	46	1.97±0.07acde	1.97±0.07acde	NUM
cuesj-1446	65	47	1.91±0.13acde	1.91±0.13acde	NUM
cuesj-1446	65	48	2.69±0.16acde	2.69±0.16acde	NUM
cuesj-1446	65	49	different	different	ADJ
cuesj-1446	65	50	letters	letter	NOUN
cuesj-1446	65	51	indicate	indicate	VERB
cuesj-1446	65	52	statistical	statistical	ADJ
cuesj-1446	65	53	significance	significance	NOUN
cuesj-1446	65	54	at	at	ADP
cuesj-1446	65	55	a	a	DET
cuesj-1446	65	56	p≤0.05	p≤0.05	NOUN
cuesj-1446	65	57	.	.	PUNCT
cuesj-1446	65	58	bph	bph	NOUN
cuesj-1446	65	59	:	:	PUNCT
cuesj-1446	65	60	benign	benign	ADJ
cuesj-1446	65	61	prostatic	prostatic	ADJ
cuesj-1446	65	62	hyperplasia	hyperplasia	NOUN
cuesj-1446	65	63	,	,	PUNCT
cuesj-1446	65	64	sem	sem	NOUN
cuesj-1446	65	65	:	:	PUNCT
cuesj-1446	65	66	standard	standard	ADJ
cuesj-1446	65	67	error	error	NOUN
cuesj-1446	65	68	of	of	ADP
cuesj-1446	65	69	the	the	DET
cuesj-1446	65	70	mean	mean	ADJ
cuesj-1446	65	71	table	table	NOUN
cuesj-1446	65	72	1	1	NUM
cuesj-1446	65	73	:	:	PUNCT
cuesj-1446	65	74	the	the	DET
cuesj-1446	65	75	mean	mean	ADJ
cuesj-1446	65	76	(	(	PUNCT
cuesj-1446	65	77	±	±	NUM
cuesj-1446	65	78	sem	sem	NOUN
cuesj-1446	65	79	)	)	PUNCT
cuesj-1446	65	80	of	of	ADP
cuesj-1446	65	81	the	the	DET
cuesj-1446	65	82	prostate	prostate	NOUN
cuesj-1446	65	83	profile	profile	NOUN
cuesj-1446	65	84	of	of	ADP
cuesj-1446	65	85	bph	bph	NOUN
cuesj-1446	65	86	-	-	PUNCT
cuesj-1446	65	87	induced	induce	VERB
cuesj-1446	65	88	(	(	PUNCT
cuesj-1446	65	89	t	t	PROPN
cuesj-1446	65	90	-	-	PUNCT
cuesj-1446	65	91	cp	cp	NOUN
cuesj-1446	65	92	)	)	PUNCT
cuesj-1446	65	93	rats	rat	NOUN
cuesj-1446	65	94	following	follow	VERB
cuesj-1446	65	95	daily	daily	ADJ
cuesj-1446	65	96	treatment	treatment	NOUN
cuesj-1446	65	97	of	of	ADP
cuesj-1446	65	98	testosterone	testosterone	NOUN
cuesj-1446	65	99	enanthate	enanthate	NOUN
cuesj-1446	65	100	(	(	PUNCT
cuesj-1446	65	101	3	3	NUM
cuesj-1446	65	102	mg	mg	PROPN
cuesj-1446	65	103	/	/	SYM
cuesj-1446	65	104	kg	kg	NOUN
cuesj-1446	65	105	)	)	PUNCT
cuesj-1446	65	106	for	for	ADP
cuesj-1446	65	107	12	12	NUM
cuesj-1446	65	108	weeks	week	NOUN
cuesj-1446	65	109	,	,	PUNCT
cuesj-1446	65	110	then	then	ADV
cuesj-1446	65	111	treated	treat	VERB
cuesj-1446	65	112	with	with	ADP
cuesj-1446	65	113	either	either	CCONJ
cuesj-1446	65	114	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	65	115	(	(	PUNCT
cuesj-1446	65	116	10	10	NUM
cuesj-1446	65	117	mg	mg	NUM
cuesj-1446	65	118	/	/	SYM
cuesj-1446	65	119	kg	kg	PROPN
cuesj-1446	65	120	)	)	PUNCT
cuesj-1446	65	121	,	,	PUNCT
cuesj-1446	65	122	empagliflozin	empagliflozin	PROPN
cuesj-1446	65	123	(	(	PUNCT
cuesj-1446	65	124	10	10	NUM
cuesj-1446	65	125	mg	mg	NUM
cuesj-1446	65	126	/	/	SYM
cuesj-1446	65	127	kg	kg	NOUN
cuesj-1446	65	128	)	)	PUNCT
cuesj-1446	65	129	,	,	PUNCT
cuesj-1446	65	130	or	or	CCONJ
cuesj-1446	65	131	finasteride	finasteride	ADJ
cuesj-1446	65	132	(	(	PUNCT
cuesj-1446	65	133	0.44	0.44	NUM
cuesj-1446	65	134	mg	mg	PROPN
cuesj-1446	65	135	/	/	SYM
cuesj-1446	65	136	kg	kg	NOUN
cuesj-1446	65	137	)	)	PUNCT
cuesj-1446	65	138	for	for	ADP
cuesj-1446	65	139	8	8	NUM
cuesj-1446	65	140	weeks	week	NOUN
cuesj-1446	65	141	post	post	ADJ
cuesj-1446	65	142	-	-	ADJ
cuesj-1446	65	143	bph	bph	NOUN
cuesj-1446	65	144	induction	induction	NOUN
cuesj-1446	65	145	group	group	NOUN
cuesj-1446	65	146	body	body	NOUN
cuesj-1446	65	147	weight	weight	NOUN
cuesj-1446	65	148	(	(	PUNCT
cuesj-1446	65	149	g	g	NOUN
cuesj-1446	65	150	)	)	PUNCT
cuesj-1446	65	151	mean±sem	mean±sem	NOUN
cuesj-1446	65	152	prostate	prostate	NOUN
cuesj-1446	65	153	weight	weight	NOUN
cuesj-1446	65	154	(	(	PUNCT
cuesj-1446	65	155	g	g	NOUN
cuesj-1446	65	156	)	)	PUNCT
cuesj-1446	65	157	mean±sem	mean±sem	NOUN
cuesj-1446	65	158	prostate	prostate	NOUN
cuesj-1446	65	159	index	index	NOUN
cuesj-1446	65	160	(	(	PUNCT
cuesj-1446	65	161	%	%	INTJ
cuesj-1446	65	162	)	)	PUNCT
cuesj-1446	66	1	mean±sem	mean±sem	PROPN
cuesj-1446	66	2	cn	cn	ADJ
cuesj-1446	66	3	341.17±27.16a	341.17±27.16a	PROPN
cuesj-1446	66	4	1.19±0.11acde	1.19±0.11acde	NUM
cuesj-1446	66	5	0.35±0.03acde	0.35±0.03acde	ADP
cuesj-1446	66	6	t	t	PROPN
cuesj-1446	66	7	-	-	PUNCT
cuesj-1446	66	8	cp	cp	PROPN
cuesj-1446	66	9	334.83±17.30a	334.83±17.30a	PROPN
cuesj-1446	66	10	2.15±0.19b	2.15±0.19b	NUM
cuesj-1446	66	11	0.64±0.05b	0.64±0.05b	NOUN
cuesj-1446	66	12	t	t	PROPN
cuesj-1446	66	13	-	-	PUNCT
cuesj-1446	66	14	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	67	1	325.17±21.75a	325.17±21.75a	NUM
cuesj-1446	67	2	1.39±0.13acde	1.39±0.13acde	NUM
cuesj-1446	68	1	0.43±0.03acde	0.43±0.03acde	NUM
cuesj-1446	68	2	t	t	PROPN
cuesj-1446	68	3	-	-	PUNCT
cuesj-1446	68	4	empagliflozin	empagliflozin	NOUN
cuesj-1446	68	5	301.17±20.05a	301.17±20.05a	NUM
cuesj-1446	68	6	1.42±0.04acde	1.42±0.04acde	NUM
cuesj-1446	68	7	0.48±0.04acde	0.48±0.04acde	PROPN
cuesj-1446	68	8	t	t	PROPN
cuesj-1446	68	9	-	-	PUNCT
cuesj-1446	68	10	finasteride	finasteride	NOUN
cuesj-1446	68	11	326.50±13.31a	326.50±13.31a	PROPN
cuesj-1446	68	12	1.36±0.06acde	1.36±0.06acde	NUM
cuesj-1446	68	13	0.42±0.02acde	0.42±0.02acde	NUM
cuesj-1446	68	14	different	different	ADJ
cuesj-1446	68	15	letters	letter	NOUN
cuesj-1446	68	16	indicate	indicate	VERB
cuesj-1446	68	17	statistical	statistical	ADJ
cuesj-1446	68	18	significance	significance	NOUN
cuesj-1446	68	19	at	at	ADP
cuesj-1446	68	20	a	a	DET
cuesj-1446	68	21	p≤0.05	p≤0.05	NOUN
cuesj-1446	68	22	.	.	PUNCT
cuesj-1446	68	23	bph	bph	NOUN
cuesj-1446	68	24	:	:	PUNCT
cuesj-1446	68	25	benign	benign	ADJ
cuesj-1446	68	26	prostatic	prostatic	ADJ
cuesj-1446	68	27	hyperplasia	hyperplasia	NOUN
cuesj-1446	68	28	,	,	PUNCT
cuesj-1446	68	29	sem	sem	NOUN
cuesj-1446	68	30	:	:	PUNCT
cuesj-1446	68	31	standard	standard	ADJ
cuesj-1446	68	32	error	error	NOUN
cuesj-1446	68	33	of	of	ADP
cuesj-1446	68	34	the	the	DET
cuesj-1446	68	35	mean	mean	ADJ
cuesj-1446	68	36	figure	figure	NOUN
cuesj-1446	68	37	1	1	NUM
cuesj-1446	68	38	:	:	PUNCT
cuesj-1446	68	39	prostate	prostate	NOUN
cuesj-1446	68	40	weight	weight	NOUN
cuesj-1446	68	41	(	(	PUNCT
cuesj-1446	68	42	a	a	NOUN
cuesj-1446	68	43	)	)	PUNCT
cuesj-1446	68	44	and	and	CCONJ
cuesj-1446	68	45	prostate	prostate	NOUN
cuesj-1446	68	46	index	index	NOUN
cuesj-1446	68	47	(	(	PUNCT
cuesj-1446	68	48	b	b	NOUN
cuesj-1446	68	49	)	)	PUNCT
cuesj-1446	68	50	in	in	ADP
cuesj-1446	68	51	the	the	DET
cuesj-1446	68	52	cn	cn	PROPN
cuesj-1446	68	53	group	group	NOUN
cuesj-1446	68	54	,	,	PUNCT
cuesj-1446	68	55	testosterone	testosterone	NOUN
cuesj-1446	68	56	-	-	PUNCT
cuesj-1446	68	57	induced	induce	VERB
cuesj-1446	68	58	benign	benign	ADJ
cuesj-1446	68	59	prostatic	prostatic	ADJ
cuesj-1446	68	60	hyperplasia	hyperplasia	NOUN
cuesj-1446	68	61	(	(	PUNCT
cuesj-1446	68	62	bph	bph	NOUN
cuesj-1446	68	63	)	)	PUNCT
cuesj-1446	68	64	positive	positive	ADJ
cuesj-1446	68	65	control	control	NOUN
cuesj-1446	68	66	group	group	NOUN
cuesj-1446	68	67	(	(	PUNCT
cuesj-1446	68	68	t	t	PROPN
cuesj-1446	68	69	-	-	PUNCT
cuesj-1446	68	70	cp	cp	NOUN
cuesj-1446	68	71	)	)	PUNCT
cuesj-1446	68	72	,	,	PUNCT
cuesj-1446	68	73	bph	bph	NOUN
cuesj-1446	68	74	-	-	PUNCT
cuesj-1446	68	75	induced	induce	VERB
cuesj-1446	68	76	group	group	NOUN
cuesj-1446	68	77	treated	treat	VERB
cuesj-1446	68	78	with	with	ADP
cuesj-1446	68	79	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	68	80	(	(	PUNCT
cuesj-1446	68	81	t	t	NOUN
cuesj-1446	68	82	-	-	PUNCT
cuesj-1446	68	83	ertu	ertu	NOUN
cuesj-1446	68	84	)	)	PUNCT
cuesj-1446	68	85	,	,	PUNCT
cuesj-1446	68	86	bph	bph	NOUN
cuesj-1446	68	87	-	-	PUNCT
cuesj-1446	68	88	induced	induce	VERB
cuesj-1446	68	89	group	group	NOUN
cuesj-1446	68	90	treated	treat	VERB
cuesj-1446	68	91	with	with	ADP
cuesj-1446	68	92	empagliflozin	empagliflozin	PROPN
cuesj-1446	68	93	(	(	PUNCT
cuesj-1446	68	94	t	t	NOUN
cuesj-1446	68	95	-	-	PUNCT
cuesj-1446	68	96	empa	empa	NOUN
cuesj-1446	68	97	)	)	PUNCT
cuesj-1446	68	98	,	,	PUNCT
cuesj-1446	68	99	and	and	CCONJ
cuesj-1446	68	100	bph	bph	NOUN
cuesj-1446	68	101	-	-	PUNCT
cuesj-1446	68	102	induced	induce	VERB
cuesj-1446	68	103	group	group	NOUN
cuesj-1446	68	104	treated	treat	VERB
cuesj-1446	68	105	with	with	ADP
cuesj-1446	68	106	finasteride	finasteride	ADJ
cuesj-1446	68	107	(	(	PUNCT
cuesj-1446	68	108	t	t	NOUN
cuesj-1446	68	109	-	-	PUNCT
cuesj-1446	68	110	fin	fin	NOUN
cuesj-1446	68	111	)	)	PUNCT
cuesj-1446	68	112	b	b	NOUN
cuesj-1446	68	113	a	a	DET
cuesj-1446	68	114	khudhur	khudhur	PROPN
cuesj-1446	68	115	and	and	CCONJ
cuesj-1446	68	116	ali	ali	PROPN
cuesj-1446	68	117	:	:	PUNCT
cuesj-1446	68	118	impact	impact	NOUN
cuesj-1446	68	119	of	of	ADP
cuesj-1446	68	120	sglt2	sglt2	ADJ
cuesj-1446	68	121	inhibitors	inhibitor	NOUN
cuesj-1446	68	122	on	on	ADP
cuesj-1446	68	123	induced	induced	ADJ
cuesj-1446	68	124	benign	benign	ADJ
cuesj-1446	68	125	prostatic	prostatic	ADJ
cuesj-1446	68	126	hyperplasia	hyperplasia	NOUN
cuesj-1446	68	127	in	in	ADP
cuesj-1446	68	128	rats	rat	NOUN
cuesj-1446	68	129	4	4	NUM
cuesj-1446	68	130	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1446	68	131	cuesj	cuesj	NOUN
cuesj-1446	68	132	2025	2025	NUM
cuesj-1446	68	133	,	,	PUNCT
cuesj-1446	68	134	9	9	NUM
cuesj-1446	68	135	(	(	PUNCT
cuesj-1446	68	136	2	2	NUM
cuesj-1446	68	137	):	):	PUNCT
cuesj-1446	68	138	1	1	NUM
cuesj-1446	68	139	-	-	SYM
cuesj-1446	68	140	6	6	NUM
cuesj-1446	68	141	association	association	NOUN
cuesj-1446	68	142	between	between	ADP
cuesj-1446	68	143	circulatory	circulatory	ADJ
cuesj-1446	68	144	testosterone	testosterone	NOUN
cuesj-1446	68	145	levels	level	NOUN
cuesj-1446	68	146	and	and	CCONJ
cuesj-1446	68	147	the	the	DET
cuesj-1446	68	148	extent	extent	NOUN
cuesj-1446	68	149	of	of	ADP
cuesj-1446	68	150	prostate	prostate	NOUN
cuesj-1446	68	151	enlargement.[28	enlargement.[28	PROPN
cuesj-1446	68	152	]	]	X
cuesj-1446	68	153	the	the	DET
cuesj-1446	68	154	statistically	statistically	ADV
cuesj-1446	68	155	(	(	PUNCT
cuesj-1446	68	156	p	p	X
cuesj-1446	68	157	<	<	X
cuesj-1446	68	158	0.05	0.05	NUM
cuesj-1446	68	159	)	)	PUNCT
cuesj-1446	68	160	increased	increase	VERB
cuesj-1446	68	161	mean	mean	NOUN
cuesj-1446	68	162	serum	serum	NOUN
cuesj-1446	68	163	testosterone	testosterone	NOUN
cuesj-1446	68	164	level	level	NOUN
cuesj-1446	68	165	in	in	ADP
cuesj-1446	68	166	the	the	DET
cuesj-1446	68	167	t	t	PROPN
cuesj-1446	68	168	-	-	PUNCT
cuesj-1446	68	169	cp	cp	PROPN
cuesj-1446	68	170	group	group	NOUN
cuesj-1446	68	171	can	can	AUX
cuesj-1446	68	172	be	be	AUX
cuesj-1446	68	173	explained	explain	VERB
cuesj-1446	68	174	by	by	ADP
cuesj-1446	68	175	the	the	DET
cuesj-1446	68	176	negative	negative	ADJ
cuesj-1446	68	177	feedback	feedback	NOUN
cuesj-1446	68	178	mechanism	mechanism	NOUN
cuesj-1446	68	179	induced	induce	VERB
cuesj-1446	68	180	by	by	ADP
cuesj-1446	68	181	the	the	DET
cuesj-1446	68	182	continuous	continuous	ADJ
cuesj-1446	68	183	administration	administration	NOUN
cuesj-1446	68	184	of	of	ADP
cuesj-1446	68	185	exogenous	exogenous	ADJ
cuesj-1446	68	186	testosterone	testosterone	NOUN
cuesj-1446	68	187	on	on	ADP
cuesj-1446	68	188	the	the	DET
cuesj-1446	68	189	hypothalamicpituitary	hypothalamicpituitary	ADJ
cuesj-1446	68	190	-	-	PUNCT
cuesj-1446	68	191	gonadal	gonadal	ADJ
cuesj-1446	68	192	axis	axis	NOUN
cuesj-1446	68	193	that	that	PRON
cuesj-1446	68	194	reduces	reduce	VERB
cuesj-1446	68	195	the	the	DET
cuesj-1446	68	196	production	production	NOUN
cuesj-1446	68	197	of	of	ADP
cuesj-1446	68	198	endogenous	endogenous	ADJ
cuesj-1446	68	199	testosterone	testosterone	NOUN
cuesj-1446	68	200	while	while	SCONJ
cuesj-1446	68	201	the	the	DET
cuesj-1446	68	202	serum	serum	NOUN
cuesj-1446	68	203	levels	level	NOUN
cuesj-1446	68	204	of	of	ADP
cuesj-1446	68	205	testosterone	testosterone	NOUN
cuesj-1446	68	206	remain	remain	VERB
cuesj-1446	68	207	elevated.[29,30	elevated.[29,30	PROPN
cuesj-1446	68	208	]	]	X
cuesj-1446	68	209	the	the	DET
cuesj-1446	68	210	histological	histological	ADJ
cuesj-1446	68	211	changes	change	NOUN
cuesj-1446	68	212	observed	observe	VERB
cuesj-1446	68	213	in	in	ADP
cuesj-1446	68	214	the	the	DET
cuesj-1446	68	215	prostate	prostate	NOUN
cuesj-1446	68	216	segment	segment	NOUN
cuesj-1446	68	217	of	of	ADP
cuesj-1446	68	218	the	the	DET
cuesj-1446	68	219	t	t	PROPN
cuesj-1446	68	220	-	-	PUNCT
cuesj-1446	68	221	cp	cp	PROPN
cuesj-1446	68	222	group	group	NOUN
cuesj-1446	68	223	compared	compare	VERB
cuesj-1446	68	224	to	to	ADP
cuesj-1446	68	225	the	the	DET
cuesj-1446	68	226	cn	cn	PROPN
cuesj-1446	68	227	group	group	NOUN
cuesj-1446	68	228	provided	provide	VERB
cuesj-1446	68	229	further	further	ADJ
cuesj-1446	68	230	evidence	evidence	NOUN
cuesj-1446	68	231	for	for	ADP
cuesj-1446	68	232	the	the	DET
cuesj-1446	68	233	significant	significant	ADJ
cuesj-1446	68	234	(	(	PUNCT
cuesj-1446	68	235	p	p	X
cuesj-1446	68	236	<	<	X
cuesj-1446	68	237	0.05	0.05	NUM
cuesj-1446	68	238	)	)	PUNCT
cuesj-1446	68	239	higher	high	ADJ
cuesj-1446	68	240	pw	pw	PROPN
cuesj-1446	68	241	,	,	PUNCT
cuesj-1446	68	242	pi	pi	NOUN
cuesj-1446	68	243	,	,	PUNCT
cuesj-1446	68	244	and	and	CCONJ
cuesj-1446	68	245	serum	serum	NOUN
cuesj-1446	68	246	testosterone	testosterone	NOUN
cuesj-1446	68	247	levels	level	NOUN
cuesj-1446	68	248	.	.	PUNCT
cuesj-1446	69	1	the	the	DET
cuesj-1446	69	2	histological	histological	ADJ
cuesj-1446	69	3	examination	examination	NOUN
cuesj-1446	69	4	of	of	ADP
cuesj-1446	69	5	prostate	prostate	NOUN
cuesj-1446	69	6	sections	section	NOUN
cuesj-1446	69	7	of	of	ADP
cuesj-1446	69	8	the	the	DET
cuesj-1446	69	9	t	t	PROPN
cuesj-1446	69	10	-	-	PUNCT
cuesj-1446	69	11	cp	cp	PROPN
cuesj-1446	69	12	group	group	NOUN
cuesj-1446	69	13	showed	show	VERB
cuesj-1446	69	14	varying	vary	VERB
cuesj-1446	69	15	degrees	degree	NOUN
cuesj-1446	69	16	of	of	ADP
cuesj-1446	69	17	hyperplastic	hyperplastic	ADJ
cuesj-1446	69	18	changes	change	NOUN
cuesj-1446	69	19	in	in	ADP
cuesj-1446	69	20	the	the	DET
cuesj-1446	69	21	epithelial	epithelial	ADJ
cuesj-1446	69	22	and	and	CCONJ
cuesj-1446	69	23	glandular	glandular	ADJ
cuesj-1446	69	24	layers[31	layers[31	NOUN
cuesj-1446	69	25	]	]	PUNCT
cuesj-1446	69	26	with	with	ADP
cuesj-1446	69	27	prominent	prominent	ADJ
cuesj-1446	69	28	papillary	papillary	ADJ
cuesj-1446	69	29	infoldings.[32	infoldings.[32	PROPN
cuesj-1446	69	30	]	]	PUNCT
cuesj-1446	69	31	furthermore	furthermore	ADV
cuesj-1446	69	32	,	,	PUNCT
cuesj-1446	69	33	significant	significant	ADJ
cuesj-1446	69	34	edema	edema	NOUN
cuesj-1446	69	35	and	and	CCONJ
cuesj-1446	69	36	elevated	elevated	ADJ
cuesj-1446	69	37	fibroblasts	fibroblast	NOUN
cuesj-1446	69	38	within	within	ADP
cuesj-1446	69	39	the	the	DET
cuesj-1446	69	40	gland	gland	NOUN
cuesj-1446	69	41	.	.	PUNCT
cuesj-1446	70	1	enlarged	enlarge	VERB
cuesj-1446	70	2	blood	blood	NOUN
cuesj-1446	70	3	vessels	vessel	NOUN
cuesj-1446	70	4	and	and	CCONJ
cuesj-1446	70	5	lymphocytic	lymphocytic	ADJ
cuesj-1446	70	6	infiltration	infiltration	NOUN
cuesj-1446	70	7	were	be	AUX
cuesj-1446	70	8	also	also	ADV
cuesj-1446	70	9	apparent	apparent	ADJ
cuesj-1446	70	10	in	in	ADP
cuesj-1446	70	11	the	the	DET
cuesj-1446	70	12	stroma	stroma	NOUN
cuesj-1446	70	13	,	,	PUNCT
cuesj-1446	70	14	indicating	indicate	VERB
cuesj-1446	70	15	advanced	advanced	ADJ
cuesj-1446	70	16	bph	bph	NOUN
cuesj-1446	70	17	disease[33	disease[33	NOUN
cuesj-1446	70	18	]	]	PUNCT
cuesj-1446	70	19	in	in	ADP
cuesj-1446	70	20	contrast	contrast	NOUN
cuesj-1446	70	21	to	to	ADP
cuesj-1446	70	22	prostatic	prostatic	ADJ
cuesj-1446	70	23	sections	section	NOUN
cuesj-1446	70	24	of	of	ADP
cuesj-1446	70	25	cn	cn	PROPN
cuesj-1446	70	26	rats	rat	NOUN
cuesj-1446	70	27	that	that	PRON
cuesj-1446	70	28	displayed	display	VERB
cuesj-1446	70	29	normal	normal	ADJ
cuesj-1446	70	30	characteristics	characteristic	NOUN
cuesj-1446	70	31	of	of	ADP
cuesj-1446	70	32	prostatic	prostatic	ADJ
cuesj-1446	70	33	architecture	architecture	NOUN
cuesj-1446	70	34	,	,	PUNCT
cuesj-1446	70	35	with	with	ADP
cuesj-1446	70	36	well	well	ADV
cuesj-1446	70	37	-	-	PUNCT
cuesj-1446	70	38	preserved	preserve	VERB
cuesj-1446	70	39	glandular	glandular	ADJ
cuesj-1446	70	40	and	and	CCONJ
cuesj-1446	70	41	stromal	stromal	ADJ
cuesj-1446	70	42	components	component	NOUN
cuesj-1446	70	43	.	.	PUNCT
cuesj-1446	71	1	finasteride	finasteride	ADV
cuesj-1446	71	2	,	,	PUNCT
cuesj-1446	71	3	a	a	DET
cuesj-1446	71	4	first	first	ADJ
cuesj-1446	71	5	-	-	PUNCT
cuesj-1446	71	6	line	line	NOUN
cuesj-1446	71	7	medication	medication	NOUN
cuesj-1446	71	8	for	for	ADP
cuesj-1446	71	9	the	the	DET
cuesj-1446	71	10	management	management	NOUN
cuesj-1446	71	11	of	of	ADP
cuesj-1446	71	12	bph[34	bph[34	PROPN
cuesj-1446	71	13	]	]	PUNCT
cuesj-1446	71	14	was	be	AUX
cuesj-1446	71	15	used	use	VERB
cuesj-1446	71	16	in	in	ADP
cuesj-1446	71	17	the	the	DET
cuesj-1446	71	18	current	current	ADJ
cuesj-1446	71	19	study	study	NOUN
cuesj-1446	71	20	for	for	ADP
cuesj-1446	71	21	the	the	DET
cuesj-1446	71	22	purpose	purpose	NOUN
cuesj-1446	71	23	of	of	ADP
cuesj-1446	71	24	comparison	comparison	NOUN
cuesj-1446	71	25	and	and	CCONJ
cuesj-1446	71	26	demonstrated	demonstrate	VERB
cuesj-1446	71	27	a	a	DET
cuesj-1446	71	28	significant	significant	ADJ
cuesj-1446	71	29	(	(	PUNCT
cuesj-1446	71	30	p	p	X
cuesj-1446	71	31	<	<	X
cuesj-1446	71	32	0.05	0.05	NUM
cuesj-1446	71	33	)	)	PUNCT
cuesj-1446	71	34	decrease	decrease	NOUN
cuesj-1446	71	35	in	in	ADP
cuesj-1446	71	36	the	the	DET
cuesj-1446	71	37	mean	mean	NOUN
cuesj-1446	71	38	pw	pw	NOUN
cuesj-1446	71	39	and	and	CCONJ
cuesj-1446	71	40	pi	pi	NOUN
cuesj-1446	71	41	as	as	ADV
cuesj-1446	71	42	well	well	ADV
cuesj-1446	71	43	as	as	ADP
cuesj-1446	71	44	in	in	ADP
cuesj-1446	71	45	the	the	DET
cuesj-1446	71	46	mean	mean	ADJ
cuesj-1446	71	47	serum	serum	NOUN
cuesj-1446	71	48	testosterone	testosterone	NOUN
cuesj-1446	71	49	levels	level	NOUN
cuesj-1446	71	50	which	which	PRON
cuesj-1446	71	51	coincide	coincide	VERB
cuesj-1446	71	52	with	with	ADP
cuesj-1446	71	53	the	the	DET
cuesj-1446	71	54	findings	finding	NOUN
cuesj-1446	71	55	of	of	ADP
cuesj-1446	71	56	elsherbini	elsherbini	PROPN
cuesj-1446	71	57	et	et	PROPN
cuesj-1446	71	58	al.[21	al.[21	NOUN
cuesj-1446	71	59	]	]	PUNCT
cuesj-1446	71	60	and	and	CCONJ
cuesj-1446	71	61	shanmugasundaram	shanmugasundaram	PROPN
cuesj-1446	71	62	et	et	PROPN
cuesj-1446	71	63	al.[26	al.[26	PROPN
cuesj-1446	71	64	]	]	PUNCT
cuesj-1446	71	65	these	these	DET
cuesj-1446	71	66	inhibitory	inhibitory	ADJ
cuesj-1446	71	67	effects	effect	NOUN
cuesj-1446	71	68	of	of	ADP
cuesj-1446	71	69	finasteride	finasteride	ADJ
cuesj-1446	71	70	were	be	AUX
cuesj-1446	71	71	further	far	ADV
cuesj-1446	71	72	supported	support	VERB
cuesj-1446	71	73	by	by	ADP
cuesj-1446	71	74	the	the	DET
cuesj-1446	71	75	amelioration	amelioration	NOUN
cuesj-1446	71	76	of	of	ADP
cuesj-1446	71	77	profound	profound	ADJ
cuesj-1446	71	78	prostatic	prostatic	ADJ
cuesj-1446	71	79	hyperplastic	hyperplastic	ADJ
cuesj-1446	71	80	changes	change	NOUN
cuesj-1446	71	81	to	to	ADP
cuesj-1446	71	82	a	a	DET
cuesj-1446	71	83	mild	mild	ADJ
cuesj-1446	71	84	hyperplasia	hyperplasia	NOUN
cuesj-1446	71	85	that	that	PRON
cuesj-1446	71	86	closely	closely	ADV
cuesj-1446	71	87	matches	match	VERB
cuesj-1446	71	88	with	with	ADP
cuesj-1446	71	89	the	the	DET
cuesj-1446	71	90	normal	normal	ADJ
cuesj-1446	71	91	architecture	architecture	NOUN
cuesj-1446	71	92	of	of	ADP
cuesj-1446	71	93	prostatic	prostatic	ADJ
cuesj-1446	71	94	tissue	tissue	NOUN
cuesj-1446	71	95	upon	upon	SCONJ
cuesj-1446	71	96	histological	histological	ADJ
cuesj-1446	71	97	examination	examination	NOUN
cuesj-1446	71	98	,	,	PUNCT
cuesj-1446	71	99	albeit	albeit	SCONJ
cuesj-1446	71	100	consistently	consistently	ADV
cuesj-1446	71	101	described	describe	VERB
cuesj-1446	71	102	by	by	ADP
cuesj-1446	71	103	alhussien	alhussien	PROPN
cuesj-1446	71	104	et	et	PROPN
cuesj-1446	71	105	al.[35	al.[35	PROPN
cuesj-1446	71	106	]	]	PUNCT
cuesj-1446	71	107	administration	administration	NOUN
cuesj-1446	71	108	of	of	ADP
cuesj-1446	71	109	both	both	CCONJ
cuesj-1446	71	110	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	71	111	and	and	CCONJ
cuesj-1446	71	112	empagliflozin	empagliflozin	PROPN
cuesj-1446	71	113	resulted	result	VERB
cuesj-1446	71	114	in	in	ADP
cuesj-1446	71	115	a	a	DET
cuesj-1446	71	116	significant	significant	ADJ
cuesj-1446	71	117	(	(	PUNCT
cuesj-1446	71	118	p	p	X
cuesj-1446	71	119	<	<	X
cuesj-1446	71	120	0.05	0.05	NUM
cuesj-1446	71	121	)	)	PUNCT
cuesj-1446	71	122	decrease	decrease	NOUN
cuesj-1446	71	123	in	in	ADP
cuesj-1446	71	124	the	the	DET
cuesj-1446	71	125	mean	mean	NOUN
cuesj-1446	71	126	pw	pw	NOUN
cuesj-1446	71	127	and	and	CCONJ
cuesj-1446	71	128	pi	pi	NOUN
cuesj-1446	71	129	compared	compare	VERB
cuesj-1446	71	130	to	to	ADP
cuesj-1446	71	131	the	the	DET
cuesj-1446	71	132	t	t	PROPN
cuesj-1446	71	133	-	-	PUNCT
cuesj-1446	71	134	cp	cp	PROPN
cuesj-1446	71	135	group	group	NOUN
cuesj-1446	71	136	by	by	ADP
cuesj-1446	71	137	79.2	79.2	NUM
cuesj-1446	71	138	%	%	NOUN
cuesj-1446	71	139	and	and	CCONJ
cuesj-1446	71	140	76.1	76.1	NUM
cuesj-1446	71	141	%	%	NOUN
cuesj-1446	71	142	,	,	PUNCT
cuesj-1446	71	143	respectively	respectively	ADV
cuesj-1446	71	144	.	.	PUNCT
cuesj-1446	72	1	this	this	DET
cuesj-1446	72	2	effect	effect	NOUN
cuesj-1446	72	3	is	be	AUX
cuesj-1446	72	4	most	most	ADV
cuesj-1446	72	5	probably	probably	ADV
cuesj-1446	72	6	due	due	ADP
cuesj-1446	72	7	to	to	ADP
cuesj-1446	72	8	the	the	DET
cuesj-1446	72	9	consequences	consequence	NOUN
cuesj-1446	72	10	of	of	ADP
cuesj-1446	72	11	the	the	DET
cuesj-1446	72	12	significant	significant	ADJ
cuesj-1446	72	13	(	(	PUNCT
cuesj-1446	72	14	p	p	X
cuesj-1446	72	15	<	<	X
cuesj-1446	72	16	0.05	0.05	NUM
cuesj-1446	72	17	)	)	PUNCT
cuesj-1446	72	18	lowering	lower	VERB
cuesj-1446	72	19	of	of	ADP
cuesj-1446	72	20	mean	mean	ADJ
cuesj-1446	72	21	figure	figure	NOUN
cuesj-1446	72	22	2	2	NUM
cuesj-1446	72	23	:	:	PUNCT
cuesj-1446	72	24	histopathological	histopathological	ADJ
cuesj-1446	72	25	sections	section	NOUN
cuesj-1446	72	26	(	(	PUNCT
cuesj-1446	72	27	×40	×40	PROPN
cuesj-1446	72	28	)	)	PUNCT
cuesj-1446	72	29	of	of	ADP
cuesj-1446	72	30	prostate	prostate	NOUN
cuesj-1446	72	31	tissues	tissue	NOUN
cuesj-1446	72	32	(	(	PUNCT
cuesj-1446	72	33	hematoxylin	hematoxylin	NOUN
cuesj-1446	72	34	and	and	CCONJ
cuesj-1446	72	35	eosin	eosin	NOUN
cuesj-1446	72	36	stain	stain	NOUN
cuesj-1446	72	37	)	)	PUNCT
cuesj-1446	72	38	from	from	ADP
cuesj-1446	72	39	rats	rat	NOUN
cuesj-1446	72	40	in	in	ADP
cuesj-1446	72	41	the	the	DET
cuesj-1446	72	42	benign	benign	ADJ
cuesj-1446	72	43	prostatic	prostatic	ADJ
cuesj-1446	72	44	hyperplasia	hyperplasia	NOUN
cuesj-1446	72	45	(	(	PUNCT
cuesj-1446	72	46	bph)-induced	bph)-induce	VERB
cuesj-1446	72	47	positive	positive	ADJ
cuesj-1446	72	48	control	control	NOUN
cuesj-1446	72	49	group	group	NOUN
cuesj-1446	72	50	(	(	PUNCT
cuesj-1446	72	51	a	a	DET
cuesj-1446	72	52	anb	anb	PROPN
cuesj-1446	72	53	b	b	PROPN
cuesj-1446	72	54	)	)	PUNCT
cuesj-1446	72	55	,	,	PUNCT
cuesj-1446	72	56	the	the	DET
cuesj-1446	72	57	negative	negative	ADJ
cuesj-1446	72	58	placebo	placebo	NOUN
cuesj-1446	72	59	control	control	NOUN
cuesj-1446	72	60	group	group	NOUN
cuesj-1446	72	61	(	(	PUNCT
cuesj-1446	72	62	c	c	NOUN
cuesj-1446	72	63	)	)	PUNCT
cuesj-1446	72	64	,	,	PUNCT
cuesj-1446	72	65	the	the	DET
cuesj-1446	72	66	bph	bph	NOUN
cuesj-1446	72	67	-	-	PUNCT
cuesj-1446	72	68	induced	induce	VERB
cuesj-1446	72	69	group	group	NOUN
cuesj-1446	72	70	treated	treat	VERB
cuesj-1446	72	71	with	with	ADP
cuesj-1446	72	72	finasteride	finasteride	ADJ
cuesj-1446	72	73	(	(	PUNCT
cuesj-1446	72	74	d	d	NOUN
cuesj-1446	72	75	)	)	PUNCT
cuesj-1446	72	76	,	,	PUNCT
cuesj-1446	72	77	the	the	DET
cuesj-1446	72	78	bph	bph	NOUN
cuesj-1446	72	79	-	-	PUNCT
cuesj-1446	72	80	induced	induce	VERB
cuesj-1446	72	81	group	group	NOUN
cuesj-1446	72	82	treated	treat	VERB
cuesj-1446	72	83	with	with	ADP
cuesj-1446	72	84	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	72	85	(	(	PUNCT
cuesj-1446	72	86	e	e	NOUN
cuesj-1446	72	87	)	)	PUNCT
cuesj-1446	72	88	,	,	PUNCT
cuesj-1446	72	89	and	and	CCONJ
cuesj-1446	72	90	the	the	DET
cuesj-1446	72	91	bph	bph	NOUN
cuesj-1446	72	92	-	-	PUNCT
cuesj-1446	72	93	induced	induce	VERB
cuesj-1446	72	94	group	group	NOUN
cuesj-1446	72	95	treated	treat	VERB
cuesj-1446	72	96	with	with	ADP
cuesj-1446	72	97	empagliflozin	empagliflozin	PROPN
cuesj-1446	72	98	(	(	PUNCT
cuesj-1446	72	99	f	f	X
cuesj-1446	72	100	)	)	PUNCT
cuesj-1446	73	1	dc	dc	PROPN
cuesj-1446	73	2	b	b	PROPN
cuesj-1446	73	3	f	f	PROPN
cuesj-1446	73	4	a	a	DET
cuesj-1446	73	5	e	e	X
cuesj-1446	73	6	khudhur	khudhur	PROPN
cuesj-1446	73	7	and	and	CCONJ
cuesj-1446	73	8	ali	ali	PROPN
cuesj-1446	73	9	:	:	PUNCT
cuesj-1446	73	10	impact	impact	NOUN
cuesj-1446	73	11	of	of	ADP
cuesj-1446	73	12	sglt2	sglt2	ADJ
cuesj-1446	73	13	inhibitors	inhibitor	NOUN
cuesj-1446	73	14	on	on	ADP
cuesj-1446	73	15	induced	induced	ADJ
cuesj-1446	73	16	benign	benign	ADJ
cuesj-1446	73	17	prostatic	prostatic	ADJ
cuesj-1446	73	18	hyperplasia	hyperplasia	NOUN
cuesj-1446	73	19	in	in	ADP
cuesj-1446	73	20	rats	rat	NOUN
cuesj-1446	73	21	5	5	NUM
cuesj-1446	73	22	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1446	73	23	cuesj	cuesj	NOUN
cuesj-1446	73	24	2025	2025	NUM
cuesj-1446	73	25	,	,	PUNCT
cuesj-1446	73	26	9	9	NUM
cuesj-1446	73	27	(	(	PUNCT
cuesj-1446	73	28	2	2	NUM
cuesj-1446	73	29	):	):	PUNCT
cuesj-1446	73	30	1	1	NUM
cuesj-1446	73	31	-	-	SYM
cuesj-1446	73	32	6	6	NUM
cuesj-1446	73	33	serum	serum	NOUN
cuesj-1446	73	34	testosterone	testosterone	NOUN
cuesj-1446	73	35	levels	level	NOUN
cuesj-1446	73	36	found	find	VERB
cuesj-1446	73	37	following	follow	VERB
cuesj-1446	73	38	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	73	39	and	and	CCONJ
cuesj-1446	73	40	empagliflozin	empagliflozin	PROPN
cuesj-1446	73	41	administration	administration	NOUN
cuesj-1446	73	42	compared	compare	VERB
cuesj-1446	73	43	to	to	ADP
cuesj-1446	73	44	the	the	DET
cuesj-1446	73	45	t	t	PROPN
cuesj-1446	73	46	-	-	PUNCT
cuesj-1446	73	47	cp	cp	PROPN
cuesj-1446	73	48	group	group	NOUN
cuesj-1446	73	49	.	.	PUNCT
cuesj-1446	74	1	these	these	DET
cuesj-1446	74	2	inhibitory	inhibitory	ADJ
cuesj-1446	74	3	effects	effect	NOUN
cuesj-1446	74	4	were	be	AUX
cuesj-1446	74	5	more	more	ADV
cuesj-1446	74	6	obviously	obviously	ADV
cuesj-1446	74	7	reflected	reflect	VERB
cuesj-1446	74	8	by	by	ADP
cuesj-1446	74	9	the	the	DET
cuesj-1446	74	10	mild	mild	ADJ
cuesj-1446	74	11	hyperplasia	hyperplasia	NOUN
cuesj-1446	74	12	in	in	ADP
cuesj-1446	74	13	the	the	DET
cuesj-1446	74	14	histological	histological	ADJ
cuesj-1446	74	15	sections	section	NOUN
cuesj-1446	74	16	of	of	ADP
cuesj-1446	74	17	the	the	DET
cuesj-1446	74	18	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	74	19	group	group	PROPN
cuesj-1446	74	20	,	,	PUNCT
cuesj-1446	74	21	whereas	whereas	SCONJ
cuesj-1446	74	22	mild	mild	ADJ
cuesj-1446	74	23	-	-	PUNCT
cuesj-1446	74	24	to	to	ADP
cuesj-1446	74	25	-	-	PUNCT
cuesj-1446	74	26	moderate	moderate	ADJ
cuesj-1446	74	27	hyperplastic	hyperplastic	ADJ
cuesj-1446	74	28	changes	change	NOUN
cuesj-1446	74	29	in	in	ADP
cuesj-1446	74	30	the	the	DET
cuesj-1446	74	31	empagliflozin	empagliflozin	PROPN
cuesj-1446	74	32	group	group	NOUN
cuesj-1446	74	33	compared	compare	VERB
cuesj-1446	74	34	to	to	ADP
cuesj-1446	74	35	the	the	DET
cuesj-1446	74	36	prominent	prominent	ADJ
cuesj-1446	74	37	prostatic	prostatic	ADJ
cuesj-1446	74	38	hyperplasia	hyperplasia	NOUN
cuesj-1446	74	39	shown	show	VERB
cuesj-1446	74	40	in	in	ADP
cuesj-1446	74	41	the	the	DET
cuesj-1446	74	42	t	t	PROPN
cuesj-1446	74	43	-	-	PUNCT
cuesj-1446	74	44	cp	cp	PROPN
cuesj-1446	74	45	group	group	NOUN
cuesj-1446	74	46	rats	rat	NOUN
cuesj-1446	74	47	.	.	PUNCT
cuesj-1446	75	1	the	the	DET
cuesj-1446	75	2	significant	significant	ADJ
cuesj-1446	75	3	inhibitory	inhibitory	ADJ
cuesj-1446	75	4	effects	effect	NOUN
cuesj-1446	75	5	indicate	indicate	VERB
cuesj-1446	75	6	that	that	SCONJ
cuesj-1446	75	7	both	both	DET
cuesj-1446	75	8	drugs	drug	NOUN
cuesj-1446	75	9	led	lead	VERB
cuesj-1446	75	10	to	to	ADP
cuesj-1446	75	11	the	the	DET
cuesj-1446	75	12	suppression	suppression	NOUN
cuesj-1446	75	13	of	of	ADP
cuesj-1446	75	14	the	the	DET
cuesj-1446	75	15	androgenic	androgenic	ADJ
cuesj-1446	75	16	axis	axis	NOUN
cuesj-1446	75	17	by	by	ADP
cuesj-1446	75	18	reducing	reduce	VERB
cuesj-1446	75	19	serum	serum	NOUN
cuesj-1446	75	20	testosterone	testosterone	NOUN
cuesj-1446	75	21	level	level	NOUN
cuesj-1446	75	22	,	,	PUNCT
cuesj-1446	75	23	thus	thus	ADV
cuesj-1446	75	24	decreasing	decrease	VERB
cuesj-1446	75	25	conversion	conversion	NOUN
cuesj-1446	75	26	to	to	PART
cuesj-1446	75	27	dht	dht	VERB
cuesj-1446	75	28	and	and	CCONJ
cuesj-1446	75	29	inhibiting	inhibit	VERB
cuesj-1446	75	30	proliferative	proliferative	ADJ
cuesj-1446	75	31	signaling	signal	VERB
cuesj-1446	75	32	factors	factor	NOUN
cuesj-1446	75	33	that	that	PRON
cuesj-1446	75	34	contribute	contribute	VERB
cuesj-1446	75	35	to	to	ADP
cuesj-1446	75	36	the	the	DET
cuesj-1446	75	37	enlargement	enlargement	NOUN
cuesj-1446	75	38	of	of	ADP
cuesj-1446	75	39	the	the	DET
cuesj-1446	75	40	prostate	prostate	NOUN
cuesj-1446	75	41	gland	gland	NOUN
cuesj-1446	75	42	.	.	PUNCT
cuesj-1446	76	1	similarly	similarly	ADV
cuesj-1446	76	2	,	,	PUNCT
cuesj-1446	76	3	canagliflozin	canagliflozin	PROPN
cuesj-1446	76	4	,	,	PUNCT
cuesj-1446	76	5	another	another	DET
cuesj-1446	76	6	sglt2	sglt2	ADJ
cuesj-1446	76	7	inhibitor	inhibitor	NOUN
cuesj-1446	76	8	,	,	PUNCT
cuesj-1446	76	9	has	have	AUX
cuesj-1446	76	10	been	be	AUX
cuesj-1446	76	11	found	find	VERB
cuesj-1446	76	12	to	to	PART
cuesj-1446	76	13	reduce	reduce	VERB
cuesj-1446	76	14	the	the	DET
cuesj-1446	76	15	expression	expression	NOUN
cuesj-1446	76	16	of	of	ADP
cuesj-1446	76	17	epidermal	epidermal	ADJ
cuesj-1446	76	18	growth	growth	NOUN
cuesj-1446	76	19	factor	factor	NOUN
cuesj-1446	76	20	in	in	ADP
cuesj-1446	76	21	bph	bph	NOUN
cuesj-1446	76	22	and	and	CCONJ
cuesj-1446	76	23	to	to	PART
cuesj-1446	76	24	alleviate	alleviate	VERB
cuesj-1446	76	25	bph	bph	NOUN
cuesj-1446	76	26	that	that	PRON
cuesj-1446	76	27	has	have	AUX
cuesj-1446	76	28	been	be	AUX
cuesj-1446	76	29	induced	induce	VERB
cuesj-1446	76	30	experimentally.[36	experimentally.[36	NOUN
cuesj-1446	76	31	]	]	PUNCT
cuesj-1446	76	32	however	however	ADV
cuesj-1446	76	33	,	,	PUNCT
cuesj-1446	76	34	it	it	PRON
cuesj-1446	76	35	is	be	AUX
cuesj-1446	76	36	worth	worth	ADJ
cuesj-1446	76	37	noting	note	VERB
cuesj-1446	76	38	that	that	SCONJ
cuesj-1446	76	39	the	the	DET
cuesj-1446	76	40	histopathological	histopathological	ADJ
cuesj-1446	76	41	sections	section	NOUN
cuesj-1446	76	42	of	of	ADP
cuesj-1446	76	43	the	the	DET
cuesj-1446	76	44	empagliflozin	empagliflozin	PROPN
cuesj-1446	76	45	group	group	NOUN
cuesj-1446	76	46	showed	show	VERB
cuesj-1446	76	47	mild	mild	ADJ
cuesj-1446	76	48	-	-	PUNCT
cuesj-1446	76	49	tomoderate	tomoderate	ADJ
cuesj-1446	76	50	hyperplasia	hyperplasia	NOUN
cuesj-1446	76	51	in	in	ADP
cuesj-1446	76	52	prostate	prostate	NOUN
cuesj-1446	76	53	sections	section	NOUN
cuesj-1446	76	54	.	.	PUNCT
cuesj-1446	77	1	the	the	DET
cuesj-1446	77	2	differences	difference	NOUN
cuesj-1446	77	3	seen	see	VERB
cuesj-1446	77	4	in	in	ADP
cuesj-1446	77	5	the	the	DET
cuesj-1446	77	6	histological	histological	ADJ
cuesj-1446	77	7	sections	section	NOUN
cuesj-1446	77	8	between	between	ADP
cuesj-1446	77	9	the	the	DET
cuesj-1446	77	10	effects	effect	NOUN
cuesj-1446	77	11	of	of	ADP
cuesj-1446	77	12	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	77	13	and	and	CCONJ
cuesj-1446	77	14	empagliflozin	empagliflozin	PROPN
cuesj-1446	77	15	may	may	AUX
cuesj-1446	77	16	be	be	AUX
cuesj-1446	77	17	due	due	ADJ
cuesj-1446	77	18	to	to	ADP
cuesj-1446	77	19	variances	variance	NOUN
cuesj-1446	77	20	in	in	ADP
cuesj-1446	77	21	their	their	PRON
cuesj-1446	77	22	physicochemical	physicochemical	ADJ
cuesj-1446	77	23	characteristics	characteristic	NOUN
cuesj-1446	77	24	,	,	PUNCT
cuesj-1446	77	25	especially	especially	ADV
cuesj-1446	77	26	their	their	PRON
cuesj-1446	77	27	pka	pka	PROPN
cuesj-1446	77	28	values	value	NOUN
cuesj-1446	77	29	.	.	PUNCT
cuesj-1446	78	1	these	these	DET
cuesj-1446	78	2	properties	property	NOUN
cuesj-1446	78	3	affect	affect	VERB
cuesj-1446	78	4	how	how	SCONJ
cuesj-1446	78	5	well	well	ADV
cuesj-1446	78	6	each	each	DET
cuesj-1446	78	7	drug	drug	NOUN
cuesj-1446	78	8	can	can	AUX
cuesj-1446	78	9	get	get	VERB
cuesj-1446	78	10	into	into	ADP
cuesj-1446	78	11	tissues	tissue	NOUN
cuesj-1446	78	12	and	and	CCONJ
cuesj-1446	78	13	spread	spread	VERB
cuesj-1446	78	14	throughout	throughout	ADP
cuesj-1446	78	15	the	the	DET
cuesj-1446	78	16	prostate	prostate	NOUN
cuesj-1446	78	17	,	,	PUNCT
cuesj-1446	78	18	which	which	PRON
cuesj-1446	78	19	may	may	AUX
cuesj-1446	78	20	help	help	VERB
cuesj-1446	78	21	explain	explain	VERB
cuesj-1446	78	22	why	why	SCONJ
cuesj-1446	78	23	they	they	PRON
cuesj-1446	78	24	have	have	VERB
cuesj-1446	78	25	different	different	ADJ
cuesj-1446	78	26	effects	effect	NOUN
cuesj-1446	78	27	on	on	ADP
cuesj-1446	78	28	prostate	prostate	NOUN
cuesj-1446	78	29	histology	histology	NOUN
cuesj-1446	78	30	.	.	PUNCT
cuesj-1446	79	1	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	79	2	is	be	AUX
cuesj-1446	79	3	more	more	ADV
cuesj-1446	79	4	lipophilic	lipophilic	ADJ
cuesj-1446	79	5	than	than	ADP
cuesj-1446	79	6	empagliflozin	empagliflozin	PROPN
cuesj-1446	79	7	,	,	PUNCT
cuesj-1446	79	8	which	which	PRON
cuesj-1446	79	9	promotes	promote	VERB
cuesj-1446	79	10	better	well	ADJ
cuesj-1446	79	11	membrane	membrane	NOUN
cuesj-1446	79	12	penetration	penetration	NOUN
cuesj-1446	79	13	in	in	ADP
cuesj-1446	79	14	lipophilic	lipophilic	ADJ
cuesj-1446	79	15	tissues	tissue	NOUN
cuesj-1446	79	16	such	such	ADJ
cuesj-1446	79	17	as	as	ADP
cuesj-1446	79	18	the	the	DET
cuesj-1446	79	19	prostate	prostate	NOUN
cuesj-1446	79	20	.	.	PUNCT
cuesj-1446	80	1	since	since	SCONJ
cuesj-1446	80	2	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	80	3	was	be	AUX
cuesj-1446	80	4	classified	classify	VERB
cuesj-1446	80	5	as	as	ADP
cuesj-1446	80	6	a	a	DET
cuesj-1446	80	7	biopharmaceutical	biopharmaceutical	ADJ
cuesj-1446	80	8	classification	classification	NOUN
cuesj-1446	80	9	system	system	NOUN
cuesj-1446	80	10	(	(	PUNCT
cuesj-1446	80	11	bcs	bcs	NOUN
cuesj-1446	80	12	)	)	PUNCT
cuesj-1446	80	13	class	class	NOUN
cuesj-1446	80	14	i	i	PRON
cuesj-1446	80	15	drug	drug	NOUN
cuesj-1446	80	16	based	base	VERB
cuesj-1446	80	17	on	on	ADP
cuesj-1446	80	18	high	high	ADJ
cuesj-1446	80	19	solubility	solubility	NOUN
cuesj-1446	80	20	and	and	CCONJ
cuesj-1446	80	21	high	high	ADJ
cuesj-1446	80	22	permeability	permeability	NOUN
cuesj-1446	80	23	characteristics,[37	characteristics,[37	X
cuesj-1446	80	24	]	]	PUNCT
cuesj-1446	80	25	while	while	SCONJ
cuesj-1446	80	26	according	accord	VERB
cuesj-1446	80	27	to	to	ADP
cuesj-1446	80	28	the	the	DET
cuesj-1446	80	29	same	same	ADJ
cuesj-1446	80	30	system	system	NOUN
cuesj-1446	80	31	(	(	PUNCT
cuesj-1446	80	32	bcs	bcs	NOUN
cuesj-1446	80	33	)	)	PUNCT
cuesj-1446	80	34	,	,	PUNCT
cuesj-1446	80	35	empagliflozin	empagliflozin	PROPN
cuesj-1446	80	36	is	be	AUX
cuesj-1446	80	37	a	a	DET
cuesj-1446	80	38	class	class	NOUN
cuesj-1446	80	39	iii	iii	NUM
cuesj-1446	80	40	drug	drug	NOUN
cuesj-1446	80	41	,	,	PUNCT
cuesj-1446	80	42	which	which	PRON
cuesj-1446	80	43	has	have	VERB
cuesj-1446	80	44	high	high	ADJ
cuesj-1446	80	45	solubility	solubility	NOUN
cuesj-1446	80	46	but	but	CCONJ
cuesj-1446	80	47	low	low	ADJ
cuesj-1446	80	48	permeability.[38	permeability.[38	NOUN
cuesj-1446	80	49	]	]	PUNCT
cuesj-1446	80	50	this	this	DET
cuesj-1446	80	51	point	point	NOUN
cuesj-1446	80	52	makes	make	VERB
cuesj-1446	80	53	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	80	54	have	have	VERB
cuesj-1446	80	55	higher	high	ADJ
cuesj-1446	80	56	oral	oral	ADJ
cuesj-1446	80	57	bioavailability	bioavailability	NOUN
cuesj-1446	80	58	,	,	PUNCT
cuesj-1446	80	59	which	which	PRON
cuesj-1446	80	60	is	be	AUX
cuesj-1446	80	61	69	69	NUM
cuesj-1446	80	62	%	%	NOUN
cuesj-1446	80	63	in	in	ADP
cuesj-1446	80	64	rats,[39	rats,[39	NOUN
cuesj-1446	80	65	]	]	PUNCT
cuesj-1446	80	66	whereas	whereas	SCONJ
cuesj-1446	80	67	only	only	ADV
cuesj-1446	80	68	31	31	NUM
cuesj-1446	80	69	%	%	NOUN
cuesj-1446	80	70	for	for	ADP
cuesj-1446	80	71	empagliflozin.[40	empagliflozin.[40	NOUN
cuesj-1446	80	72	]	]	PUNCT
cuesj-1446	80	73	another	another	DET
cuesj-1446	80	74	influencing	influence	VERB
cuesj-1446	80	75	factor	factor	NOUN
cuesj-1446	80	76	apart	apart	ADV
cuesj-1446	80	77	from	from	ADP
cuesj-1446	80	78	their	their	PRON
cuesj-1446	80	79	anti	anti	ADJ
cuesj-1446	80	80	-	-	ADJ
cuesj-1446	80	81	inflammatory	inflammatory	ADJ
cuesj-1446	80	82	effects	effect	NOUN
cuesj-1446	80	83	that	that	PRON
cuesj-1446	80	84	most	most	ADV
cuesj-1446	80	85	likely	likely	ADV
cuesj-1446	80	86	contributed	contribute	VERB
cuesj-1446	80	87	to	to	ADP
cuesj-1446	80	88	the	the	DET
cuesj-1446	80	89	mild	mild	ADJ
cuesj-1446	80	90	hyperplasia	hyperplasia	NOUN
cuesj-1446	80	91	seen	see	VERB
cuesj-1446	80	92	following	follow	VERB
cuesj-1446	80	93	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	80	94	in	in	ADP
cuesj-1446	80	95	contrast	contrast	NOUN
cuesj-1446	80	96	to	to	ADP
cuesj-1446	80	97	mild	mild	ADJ
cuesj-1446	80	98	–	–	PUNCT
cuesj-1446	80	99	moderate	moderate	ADJ
cuesj-1446	80	100	hyperplasia	hyperplasia	NOUN
cuesj-1446	80	101	observed	observe	VERB
cuesj-1446	80	102	with	with	ADP
cuesj-1446	80	103	empagliflozin	empagliflozin	PROPN
cuesj-1446	80	104	in	in	ADP
cuesj-1446	80	105	this	this	DET
cuesj-1446	80	106	study	study	NOUN
cuesj-1446	80	107	is	be	AUX
cuesj-1446	80	108	related	relate	VERB
cuesj-1446	80	109	to	to	ADP
cuesj-1446	80	110	differences	difference	NOUN
cuesj-1446	80	111	in	in	ADP
cuesj-1446	80	112	their	their	PRON
cuesj-1446	80	113	affinity	affinity	NOUN
cuesj-1446	80	114	to	to	PART
cuesj-1446	80	115	inhibit	inhibit	VERB
cuesj-1446	80	116	sglt	sglt	ADJ
cuesj-1446	80	117	transporters	transporter	NOUN
cuesj-1446	80	118	.	.	PUNCT
cuesj-1446	81	1	it	it	PRON
cuesj-1446	81	2	was	be	AUX
cuesj-1446	81	3	demonstrated	demonstrate	VERB
cuesj-1446	81	4	that	that	SCONJ
cuesj-1446	81	5	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	81	6	is	be	AUX
cuesj-1446	81	7	more	more	ADV
cuesj-1446	81	8	selective	selective	ADJ
cuesj-1446	81	9	to	to	ADP
cuesj-1446	81	10	sglt1	sglt1	NOUN
cuesj-1446	81	11	inhibition	inhibition	NOUN
cuesj-1446	81	12	than	than	ADP
cuesj-1446	81	13	empagliflozin,[39	empagliflozin,[39	NOUN
cuesj-1446	81	14	]	]	PUNCT
cuesj-1446	81	15	which	which	PRON
cuesj-1446	81	16	is	be	AUX
cuesj-1446	81	17	upregulated	upregulate	VERB
cuesj-1446	81	18	in	in	ADP
cuesj-1446	81	19	prostatic	prostatic	ADJ
cuesj-1446	81	20	diseases	disease	NOUN
cuesj-1446	81	21	such	such	ADJ
cuesj-1446	81	22	as	as	ADP
cuesj-1446	81	23	bph.[41	bph.[41	NOUN
cuesj-1446	81	24	]	]	X
cuesj-1446	81	25	it	it	PRON
cuesj-1446	81	26	is	be	AUX
cuesj-1446	81	27	also	also	ADV
cuesj-1446	81	28	worth	worth	ADJ
cuesj-1446	81	29	noting	note	VERB
cuesj-1446	81	30	that	that	SCONJ
cuesj-1446	81	31	the	the	DET
cuesj-1446	81	32	limitations	limitation	NOUN
cuesj-1446	81	33	of	of	ADP
cuesj-1446	81	34	this	this	DET
cuesj-1446	81	35	study	study	NOUN
cuesj-1446	81	36	are	be	AUX
cuesj-1446	81	37	the	the	DET
cuesj-1446	81	38	number	number	NOUN
cuesj-1446	81	39	of	of	ADP
cuesj-1446	81	40	rats	rat	NOUN
cuesj-1446	81	41	.	.	PUNCT
cuesj-1446	82	1	however	however	ADV
cuesj-1446	82	2	,	,	PUNCT
cuesj-1446	82	3	utilizing	utilize	VERB
cuesj-1446	82	4	animal	animal	NOUN
cuesj-1446	82	5	models	model	NOUN
cuesj-1446	82	6	is	be	AUX
cuesj-1446	82	7	found	find	VERB
cuesj-1446	82	8	to	to	PART
cuesj-1446	82	9	mimic	mimic	VERB
cuesj-1446	82	10	human	human	ADJ
cuesj-1446	82	11	disease	disease	NOUN
cuesj-1446	82	12	and	and	CCONJ
cuesj-1446	82	13	is	be	AUX
cuesj-1446	82	14	cost	cost	NOUN
cuesj-1446	82	15	-	-	PUNCT
cuesj-1446	82	16	effective	effective	ADJ
cuesj-1446	82	17	,	,	PUNCT
cuesj-1446	82	18	although	although	SCONJ
cuesj-1446	82	19	it	it	PRON
cuesj-1446	82	20	requires	require	VERB
cuesj-1446	82	21	testing	test	VERB
cuesj-1446	82	22	in	in	ADP
cuesj-1446	82	23	clinical	clinical	ADJ
cuesj-1446	82	24	settings	setting	NOUN
cuesj-1446	82	25	for	for	ADP
cuesj-1446	82	26	high	high	ADJ
cuesj-1446	82	27	reproducibility	reproducibility	NOUN
cuesj-1446	82	28	to	to	PART
cuesj-1446	82	29	validate	validate	VERB
cuesj-1446	82	30	the	the	DET
cuesj-1446	82	31	effectiveness	effectiveness	NOUN
cuesj-1446	82	32	and	and	CCONJ
cuesj-1446	82	33	safety	safety	NOUN
cuesj-1446	82	34	of	of	ADP
cuesj-1446	82	35	sglt2	sglt2	ADJ
cuesj-1446	82	36	inhibitors	inhibitor	NOUN
cuesj-1446	82	37	in	in	ADP
cuesj-1446	82	38	the	the	DET
cuesj-1446	82	39	therapy	therapy	NOUN
cuesj-1446	82	40	of	of	ADP
cuesj-1446	82	41	bph	bph	NOUN
cuesj-1446	82	42	in	in	ADP
cuesj-1446	82	43	human	human	ADJ
cuesj-1446	82	44	subjects	subject	NOUN
cuesj-1446	82	45	.	.	PUNCT
cuesj-1446	83	1	conclusion	conclusion	NOUN
cuesj-1446	83	2	the	the	DET
cuesj-1446	83	3	present	present	ADJ
cuesj-1446	83	4	study	study	NOUN
cuesj-1446	83	5	’s	’s	PART
cuesj-1446	83	6	findings	finding	NOUN
cuesj-1446	83	7	indicate	indicate	VERB
cuesj-1446	83	8	oral	oral	ADJ
cuesj-1446	83	9	administration	administration	NOUN
cuesj-1446	83	10	of	of	ADP
cuesj-1446	83	11	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	83	12	and	and	CCONJ
cuesj-1446	83	13	empagliflozin	empagliflozin	PROPN
cuesj-1446	83	14	at	at	ADP
cuesj-1446	83	15	a	a	DET
cuesj-1446	83	16	dosage	dosage	NOUN
cuesj-1446	83	17	of	of	ADP
cuesj-1446	83	18	10	10	NUM
cuesj-1446	83	19	mg	mg	NUM
cuesj-1446	83	20	/	/	SYM
cuesj-1446	83	21	kg	kg	NOUN
cuesj-1446	83	22	significantly	significantly	ADV
cuesj-1446	83	23	reduced	reduce	VERB
cuesj-1446	83	24	the	the	DET
cuesj-1446	83	25	progression	progression	NOUN
cuesj-1446	83	26	of	of	ADP
cuesj-1446	83	27	bph	bph	NOUN
cuesj-1446	83	28	by	by	ADP
cuesj-1446	83	29	79.2	79.2	NUM
cuesj-1446	83	30	%	%	NOUN
cuesj-1446	83	31	and	and	CCONJ
cuesj-1446	83	32	76.1	76.1	NUM
cuesj-1446	83	33	%	%	NOUN
cuesj-1446	83	34	,	,	PUNCT
cuesj-1446	83	35	respectively	respectively	ADV
cuesj-1446	83	36	,	,	PUNCT
cuesj-1446	83	37	as	as	SCONJ
cuesj-1446	83	38	demonstrated	demonstrate	VERB
cuesj-1446	83	39	by	by	ADP
cuesj-1446	83	40	decreased	decrease	VERB
cuesj-1446	83	41	pws	pws	NOUN
cuesj-1446	83	42	,	,	PUNCT
cuesj-1446	83	43	pi	pi	NOUN
cuesj-1446	83	44	,	,	PUNCT
cuesj-1446	83	45	serum	serum	NOUN
cuesj-1446	83	46	testosterone	testosterone	NOUN
cuesj-1446	83	47	levels	level	NOUN
cuesj-1446	83	48	,	,	PUNCT
cuesj-1446	83	49	and	and	CCONJ
cuesj-1446	83	50	marked	mark	VERB
cuesj-1446	83	51	improvement	improvement	NOUN
cuesj-1446	83	52	in	in	ADP
cuesj-1446	83	53	the	the	DET
cuesj-1446	83	54	histopathological	histopathological	ADJ
cuesj-1446	83	55	changes	change	NOUN
cuesj-1446	83	56	in	in	ADP
cuesj-1446	83	57	the	the	DET
cuesj-1446	83	58	prostate	prostate	NOUN
cuesj-1446	83	59	tissues	tissue	NOUN
cuesj-1446	83	60	of	of	ADP
cuesj-1446	83	61	testosterone	testosterone	NOUN
cuesj-1446	83	62	induced	induce	VERB
cuesj-1446	83	63	-	-	PUNCT
cuesj-1446	83	64	bph	bph	NOUN
cuesj-1446	83	65	rats	rat	NOUN
cuesj-1446	83	66	.	.	PUNCT
cuesj-1446	84	1	these	these	DET
cuesj-1446	84	2	findings	finding	NOUN
cuesj-1446	84	3	illustrate	illustrate	VERB
cuesj-1446	84	4	that	that	SCONJ
cuesj-1446	84	5	sglt2	sglt2	ADJ
cuesj-1446	84	6	inhibitors	inhibitor	NOUN
cuesj-1446	84	7	may	may	AUX
cuesj-1446	84	8	have	have	VERB
cuesj-1446	84	9	therapeutic	therapeutic	ADJ
cuesj-1446	84	10	advantages	advantage	NOUN
cuesj-1446	84	11	beyond	beyond	ADP
cuesj-1446	84	12	glycemic	glycemic	ADJ
cuesj-1446	84	13	management	management	NOUN
cuesj-1446	84	14	and	and	CCONJ
cuesj-1446	84	15	could	could	AUX
cuesj-1446	84	16	be	be	AUX
cuesj-1446	84	17	advantageous	advantageous	ADJ
cuesj-1446	84	18	in	in	ADP
cuesj-1446	84	19	the	the	DET
cuesj-1446	84	20	management	management	NOUN
cuesj-1446	84	21	of	of	ADP
cuesj-1446	84	22	both	both	DET
cuesj-1446	84	23	hyperglycemia	hyperglycemia	NOUN
cuesj-1446	84	24	and	and	CCONJ
cuesj-1446	84	25	bph	bph	NOUN
cuesj-1446	84	26	.	.	PUNCT
cuesj-1446	85	1	further	further	ADJ
cuesj-1446	85	2	studies	study	NOUN
cuesj-1446	85	3	are	be	AUX
cuesj-1446	85	4	required	require	VERB
cuesj-1446	85	5	to	to	PART
cuesj-1446	85	6	investigate	investigate	VERB
cuesj-1446	85	7	their	their	PRON
cuesj-1446	85	8	molecular	molecular	ADJ
cuesj-1446	85	9	role	role	NOUN
cuesj-1446	85	10	and	and	CCONJ
cuesj-1446	85	11	clinical	clinical	ADJ
cuesj-1446	85	12	significance	significance	NOUN
cuesj-1446	85	13	in	in	ADP
cuesj-1446	85	14	managing	manage	VERB
cuesj-1446	85	15	and	and	CCONJ
cuesj-1446	85	16	alleviating	alleviate	VERB
cuesj-1446	85	17	the	the	DET
cuesj-1446	85	18	progression	progression	NOUN
cuesj-1446	85	19	of	of	ADP
cuesj-1446	85	20	bph	bph	NOUN
cuesj-1446	85	21	in	in	ADP
cuesj-1446	85	22	the	the	DET
cuesj-1446	85	23	human	human	ADJ
cuesj-1446	85	24	population	population	NOUN
cuesj-1446	85	25	.	.	PUNCT
cuesj-1446	86	1	furthermore	furthermore	ADV
cuesj-1446	86	2	,	,	PUNCT
cuesj-1446	86	3	the	the	DET
cuesj-1446	86	4	experiment	experiment	NOUN
cuesj-1446	86	5	was	be	AUX
cuesj-1446	86	6	performed	perform	VERB
cuesj-1446	86	7	over	over	ADP
cuesj-1446	86	8	a	a	DET
cuesj-1446	86	9	limited	limited	ADJ
cuesj-1446	86	10	timeframe	timeframe	NOUN
cuesj-1446	86	11	,	,	PUNCT
cuesj-1446	86	12	leaving	leave	VERB
cuesj-1446	86	13	long	long	ADJ
cuesj-1446	86	14	-	-	PUNCT
cuesj-1446	86	15	term	term	NOUN
cuesj-1446	86	16	consequences	consequence	NOUN
cuesj-1446	86	17	,	,	PUNCT
cuesj-1446	86	18	such	such	ADJ
cuesj-1446	86	19	as	as	ADP
cuesj-1446	86	20	hormonal	hormonal	ADJ
cuesj-1446	86	21	and	and	CCONJ
cuesj-1446	86	22	histological	histological	ADJ
cuesj-1446	86	23	alterations	alteration	NOUN
cuesj-1446	86	24	unknown	unknown	ADJ
cuesj-1446	86	25	.	.	PUNCT
cuesj-1446	87	1	subsequent	subsequent	ADJ
cuesj-1446	87	2	research	research	NOUN
cuesj-1446	87	3	should	should	AUX
cuesj-1446	87	4	incorporate	incorporate	VERB
cuesj-1446	87	5	prolonged	prolonged	ADJ
cuesj-1446	87	6	follow	follow	NOUN
cuesj-1446	87	7	-	-	PUNCT
cuesj-1446	87	8	up	up	ADP
cuesj-1446	87	9	periods	period	NOUN
cuesj-1446	87	10	to	to	PART
cuesj-1446	87	11	assess	assess	VERB
cuesj-1446	87	12	the	the	DET
cuesj-1446	87	13	long	long	ADJ
cuesj-1446	87	14	-	-	PUNCT
cuesj-1446	87	15	term	term	NOUN
cuesj-1446	87	16	effects	effect	NOUN
cuesj-1446	87	17	of	of	ADP
cuesj-1446	87	18	therapy	therapy	NOUN
cuesj-1446	87	19	.	.	PUNCT
cuesj-1446	88	1	references	reference	NOUN
cuesj-1446	88	2	1	1	NUM
cuesj-1446	88	3	.	.	PUNCT
cuesj-1446	88	4	gbd	gbd	NOUN
cuesj-1446	88	5	2019	2019	NUM
cuesj-1446	88	6	benign	benign	ADJ
cuesj-1446	88	7	prostatic	prostatic	ADJ
cuesj-1446	88	8	hyperplasia	hyperplasia	NOUN
cuesj-1446	88	9	collaborators	collaborator	NOUN
cuesj-1446	88	10	.	.	PUNCT
cuesj-1446	89	1	the	the	DET
cuesj-1446	89	2	global	global	ADJ
cuesj-1446	89	3	,	,	PUNCT
cuesj-1446	89	4	regional	regional	ADJ
cuesj-1446	89	5	,	,	PUNCT
cuesj-1446	89	6	and	and	CCONJ
cuesj-1446	89	7	national	national	ADJ
cuesj-1446	89	8	burden	burden	NOUN
cuesj-1446	89	9	of	of	ADP
cuesj-1446	89	10	benign	benign	ADJ
cuesj-1446	89	11	prostatic	prostatic	ADJ
cuesj-1446	89	12	hyperplasia	hyperplasia	NOUN
cuesj-1446	89	13	in	in	ADP
cuesj-1446	89	14	204	204	NUM
cuesj-1446	89	15	countries	country	NOUN
cuesj-1446	89	16	and	and	CCONJ
cuesj-1446	89	17	territories	territory	NOUN
cuesj-1446	89	18	from	from	ADP
cuesj-1446	89	19	2000	2000	NUM
cuesj-1446	89	20	to	to	ADP
cuesj-1446	89	21	2019	2019	NUM
cuesj-1446	89	22	:	:	PUNCT
cuesj-1446	89	23	a	a	DET
cuesj-1446	89	24	systematic	systematic	ADJ
cuesj-1446	89	25	analysis	analysis	NOUN
cuesj-1446	89	26	for	for	ADP
cuesj-1446	89	27	the	the	DET
cuesj-1446	89	28	global	global	ADJ
cuesj-1446	89	29	burden	burden	NOUN
cuesj-1446	89	30	of	of	ADP
cuesj-1446	89	31	disease	disease	NOUN
cuesj-1446	89	32	study	study	NOUN
cuesj-1446	89	33	2019	2019	NUM
cuesj-1446	89	34	.	.	PUNCT
cuesj-1446	90	1	lancet	lancet	VERB
cuesj-1446	90	2	healthy	healthy	ADJ
cuesj-1446	90	3	longevity	longevity	NOUN
cuesj-1446	90	4	,	,	PUNCT
cuesj-1446	90	5	vol	vol	NOUN
cuesj-1446	90	6	.	.	PROPN
cuesj-1446	91	1	3	3	NUM
cuesj-1446	91	2	,	,	PUNCT
cuesj-1446	91	3	no	no	INTJ
cuesj-1446	91	4	.	.	NOUN
cuesj-1446	91	5	11	11	NUM
cuesj-1446	91	6	,	,	PUNCT
cuesj-1446	91	7	pp	pp	ADJ
cuesj-1446	91	8	.	.	PUNCT
cuesj-1446	92	1	e754	e754	PROPN
cuesj-1446	92	2	-	-	PUNCT
cuesj-1446	92	3	e776	e776	PROPN
cuesj-1446	92	4	,	,	PUNCT
cuesj-1446	92	5	2022	2022	NUM
cuesj-1446	92	6	.	.	PUNCT
cuesj-1446	93	1	2	2	X
cuesj-1446	93	2	.	.	X
cuesj-1446	93	3	c.	c.	PROPN
cuesj-1446	93	4	g.	g.	PROPN
cuesj-1446	93	5	roehrborn	roehrborn	PROPN
cuesj-1446	93	6	.	.	PUNCT
cuesj-1446	94	1	pathology	pathology	NOUN
cuesj-1446	94	2	of	of	ADP
cuesj-1446	94	3	benign	benign	ADJ
cuesj-1446	94	4	prostatic	prostatic	ADJ
cuesj-1446	94	5	hyperplasia	hyperplasia	NOUN
cuesj-1446	94	6	.	.	PUNCT
cuesj-1446	95	1	international	international	ADJ
cuesj-1446	95	2	journal	journal	PROPN
cuesj-1446	95	3	impotence	impotence	NOUN
cuesj-1446	95	4	research	research	NOUN
cuesj-1446	95	5	,	,	PUNCT
cuesj-1446	95	6	vol	vol	NOUN
cuesj-1446	95	7	.	.	PROPN
cuesj-1446	95	8	20	20	NUM
cuesj-1446	95	9	,	,	PUNCT
cuesj-1446	95	10	no	no	INTJ
cuesj-1446	95	11	.	.	PUNCT
cuesj-1446	96	1	s3	s3	PROPN
cuesj-1446	96	2	,	,	PUNCT
cuesj-1446	96	3	pp	pp	PROPN
cuesj-1446	96	4	.	.	PUNCT
cuesj-1446	97	1	s11	s11	NOUN
cuesj-1446	97	2	-	-	PUNCT
cuesj-1446	97	3	s18	s18	PROPN
cuesj-1446	97	4	,	,	PUNCT
cuesj-1446	97	5	2008	2008	NUM
cuesj-1446	97	6	.	.	PUNCT
cuesj-1446	98	1	3	3	X
cuesj-1446	98	2	.	.	PUNCT
cuesj-1446	98	3	j.	j.	PROPN
cuesj-1446	98	4	li	li	PROPN
cuesj-1446	98	5	,	,	PUNCT
cuesj-1446	98	6	y.	y.	PROPN
cuesj-1446	98	7	li	li	PROPN
cuesj-1446	98	8	,	,	PUNCT
cuesj-1446	98	9	d.	d.	PROPN
cuesj-1446	98	10	cao	cao	PROPN
cuesj-1446	98	11	,	,	PUNCT
cuesj-1446	98	12	y.	y.	PROPN
cuesj-1446	98	13	huang	huang	PROPN
cuesj-1446	98	14	,	,	PUNCT
cuesj-1446	98	15	l.	l.	PROPN
cuesj-1446	98	16	peng	peng	PROPN
cuesj-1446	98	17	,	,	PUNCT
cuesj-1446	98	18	c.	c.	PROPN
cuesj-1446	98	19	meng	meng	PROPN
cuesj-1446	98	20	and	and	CCONJ
cuesj-1446	98	21	q.	q.	PROPN
cuesj-1446	98	22	wei	wei	PROPN
cuesj-1446	98	23	.	.	PUNCT
cuesj-1446	99	1	the	the	DET
cuesj-1446	99	2	association	association	NOUN
cuesj-1446	99	3	between	between	ADP
cuesj-1446	99	4	histological	histological	ADJ
cuesj-1446	99	5	prostatitis	prostatitis	NOUN
cuesj-1446	99	6	and	and	CCONJ
cuesj-1446	99	7	benign	benign	ADJ
cuesj-1446	99	8	prostatic	prostatic	ADJ
cuesj-1446	99	9	hyperplasia	hyperplasia	NOUN
cuesj-1446	99	10	:	:	PUNCT
cuesj-1446	99	11	a	a	DET
cuesj-1446	99	12	single	single	ADJ
cuesj-1446	99	13	-	-	PUNCT
cuesj-1446	99	14	center	center	NOUN
cuesj-1446	99	15	retrospective	retrospective	ADJ
cuesj-1446	99	16	study	study	NOUN
cuesj-1446	99	17	.	.	PUNCT
cuesj-1446	100	1	aging	age	VERB
cuesj-1446	100	2	male	male	NOUN
cuesj-1446	100	3	,	,	PUNCT
cuesj-1446	100	4	vol	vol	NOUN
cuesj-1446	100	5	.	.	PROPN
cuesj-1446	100	6	25	25	NUM
cuesj-1446	100	7	,	,	PUNCT
cuesj-1446	100	8	no	no	INTJ
cuesj-1446	100	9	.	.	NOUN
cuesj-1446	100	10	1	1	NUM
cuesj-1446	100	11	,	,	PUNCT
cuesj-1446	100	12	pp	pp	ADJ
cuesj-1446	100	13	.	.	PUNCT
cuesj-1446	101	1	88	88	NUM
cuesj-1446	101	2	-	-	SYM
cuesj-1446	101	3	93	93	NUM
cuesj-1446	101	4	,	,	PUNCT
cuesj-1446	101	5	2022	2022	NUM
cuesj-1446	101	6	.	.	PUNCT
cuesj-1446	102	1	4	4	X
cuesj-1446	102	2	.	.	X
cuesj-1446	102	3	m.	m.	NOUN
cuesj-1446	102	4	bishr	bishr	PROPN
cuesj-1446	102	5	,	,	PUNCT
cuesj-1446	102	6	k.	k.	PROPN
cuesj-1446	102	7	boehm	boehm	PROPN
cuesj-1446	102	8	,	,	PUNCT
cuesj-1446	102	9	v.	v.	ADP
cuesj-1446	102	10	trudeau	trudeau	NOUN
cuesj-1446	102	11	,	,	PUNCT
cuesj-1446	102	12	z.	z.	PROPN
cuesj-1446	102	13	tian	tian	PROPN
cuesj-1446	102	14	,	,	PUNCT
cuesj-1446	102	15	p.	p.	NOUN
cuesj-1446	102	16	dell’oglio	dell’oglio	NOUN
cuesj-1446	102	17	,	,	PUNCT
cuesj-1446	102	18	j.	j.	PROPN
cuesj-1446	102	19	schiffmann	schiffmann	PROPN
cuesj-1446	102	20	,	,	PUNCT
cuesj-1446	102	21	c.	c.	PROPN
cuesj-1446	102	22	jeldres	jeldres	PROPN
cuesj-1446	102	23	,	,	PUNCT
cuesj-1446	102	24	m.	m.	NOUN
cuesj-1446	102	25	sun	sun	PROPN
cuesj-1446	102	26	,	,	PUNCT
cuesj-1446	102	27	s.	s.	PROPN
cuesj-1446	102	28	f.	f.	PROPN
cuesj-1446	102	29	shariat	shariat	PROPN
cuesj-1446	102	30	,	,	PUNCT
cuesj-1446	102	31	m.	m.	NOUN
cuesj-1446	102	32	graefen	graefen	PROPN
cuesj-1446	102	33	,	,	PUNCT
cuesj-1446	102	34	f.	f.	PROPN
cuesj-1446	102	35	saad	saad	PROPN
cuesj-1446	102	36	and	and	CCONJ
cuesj-1446	102	37	p.	p.	PROPN
cuesj-1446	102	38	i.	i.	PROPN
cuesj-1446	102	39	karakiewicz	karakiewicz	PROPN
cuesj-1446	102	40	.	.	PUNCT
cuesj-1446	103	1	medical	medical	ADJ
cuesj-1446	103	2	management	management	NOUN
cuesj-1446	103	3	of	of	ADP
cuesj-1446	103	4	benign	benign	ADJ
cuesj-1446	103	5	prostatic	prostatic	ADJ
cuesj-1446	103	6	hyperplasia	hyperplasia	NOUN
cuesj-1446	103	7	:	:	PUNCT
cuesj-1446	103	8	results	result	VERB
cuesj-1446	103	9	from	from	ADP
cuesj-1446	103	10	a	a	DET
cuesj-1446	103	11	population	population	NOUN
cuesj-1446	103	12	-	-	PUNCT
cuesj-1446	103	13	based	base	VERB
cuesj-1446	103	14	study	study	NOUN
cuesj-1446	103	15	.	.	PUNCT
cuesj-1446	104	1	canadian	canadian	ADJ
cuesj-1446	104	2	urological	urological	PROPN
cuesj-1446	104	3	association	association	PROPN
cuesj-1446	104	4	journal	journal	PROPN
cuesj-1446	104	5	,	,	PUNCT
cuesj-1446	104	6	vol	vol	NOUN
cuesj-1446	104	7	.	.	PROPN
cuesj-1446	104	8	10	10	NUM
cuesj-1446	104	9	,	,	PUNCT
cuesj-1446	104	10	no	no	INTJ
cuesj-1446	104	11	.	.	NOUN
cuesj-1446	104	12	1	1	NUM
cuesj-1446	104	13	-	-	SYM
cuesj-1446	104	14	2	2	NUM
cuesj-1446	104	15	,	,	PUNCT
cuesj-1446	104	16	pp	pp	ADJ
cuesj-1446	104	17	.	.	PUNCT
cuesj-1446	105	1	55	55	NUM
cuesj-1446	105	2	-	-	SYM
cuesj-1446	105	3	9	9	NUM
cuesj-1446	105	4	,	,	PUNCT
cuesj-1446	105	5	2016	2016	NUM
cuesj-1446	105	6	.	.	PUNCT
cuesj-1446	106	1	5	5	NUM
cuesj-1446	106	2	.	.	PUNCT
cuesj-1446	106	3	h.	h.	PROPN
cuesj-1446	106	4	lepor	lepor	PROPN
cuesj-1446	106	5	.	.	PUNCT
cuesj-1446	107	1	medical	medical	ADJ
cuesj-1446	107	2	treatment	treatment	NOUN
cuesj-1446	107	3	of	of	ADP
cuesj-1446	107	4	benign	benign	ADJ
cuesj-1446	107	5	prostatic	prostatic	ADJ
cuesj-1446	107	6	hyperplasia	hyperplasia	NOUN
cuesj-1446	107	7	.	.	PUNCT
cuesj-1446	108	1	reviews	review	NOUN
cuesj-1446	108	2	in	in	ADP
cuesj-1446	108	3	urology	urology	NOUN
cuesj-1446	108	4	,	,	PUNCT
cuesj-1446	108	5	vol	vol	NOUN
cuesj-1446	108	6	.	.	PROPN
cuesj-1446	108	7	13	13	NUM
cuesj-1446	108	8	,	,	PUNCT
cuesj-1446	108	9	no	no	INTJ
cuesj-1446	108	10	.	.	NOUN
cuesj-1446	108	11	1	1	NUM
cuesj-1446	108	12	,	,	PUNCT
cuesj-1446	108	13	pp	pp	ADJ
cuesj-1446	108	14	.	.	PUNCT
cuesj-1446	109	1	20	20	NUM
cuesj-1446	109	2	-	-	SYM
cuesj-1446	109	3	33	33	NUM
cuesj-1446	109	4	,	,	PUNCT
cuesj-1446	109	5	2011	2011	NUM
cuesj-1446	109	6	.	.	PUNCT
cuesj-1446	110	1	6	6	NUM
cuesj-1446	110	2	.	.	PUNCT
cuesj-1446	110	3	s.	s.	PROPN
cuesj-1446	110	4	paba	paba	PROPN
cuesj-1446	110	5	,	,	PUNCT
cuesj-1446	110	6	r.	r.	PROPN
cuesj-1446	110	7	frau	frau	PROPN
cuesj-1446	110	8	,	,	PUNCT
cuesj-1446	110	9	s.	s.	PROPN
cuesj-1446	110	10	c.	c.	PROPN
cuesj-1446	110	11	godar	godar	PROPN
cuesj-1446	110	12	,	,	PUNCT
cuesj-1446	110	13	p.	p.	PROPN
cuesj-1446	110	14	devoto	devoto	PROPN
cuesj-1446	110	15	,	,	PUNCT
cuesj-1446	110	16	f.	f.	PROPN
cuesj-1446	110	17	marrosu	marrosu	PROPN
cuesj-1446	110	18	and	and	CCONJ
cuesj-1446	110	19	m.	m.	NOUN
cuesj-1446	110	20	bortolato	bortolato	PROPN
cuesj-1446	110	21	.	.	PUNCT
cuesj-1446	111	1	steroid	steroid	PROPN
cuesj-1446	111	2	5α	5α	ADJ
cuesj-1446	111	3	-	-	PUNCT
cuesj-1446	111	4	reductase	reductase	NOUN
cuesj-1446	111	5	as	as	ADP
cuesj-1446	111	6	a	a	DET
cuesj-1446	111	7	novel	novel	ADJ
cuesj-1446	111	8	therapeutic	therapeutic	ADJ
cuesj-1446	111	9	target	target	NOUN
cuesj-1446	111	10	for	for	ADP
cuesj-1446	111	11	schizophrenia	schizophrenia	NOUN
cuesj-1446	111	12	and	and	CCONJ
cuesj-1446	111	13	other	other	ADJ
cuesj-1446	111	14	neuropsychiatric	neuropsychiatric	ADJ
cuesj-1446	111	15	disorders	disorder	NOUN
cuesj-1446	111	16	.	.	PUNCT
cuesj-1446	112	1	current	current	ADJ
cuesj-1446	112	2	pharmaceutical	pharmaceutical	ADJ
cuesj-1446	112	3	design	design	NOUN
cuesj-1446	112	4	,	,	PUNCT
cuesj-1446	112	5	vol	vol	NOUN
cuesj-1446	112	6	.	.	PROPN
cuesj-1446	112	7	17	17	NUM
cuesj-1446	112	8	,	,	PUNCT
cuesj-1446	112	9	no	no	INTJ
cuesj-1446	112	10	.	.	NOUN
cuesj-1446	112	11	2	2	NUM
cuesj-1446	112	12	,	,	PUNCT
cuesj-1446	112	13	pp	pp	ADJ
cuesj-1446	112	14	.	.	PUNCT
cuesj-1446	113	1	151	151	NUM
cuesj-1446	113	2	-	-	SYM
cuesj-1446	113	3	167	167	NUM
cuesj-1446	113	4	,	,	PUNCT
cuesj-1446	113	5	2011	2011	NUM
cuesj-1446	113	6	.	.	PUNCT
cuesj-1446	114	1	7	7	X
cuesj-1446	114	2	.	.	X
cuesj-1446	114	3	american	american	ADJ
cuesj-1446	114	4	diabetes	diabetes	PROPN
cuesj-1446	114	5	association	association	PROPN
cuesj-1446	114	6	professional	professional	PROPN
cuesj-1446	114	7	practice	practice	NOUN
cuesj-1446	114	8	committee	committee	NOUN
cuesj-1446	114	9	.	.	PUNCT
cuesj-1446	115	1	9	9	X
cuesj-1446	115	2	.	.	X
cuesj-1446	115	3	pharmacologic	pharmacologic	ADJ
cuesj-1446	115	4	approaches	approach	NOUN
cuesj-1446	115	5	to	to	ADP
cuesj-1446	115	6	glycemic	glycemic	ADJ
cuesj-1446	115	7	treatment	treatment	NOUN
cuesj-1446	115	8	:	:	PUNCT
cuesj-1446	115	9	standards	standard	NOUN
cuesj-1446	115	10	of	of	ADP
cuesj-1446	115	11	medical	medical	ADJ
cuesj-1446	115	12	care	care	NOUN
cuesj-1446	115	13	in	in	ADP
cuesj-1446	115	14	diabetes-2022	diabetes-2022	NOUN
cuesj-1446	115	15	.	.	PUNCT
cuesj-1446	116	1	diabetes	diabetes	NOUN
cuesj-1446	116	2	care	care	NOUN
cuesj-1446	116	3	,	,	PUNCT
cuesj-1446	116	4	vol	vol	NOUN
cuesj-1446	116	5	.	.	PROPN
cuesj-1446	117	1	45	45	NUM
cuesj-1446	117	2	,	,	PUNCT
cuesj-1446	117	3	no	no	INTJ
cuesj-1446	117	4	.	.	PUNCT
cuesj-1446	118	1	suppl	suppl	PROPN
cuesj-1446	118	2	1	1	NUM
cuesj-1446	118	3	,	,	PUNCT
cuesj-1446	118	4	pp	pp	ADJ
cuesj-1446	118	5	.	.	PUNCT
cuesj-1446	119	1	s125	s125	PROPN
cuesj-1446	119	2	-	-	PUNCT
cuesj-1446	119	3	s143	s143	PROPN
cuesj-1446	119	4	,	,	PUNCT
cuesj-1446	119	5	2022	2022	NUM
cuesj-1446	119	6	.	.	PUNCT
cuesj-1446	120	1	8	8	NUM
cuesj-1446	120	2	.	.	PUNCT
cuesj-1446	120	3	j.	j.	PROPN
cuesj-1446	120	4	a.	a.	PROPN
cuesj-1446	120	5	davidson	davidson	PROPN
cuesj-1446	120	6	and	and	CCONJ
cuesj-1446	120	7	l.	l.	PROPN
cuesj-1446	120	8	kuritzky	kuritzky	PROPN
cuesj-1446	120	9	.	.	PUNCT
cuesj-1446	121	1	sodium	sodium	NOUN
cuesj-1446	121	2	glucose	glucose	NOUN
cuesj-1446	121	3	co	co	NOUN
cuesj-1446	121	4	-	-	NOUN
cuesj-1446	121	5	transporter	transporter	ADJ
cuesj-1446	121	6	2	2	NUM
cuesj-1446	121	7	inhibitors	inhibitor	NOUN
cuesj-1446	121	8	and	and	CCONJ
cuesj-1446	121	9	their	their	PRON
cuesj-1446	121	10	mechanism	mechanism	NOUN
cuesj-1446	121	11	for	for	ADP
cuesj-1446	121	12	improving	improve	VERB
cuesj-1446	121	13	glycemia	glycemia	NOUN
cuesj-1446	121	14	in	in	ADP
cuesj-1446	121	15	patients	patient	NOUN
cuesj-1446	121	16	with	with	ADP
cuesj-1446	121	17	type	type	NOUN
cuesj-1446	121	18	2	2	NUM
cuesj-1446	121	19	diabetes	diabetes	NOUN
cuesj-1446	121	20	.	.	PUNCT
cuesj-1446	122	1	postgraduate	postgraduate	NOUN
cuesj-1446	122	2	.	.	PUNCT
cuesj-1446	123	1	medicine	medicine	NOUN
cuesj-1446	123	2	,	,	PUNCT
cuesj-1446	123	3	vol	vol	NOUN
cuesj-1446	123	4	.	.	PROPN
cuesj-1446	123	5	126	126	NUM
cuesj-1446	123	6	,	,	PUNCT
cuesj-1446	123	7	no	no	INTJ
cuesj-1446	123	8	.	.	NOUN
cuesj-1446	123	9	6	6	NUM
cuesj-1446	123	10	,	,	PUNCT
cuesj-1446	123	11	pp	pp	ADJ
cuesj-1446	123	12	.	.	PUNCT
cuesj-1446	124	1	33	33	NUM
cuesj-1446	124	2	-	-	SYM
cuesj-1446	124	3	48	48	NUM
cuesj-1446	124	4	,	,	PUNCT
cuesj-1446	124	5	2014	2014	NUM
cuesj-1446	124	6	.	.	PUNCT
cuesj-1446	125	1	9	9	NUM
cuesj-1446	125	2	.	.	PUNCT
cuesj-1446	125	3	t.	t.	PROPN
cuesj-1446	125	4	a.	a.	PROPN
cuesj-1446	125	5	zelniker	zelniker	PROPN
cuesj-1446	125	6	,	,	PUNCT
cuesj-1446	125	7	s.	s.	PROPN
cuesj-1446	125	8	d.	d.	PROPN
cuesj-1446	125	9	wiviott	wiviott	PROPN
cuesj-1446	125	10	,	,	PUNCT
cuesj-1446	125	11	i.	i.	PROPN
cuesj-1446	125	12	raz	raz	PROPN
cuesj-1446	125	13	,	,	PUNCT
cuesj-1446	125	14	k.	k.	PROPN
cuesj-1446	126	1	i	i	PRON
cuesj-1446	126	2	m	m	PROPN
cuesj-1446	126	3	,	,	PUNCT
cuesj-1446	126	4	e.	e.	PROPN
cuesj-1446	126	5	l.	l.	PROPN
cuesj-1446	126	6	goodrich	goodrich	PROPN
cuesj-1446	126	7	,	,	PUNCT
cuesj-1446	126	8	m.	m.	NOUN
cuesj-1446	126	9	p.	p.	PROPN
cuesj-1446	126	10	bonaca	bonaca	PROPN
cuesj-1446	126	11	,	,	PUNCT
cuesj-1446	126	12	o.	o.	PROPN
cuesj-1446	126	13	mosenzon	mosenzon	PROPN
cuesj-1446	126	14	,	,	PUNCT
cuesj-1446	126	15	e.	e.	PROPN
cuesj-1446	126	16	t.	t.	PROPN
cuesj-1446	126	17	kato	kato	PROPN
cuesj-1446	126	18	,	,	PUNCT
cuesj-1446	126	19	a.	a.	NOUN
cuesj-1446	126	20	cahn	cahn	PROPN
cuesj-1446	126	21	,	,	PUNCT
cuesj-1446	126	22	r.	r.	PROPN
cuesj-1446	126	23	h.	h.	PROPN
cuesj-1446	126	24	m.	m.	PROPN
cuesj-1446	126	25	furtado	furtado	PROPN
cuesj-1446	126	26	,	,	PUNCT
cuesj-1446	126	27	d.	d.	PROPN
cuesj-1446	126	28	l.	l.	PROPN
cuesj-1446	126	29	bhatt	bhatt	PROPN
cuesj-1446	126	30	,	,	PUNCT
cuesj-1446	126	31	l.	l.	PROPN
cuesj-1446	126	32	a.	a.	PROPN
cuesj-1446	126	33	leiter	leiter	PROPN
cuesj-1446	126	34	,	,	PUNCT
cuesj-1446	126	35	d.	d.	PROPN
cuesj-1446	126	36	k.	k.	PROPN
cuesj-1446	126	37	mcguire	mcguire	PROPN
cuesj-1446	126	38	,	,	PUNCT
cuesj-1446	126	39	j.	j.	PROPN
cuesj-1446	126	40	p.	p.	PROPN
cuesj-1446	126	41	h.	h.	PROPN
cuesj-1446	126	42	wilding	wilding	NOUN
cuesj-1446	126	43	and	and	CCONJ
cuesj-1446	126	44	m.	m.	NOUN
cuesj-1446	126	45	s.	s.	PROPN
cuesj-1446	126	46	sabatine	sabatine	PROPN
cuesj-1446	126	47	.	.	PUNCT
cuesj-1446	127	1	sglt2	sglt2	PROPN
cuesj-1446	127	2	inhibitors	inhibitor	NOUN
cuesj-1446	127	3	for	for	ADP
cuesj-1446	127	4	primary	primary	ADJ
cuesj-1446	127	5	and	and	CCONJ
cuesj-1446	127	6	secondary	secondary	ADJ
cuesj-1446	127	7	prevention	prevention	NOUN
cuesj-1446	127	8	of	of	ADP
cuesj-1446	127	9	cardiovascular	cardiovascular	ADJ
cuesj-1446	127	10	and	and	CCONJ
cuesj-1446	127	11	renal	renal	ADJ
cuesj-1446	127	12	outcomes	outcome	NOUN
cuesj-1446	127	13	in	in	ADP
cuesj-1446	127	14	type	type	NOUN
cuesj-1446	127	15	2	2	NUM
cuesj-1446	127	16	diabetes	diabetes	NOUN
cuesj-1446	127	17	:	:	PUNCT
cuesj-1446	127	18	a	a	DET
cuesj-1446	127	19	systematic	systematic	ADJ
cuesj-1446	127	20	review	review	NOUN
cuesj-1446	127	21	and	and	CCONJ
cuesj-1446	127	22	meta	meta	NOUN
cuesj-1446	127	23	-	-	PUNCT
cuesj-1446	127	24	analysis	analysis	NOUN
cuesj-1446	127	25	of	of	ADP
cuesj-1446	127	26	cardiovascular	cardiovascular	ADJ
cuesj-1446	127	27	outcome	outcome	NOUN
cuesj-1446	127	28	trials	trial	NOUN
cuesj-1446	127	29	.	.	PUNCT
cuesj-1446	128	1	the	the	DET
cuesj-1446	128	2	lancet	lancet	PROPN
cuesj-1446	128	3	,	,	PUNCT
cuesj-1446	128	4	vol	vol	NOUN
cuesj-1446	128	5	.	.	PROPN
cuesj-1446	128	6	393	393	NUM
cuesj-1446	128	7	,	,	PUNCT
cuesj-1446	128	8	no	no	NOUN
cuesj-1446	128	9	.	.	NOUN
cuesj-1446	128	10	10166	10166	NUM
cuesj-1446	128	11	,	,	PUNCT
cuesj-1446	128	12	pp	pp	ADJ
cuesj-1446	128	13	.	.	PUNCT
cuesj-1446	129	1	31	31	NUM
cuesj-1446	129	2	-	-	SYM
cuesj-1446	129	3	39	39	NUM
cuesj-1446	129	4	,	,	PUNCT
cuesj-1446	129	5	2019	2019	NUM
cuesj-1446	129	6	.	.	PUNCT
cuesj-1446	130	1	10	10	NUM
cuesj-1446	130	2	.	.	PUNCT
cuesj-1446	130	3	l.	l.	PROPN
cuesj-1446	130	4	monzo	monzo	PROPN
cuesj-1446	130	5	,	,	PUNCT
cuesj-1446	130	6	i.	i.	PROPN
cuesj-1446	130	7	ferrari	ferrari	PROPN
cuesj-1446	130	8	,	,	PUNCT
cuesj-1446	130	9	f.	f.	PROPN
cuesj-1446	130	10	cicogna	cicogna	PROPN
cuesj-1446	130	11	,	,	PUNCT
cuesj-1446	130	12	c.	c.	PROPN
cuesj-1446	130	13	tota	tota	PROPN
cuesj-1446	130	14	and	and	CCONJ
cuesj-1446	130	15	l.	l.	PROPN
cuesj-1446	130	16	calò	calò	PROPN
cuesj-1446	130	17	.	.	PUNCT
cuesj-1446	131	1	sodiumglucose	sodiumglucose	VERB
cuesj-1446	131	2	co	co	NOUN
cuesj-1446	131	3	-	-	NOUN
cuesj-1446	131	4	transporter-2	transporter-2	DET
cuesj-1446	131	5	inhibitors	inhibitor	NOUN
cuesj-1446	131	6	eligibility	eligibility	NOUN
cuesj-1446	131	7	in	in	ADP
cuesj-1446	131	8	patients	patient	NOUN
cuesj-1446	131	9	with	with	ADP
cuesj-1446	131	10	heart	heart	NOUN
cuesj-1446	131	11	failure	failure	NOUN
cuesj-1446	131	12	with	with	ADP
cuesj-1446	131	13	reduced	reduce	VERB
cuesj-1446	131	14	ejection	ejection	NOUN
cuesj-1446	131	15	fraction	fraction	NOUN
cuesj-1446	131	16	.	.	PUNCT
cuesj-1446	132	1	international	international	ADJ
cuesj-1446	132	2	journal	journal	PROPN
cuesj-1446	132	3	of	of	ADP
cuesj-1446	132	4	cardiology	cardiology	NOUN
cuesj-1446	132	5	,	,	PUNCT
cuesj-1446	132	6	vol	vol	NOUN
cuesj-1446	132	7	.	.	PROPN
cuesj-1446	132	8	341	341	NUM
cuesj-1446	132	9	,	,	PUNCT
cuesj-1446	132	10	pp	pp	ADJ
cuesj-1446	132	11	.	.	PUNCT
cuesj-1446	133	1	56	56	NUM
cuesj-1446	133	2	-	-	SYM
cuesj-1446	133	3	59	59	NUM
cuesj-1446	133	4	,	,	PUNCT
cuesj-1446	133	5	2021	2021	NUM
cuesj-1446	133	6	.	.	PUNCT
cuesj-1446	134	1	11	11	NUM
cuesj-1446	134	2	.	.	PUNCT
cuesj-1446	135	1	k.	k.	PROPN
cuesj-1446	135	2	cusi	cusi	PROPN
cuesj-1446	135	3	,	,	PUNCT
cuesj-1446	135	4	s.	s.	PROPN
cuesj-1446	135	5	isaacs	isaacs	PROPN
cuesj-1446	135	6	,	,	PUNCT
cuesj-1446	135	7	d.	d.	PROPN
cuesj-1446	135	8	barb	barb	PROPN
cuesj-1446	135	9	,	,	PUNCT
cuesj-1446	135	10	r.	r.	PROPN
cuesj-1446	135	11	basu	basu	PROPN
cuesj-1446	135	12	,	,	PUNCT
cuesj-1446	135	13	s.	s.	PROPN
cuesj-1446	135	14	caprio	caprio	PROPN
cuesj-1446	135	15	,	,	PUNCT
cuesj-1446	135	16	w.	w.	PROPN
cuesj-1446	135	17	t.	t.	PROPN
cuesj-1446	135	18	garvey	garvey	PROPN
cuesj-1446	135	19	,	,	PUNCT
cuesj-1446	135	20	s.	s.	PROPN
cuesj-1446	135	21	kashyap	kashyap	PROPN
cuesj-1446	135	22	,	,	PUNCT
cuesj-1446	135	23	j.	j.	PROPN
cuesj-1446	135	24	i.	i.	PROPN
cuesj-1446	135	25	mechanick	mechanick	PROPN
cuesj-1446	135	26	,	,	PUNCT
cuesj-1446	135	27	m.	m.	NOUN
cuesj-1446	135	28	mouzaki	mouzaki	NOUN
cuesj-1446	135	29	,	,	PUNCT
cuesj-1446	135	30	k.	k.	PROPN
cuesj-1446	135	31	nadolsky	nadolsky	PROPN
cuesj-1446	135	32	,	,	PUNCT
cuesj-1446	135	33	m.	m.	PROPN
cuesj-1446	135	34	e.	e.	PROPN
cuesj-1446	135	35	rinella	rinella	PROPN
cuesj-1446	135	36	,	,	PUNCT
cuesj-1446	135	37	m.	m.	PROPN
cuesj-1446	135	38	b.	b.	PROPN
cuesj-1446	135	39	vos	vos	PROPN
cuesj-1446	135	40	and	and	CCONJ
cuesj-1446	135	41	z.	z.	PROPN
cuesj-1446	135	42	younossi	younossi	PROPN
cuesj-1446	135	43	.	.	PUNCT
cuesj-1446	136	1	american	american	PROPN
cuesj-1446	136	2	association	association	PROPN
cuesj-1446	136	3	of	of	ADP
cuesj-1446	136	4	clinical	clinical	ADJ
cuesj-1446	136	5	endocrinology	endocrinology	NOUN
cuesj-1446	136	6	clinical	clinical	ADJ
cuesj-1446	136	7	practice	practice	NOUN
cuesj-1446	136	8	guideline	guideline	NOUN
cuesj-1446	136	9	for	for	ADP
cuesj-1446	136	10	the	the	DET
cuesj-1446	136	11	diagnosis	diagnosis	NOUN
cuesj-1446	136	12	and	and	CCONJ
cuesj-1446	136	13	management	management	NOUN
cuesj-1446	136	14	of	of	ADP
cuesj-1446	136	15	nonalcoholic	nonalcoholic	NOUN
cuesj-1446	136	16	fatty	fatty	NOUN
cuesj-1446	136	17	liver	liver	NOUN
cuesj-1446	136	18	disease	disease	NOUN
cuesj-1446	136	19	in	in	ADP
cuesj-1446	136	20	primary	primary	ADJ
cuesj-1446	136	21	care	care	NOUN
cuesj-1446	136	22	and	and	CCONJ
cuesj-1446	136	23	endocrinology	endocrinology	NOUN
cuesj-1446	136	24	clinical	clinical	ADJ
cuesj-1446	136	25	settings	setting	NOUN
cuesj-1446	136	26	:	:	PUNCT
cuesj-1446	136	27	co	co	VERB
cuesj-1446	136	28	-	-	VERB
cuesj-1446	136	29	sponsored	sponsor	VERB
cuesj-1446	136	30	by	by	ADP
cuesj-1446	136	31	the	the	DET
cuesj-1446	136	32	american	american	PROPN
cuesj-1446	136	33	association	association	PROPN
cuesj-1446	136	34	for	for	ADP
cuesj-1446	136	35	the	the	DET
cuesj-1446	136	36	study	study	NOUN
cuesj-1446	136	37	of	of	ADP
cuesj-1446	136	38	liver	liver	NOUN
cuesj-1446	136	39	diseases	disease	NOUN
cuesj-1446	136	40	(	(	PUNCT
cuesj-1446	136	41	aasld	aasld	NOUN
cuesj-1446	136	42	)	)	PUNCT
cuesj-1446	136	43	.	.	PUNCT
cuesj-1446	137	1	endocrine	endocrine	ADJ
cuesj-1446	137	2	practice	practice	NOUN
cuesj-1446	137	3	,	,	PUNCT
cuesj-1446	137	4	vol	vol	NOUN
cuesj-1446	137	5	.	.	PROPN
cuesj-1446	137	6	28	28	NUM
cuesj-1446	137	7	,	,	PUNCT
cuesj-1446	137	8	no	no	INTJ
cuesj-1446	137	9	.	.	NOUN
cuesj-1446	137	10	5	5	NUM
cuesj-1446	137	11	,	,	PUNCT
cuesj-1446	137	12	pp	pp	ADJ
cuesj-1446	137	13	.	.	PUNCT
cuesj-1446	138	1	528	528	NUM
cuesj-1446	138	2	-	-	SYM
cuesj-1446	138	3	562	562	NUM
cuesj-1446	138	4	,	,	PUNCT
cuesj-1446	138	5	2022	2022	NUM
cuesj-1446	138	6	.	.	PUNCT
cuesj-1446	139	1	12	12	NUM
cuesj-1446	139	2	.	.	PUNCT
cuesj-1446	140	1	p.	p.	NOUN
cuesj-1446	140	2	rossing	rossing	NOUN
cuesj-1446	140	3	,	,	PUNCT
cuesj-1446	140	4	m.	m.	NOUN
cuesj-1446	140	5	l.	l.	PROPN
cuesj-1446	140	6	caramori	caramori	PROPN
cuesj-1446	140	7	,	,	PUNCT
cuesj-1446	140	8	j.	j.	PROPN
cuesj-1446	140	9	c.	c.	PROPN
cuesj-1446	140	10	n.	n.	PROPN
cuesj-1446	140	11	chan	chan	PROPN
cuesj-1446	140	12	,	,	PUNCT
cuesj-1446	140	13	h.	h.	PROPN
cuesj-1446	140	14	j.	j.	PROPN
cuesj-1446	140	15	l.	l.	PROPN
cuesj-1446	140	16	heerspink	heerspink	PROPN
cuesj-1446	140	17	,	,	PUNCT
cuesj-1446	140	18	c.	c.	PROPN
cuesj-1446	140	19	hurst	hurst	PROPN
cuesj-1446	140	20	,	,	PUNCT
cuesj-1446	140	21	k.	k.	PROPN
cuesj-1446	140	22	khunti	khunti	PROPN
cuesj-1446	140	23	,	,	PUNCT
cuesj-1446	140	24	a.	a.	PROPN
cuesj-1446	140	25	liew	liew	PROPN
cuesj-1446	140	26	,	,	PUNCT
cuesj-1446	140	27	e.	e.	PROPN
cuesj-1446	140	28	d.	d.	PROPN
cuesj-1446	140	29	michos	michos	PROPN
cuesj-1446	140	30	,	,	PUNCT
cuesj-1446	140	31	s.	s.	PROPN
cuesj-1446	140	32	d.	d.	PROPN
cuesj-1446	140	33	navaneethan	navaneethan	PROPN
cuesj-1446	140	34	,	,	PUNCT
cuesj-1446	140	35	w.	w.	PROPN
cuesj-1446	140	36	a.	a.	NOUN
cuesj-1446	140	37	olowu	olowu	PROPN
cuesj-1446	140	38	,	,	PUNCT
cuesj-1446	140	39	t.	t.	PROPN
cuesj-1446	140	40	sadusky	sadusky	PROPN
cuesj-1446	140	41	,	,	PUNCT
cuesj-1446	140	42	n.	n.	PROPN
cuesj-1446	140	43	tandon	tandon	PROPN
cuesj-1446	140	44	,	,	PUNCT
cuesj-1446	140	45	k.	k.	PROPN
cuesj-1446	140	46	r.	r.	PROPN
cuesj-1446	140	47	tuttle	tuttle	PROPN
cuesj-1446	140	48	,	,	PUNCT
cuesj-1446	140	49	c.	c.	PROPN
cuesj-1446	140	50	wanner	wanner	PROPN
cuesj-1446	140	51	…	…	PUNCT
cuesj-1446	140	52	&	&	CCONJ
cuesj-1446	140	53	i.	i.	PROPN
cuesj-1446	140	54	h.	h.	PROPN
cuesj-1446	140	55	de	de	PROPN
cuesj-1446	140	56	boer	boer	PROPN
cuesj-1446	140	57	.	.	PUNCT
cuesj-1446	141	1	kdigo	kdigo	PROPN
cuesj-1446	141	2	2022	2022	NUM
cuesj-1446	141	3	clinical	clinical	ADJ
cuesj-1446	141	4	practice	practice	NOUN
cuesj-1446	141	5	guideline	guideline	NOUN
cuesj-1446	141	6	for	for	ADP
cuesj-1446	141	7	diabetes	diabetes	NOUN
cuesj-1446	141	8	management	management	NOUN
cuesj-1446	141	9	in	in	ADP
cuesj-1446	141	10	chronic	chronic	ADJ
cuesj-1446	141	11	kidney	kidney	NOUN
cuesj-1446	141	12	disease	disease	NOUN
cuesj-1446	141	13	.	.	PUNCT
cuesj-1446	142	1	kidney	kidney	PROPN
cuesj-1446	142	2	international	international	PROPN
cuesj-1446	142	3	,	,	PUNCT
cuesj-1446	142	4	khudhur	khudhur	PROPN
cuesj-1446	142	5	and	and	CCONJ
cuesj-1446	142	6	ali	ali	PROPN
cuesj-1446	142	7	:	:	PUNCT
cuesj-1446	142	8	impact	impact	NOUN
cuesj-1446	142	9	of	of	ADP
cuesj-1446	142	10	sglt2	sglt2	ADJ
cuesj-1446	142	11	inhibitors	inhibitor	NOUN
cuesj-1446	142	12	on	on	ADP
cuesj-1446	142	13	induced	induced	ADJ
cuesj-1446	142	14	benign	benign	ADJ
cuesj-1446	142	15	prostatic	prostatic	ADJ
cuesj-1446	142	16	hyperplasia	hyperplasia	NOUN
cuesj-1446	142	17	in	in	ADP
cuesj-1446	142	18	rats	rat	NOUN
cuesj-1446	142	19	6	6	NUM
cuesj-1446	142	20	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1446	142	21	cuesj	cuesj	NOUN
cuesj-1446	142	22	2025	2025	NUM
cuesj-1446	142	23	,	,	PUNCT
cuesj-1446	142	24	9	9	NUM
cuesj-1446	142	25	(	(	PUNCT
cuesj-1446	142	26	2	2	NUM
cuesj-1446	142	27	):	):	PUNCT
cuesj-1446	142	28	1	1	NUM
cuesj-1446	142	29	-	-	SYM
cuesj-1446	142	30	6	6	NUM
cuesj-1446	142	31	vol	vol	NOUN
cuesj-1446	142	32	.	.	PUNCT
cuesj-1446	143	1	102	102	NUM
cuesj-1446	143	2	,	,	PUNCT
cuesj-1446	143	3	no	no	INTJ
cuesj-1446	143	4	.	.	NOUN
cuesj-1446	143	5	5	5	NUM
cuesj-1446	143	6	,	,	PUNCT
cuesj-1446	143	7	pp	pp	ADJ
cuesj-1446	143	8	.	.	PUNCT
cuesj-1446	144	1	s1	s1	PROPN
cuesj-1446	144	2	-	-	PUNCT
cuesj-1446	144	3	s127	s127	PROPN
cuesj-1446	144	4	,	,	PUNCT
cuesj-1446	144	5	2022	2022	NUM
cuesj-1446	144	6	.	.	PUNCT
cuesj-1446	145	1	13	13	NUM
cuesj-1446	145	2	.	.	PUNCT
cuesj-1446	145	3	d.	d.	PROPN
cuesj-1446	145	4	basak	basak	PROPN
cuesj-1446	145	5	,	,	PUNCT
cuesj-1446	145	6	d.	d.	PROPN
cuesj-1446	145	7	gamez	gamez	PROPN
cuesj-1446	145	8	and	and	CCONJ
cuesj-1446	145	9	s.	s.	PROPN
cuesj-1446	145	10	deb	deb	PROPN
cuesj-1446	145	11	.	.	PUNCT
cuesj-1446	146	1	sglt2	sglt2	PROPN
cuesj-1446	146	2	inhibitors	inhibitor	NOUN
cuesj-1446	146	3	as	as	ADP
cuesj-1446	146	4	potential	potential	ADJ
cuesj-1446	146	5	anticancer	anticancer	NOUN
cuesj-1446	146	6	agents	agent	NOUN
cuesj-1446	146	7	.	.	PUNCT
cuesj-1446	147	1	biomedicines	biomedicine	NOUN
cuesj-1446	147	2	,	,	PUNCT
cuesj-1446	147	3	vol	vol	NOUN
cuesj-1446	147	4	.	.	PROPN
cuesj-1446	147	5	11	11	NUM
cuesj-1446	147	6	,	,	PUNCT
cuesj-1446	147	7	no	no	INTJ
cuesj-1446	147	8	.	.	NOUN
cuesj-1446	147	9	7	7	NUM
cuesj-1446	147	10	,	,	PUNCT
cuesj-1446	147	11	p.	p.	NOUN
cuesj-1446	147	12	1867	1867	NUM
cuesj-1446	147	13	,	,	PUNCT
cuesj-1446	147	14	2023	2023	NUM
cuesj-1446	147	15	.	.	PUNCT
cuesj-1446	148	1	14	14	NUM
cuesj-1446	148	2	.	.	PUNCT
cuesj-1446	149	1	c.	c.	PROPN
cuesj-1446	149	2	xin	xin	PROPN
cuesj-1446	149	3	,	,	PUNCT
cuesj-1446	149	4	h.	h.	PROPN
cuesj-1446	149	5	fan	fan	PROPN
cuesj-1446	149	6	,	,	PUNCT
cuesj-1446	149	7	j.	j.	PROPN
cuesj-1446	149	8	xie	xie	PROPN
cuesj-1446	149	9	,	,	PUNCT
cuesj-1446	149	10	j.	j.	PROPN
cuesj-1446	149	11	hu	hu	PROPN
cuesj-1446	149	12	,	,	PUNCT
cuesj-1446	149	13	x.	x.	PROPN
cuesj-1446	149	14	sun	sun	PROPN
cuesj-1446	149	15	,	,	PUNCT
cuesj-1446	149	16	and	and	CCONJ
cuesj-1446	149	17	q.	q.	PROPN
cuesj-1446	149	18	liu	liu	PROPN
cuesj-1446	149	19	.	.	PUNCT
cuesj-1446	150	1	impact	impact	NOUN
cuesj-1446	150	2	of	of	ADP
cuesj-1446	150	3	diabetes	diabetes	NOUN
cuesj-1446	150	4	mellitus	mellitus	NOUN
cuesj-1446	150	5	on	on	ADP
cuesj-1446	150	6	lower	low	ADJ
cuesj-1446	150	7	urinary	urinary	ADJ
cuesj-1446	150	8	tract	tract	NOUN
cuesj-1446	150	9	symptoms	symptom	NOUN
cuesj-1446	150	10	in	in	ADP
cuesj-1446	150	11	benign	benign	ADJ
cuesj-1446	150	12	prostatic	prostatic	ADJ
cuesj-1446	150	13	hyperplasia	hyperplasia	NOUN
cuesj-1446	150	14	patients	patient	NOUN
cuesj-1446	150	15	:	:	PUNCT
cuesj-1446	150	16	a	a	DET
cuesj-1446	150	17	meta	meta	ADJ
cuesj-1446	150	18	-	-	PUNCT
cuesj-1446	150	19	analysis	analysis	NOUN
cuesj-1446	150	20	.	.	PUNCT
cuesj-1446	151	1	frontiers	frontier	NOUN
cuesj-1446	151	2	in	in	ADP
cuesj-1446	151	3	endocrinology	endocrinology	NOUN
cuesj-1446	151	4	(	(	PUNCT
cuesj-1446	151	5	lausanne	lausanne	PROPN
cuesj-1446	151	6	)	)	PUNCT
cuesj-1446	151	7	,	,	PUNCT
cuesj-1446	151	8	vol	vol	NOUN
cuesj-1446	151	9	.	.	PROPN
cuesj-1446	151	10	12	12	NUM
cuesj-1446	151	11	,	,	PUNCT
cuesj-1446	151	12	2022	2022	NUM
cuesj-1446	151	13	,	,	PUNCT
cuesj-1446	151	14	p.	p.	NOUN
cuesj-1446	151	15	741748	741748	NUM
cuesj-1446	151	16	.	.	PUNCT
cuesj-1446	152	1	15	15	X
cuesj-1446	152	2	.	.	PUNCT
cuesj-1446	153	1	n.	n.	PROPN
cuesj-1446	153	2	h.	h.	PROPN
cuesj-1446	153	3	el	el	PROPN
cuesj-1446	153	4	-	-	PUNCT
cuesj-1446	153	5	shafei	shafei	PROPN
cuesj-1446	153	6	,	,	PUNCT
cuesj-1446	153	7	m.	m.	NOUN
cuesj-1446	153	8	a.	a.	PROPN
cuesj-1446	153	9	zaafan	zaafan	PROPN
cuesj-1446	153	10	,	,	PUNCT
cuesj-1446	153	11	e.	e.	PROPN
cuesj-1446	153	12	a.	a.	PROPN
cuesj-1446	153	13	kandil	kandil	PROPN
cuesj-1446	153	14	and	and	CCONJ
cuesj-1446	153	15	r.	r.	PROPN
cuesj-1446	153	16	h.	h.	PROPN
cuesj-1446	153	17	sayed	sayed	PROPN
cuesj-1446	153	18	.	.	PUNCT
cuesj-1446	154	1	simvastatin	simvastatin	PROPN
cuesj-1446	154	2	ameliorates	ameliorate	VERB
cuesj-1446	154	3	testosterone	testosterone	NOUN
cuesj-1446	154	4	-	-	PUNCT
cuesj-1446	154	5	induced	induce	VERB
cuesj-1446	154	6	prostatic	prostatic	ADJ
cuesj-1446	154	7	hyperplasia	hyperplasia	NOUN
cuesj-1446	154	8	in	in	ADP
cuesj-1446	154	9	rats	rat	NOUN
cuesj-1446	154	10	via	via	ADP
cuesj-1446	154	11	modulating	modulate	VERB
cuesj-1446	154	12	igf-1	igf-1	NOUN
cuesj-1446	154	13	/	/	SYM
cuesj-1446	154	14	pi3k	pi3k	NOUN
cuesj-1446	154	15	/	/	SYM
cuesj-1446	154	16	akt	akt	PROPN
cuesj-1446	154	17	/	/	SYM
cuesj-1446	154	18	foxo	foxo	PROPN
cuesj-1446	154	19	signaling	signal	VERB
cuesj-1446	154	20	.	.	PUNCT
cuesj-1446	155	1	european	european	PROPN
cuesj-1446	155	2	journal	journal	PROPN
cuesj-1446	155	3	of	of	ADP
cuesj-1446	155	4	pharmacology	pharmacology	NOUN
cuesj-1446	155	5	,	,	PUNCT
cuesj-1446	155	6	vol	vol	NOUN
cuesj-1446	155	7	.	.	PROPN
cuesj-1446	155	8	950	950	NUM
cuesj-1446	155	9	,	,	PUNCT
cuesj-1446	155	10	p.	p.	NOUN
cuesj-1446	155	11	175762	175762	NUM
cuesj-1446	155	12	,	,	PUNCT
cuesj-1446	155	13	2023	2023	NUM
cuesj-1446	155	14	.	.	PUNCT
cuesj-1446	156	1	16	16	NUM
cuesj-1446	156	2	.	.	PUNCT
cuesj-1446	156	3	b.	b.	PROPN
cuesj-1446	156	4	pang	pang	PROPN
cuesj-1446	156	5	,	,	PUNCT
cuesj-1446	156	6	l.	l.	PROPN
cuesj-1446	156	7	l.	l.	PROPN
cuesj-1446	156	8	zhang	zhang	PROPN
cuesj-1446	156	9	,	,	PUNCT
cuesj-1446	156	10	b.	b.	PROPN
cuesj-1446	156	11	li	li	PROPN
cuesj-1446	156	12	,	,	PUNCT
cuesj-1446	156	13	f.	f.	PROPN
cuesj-1446	156	14	x.	x.	PROPN
cuesj-1446	156	15	sun	sun	PROPN
cuesj-1446	156	16	and	and	CCONJ
cuesj-1446	156	17	z.	z.	PROPN
cuesj-1446	156	18	d.	d.	PROPN
cuesj-1446	156	19	wang	wang	PROPN
cuesj-1446	156	20	.	.	PUNCT
cuesj-1446	157	1	the	the	DET
cuesj-1446	157	2	sodium	sodium	NOUN
cuesj-1446	157	3	glucose	glucose	NOUN
cuesj-1446	157	4	co	co	NOUN
cuesj-1446	157	5	-	-	NOUN
cuesj-1446	157	6	transporter	transporter	ADJ
cuesj-1446	157	7	2	2	NUM
cuesj-1446	157	8	inhibitor	inhibitor	NOUN
cuesj-1446	157	9	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	157	10	for	for	ADP
cuesj-1446	157	11	alzheimer	alzheimer	PROPN
cuesj-1446	157	12	’s	’s	PART
cuesj-1446	157	13	disease	disease	NOUN
cuesj-1446	157	14	:	:	PUNCT
cuesj-1446	157	15	inhibition	inhibition	NOUN
cuesj-1446	157	16	of	of	ADP
cuesj-1446	157	17	brain	brain	NOUN
cuesj-1446	157	18	insulin	insulin	NOUN
cuesj-1446	157	19	signaling	signal	VERB
cuesj-1446	157	20	disruption	disruption	NOUN
cuesj-1446	157	21	-	-	PUNCT
cuesj-1446	157	22	induced	induce	VERB
cuesj-1446	157	23	tau	tau	PROPN
cuesj-1446	157	24	hyperphosphorylation	hyperphosphorylation	NOUN
cuesj-1446	157	25	.	.	PUNCT
cuesj-1446	158	1	physiology	physiology	NOUN
cuesj-1446	158	2	and	and	CCONJ
cuesj-1446	158	3	behavior	behavior	NOUN
cuesj-1446	158	4	,	,	PUNCT
cuesj-1446	158	5	vol	vol	NOUN
cuesj-1446	158	6	.	.	PROPN
cuesj-1446	158	7	263	263	NUM
cuesj-1446	158	8	,	,	PUNCT
cuesj-1446	158	9	p.	p.	NOUN
cuesj-1446	158	10	114134	114134	NUM
cuesj-1446	158	11	,	,	PUNCT
cuesj-1446	158	12	2023	2023	NUM
cuesj-1446	158	13	.	.	PUNCT
cuesj-1446	159	1	17	17	NUM
cuesj-1446	159	2	.	.	PUNCT
cuesj-1446	160	1	h.	h.	PROPN
cuesj-1446	160	2	malínská	malínská	PROPN
cuesj-1446	160	3	,	,	PUNCT
cuesj-1446	160	4	m.	m.	NOUN
cuesj-1446	160	5	hüttl	hüttl	PROPN
cuesj-1446	160	6	,	,	PUNCT
cuesj-1446	160	7	i.	i.	PROPN
cuesj-1446	160	8	marková	marková	PROPN
cuesj-1446	160	9	,	,	PUNCT
cuesj-1446	160	10	d.	d.	PROPN
cuesj-1446	160	11	miklánková	miklánková	PROPN
cuesj-1446	160	12	,	,	PUNCT
cuesj-1446	160	13	s.	s.	PROPN
cuesj-1446	160	14	hojná	hojná	PROPN
cuesj-1446	160	15	,	,	PUNCT
cuesj-1446	160	16	f.	f.	PROPN
cuesj-1446	160	17	papoušek	papoušek	PROPN
cuesj-1446	160	18	,	,	PUNCT
cuesj-1446	160	19	j.	j.	PROPN
cuesj-1446	160	20	šilhavý	šilhavý	PROPN
cuesj-1446	160	21	,	,	PUNCT
cuesj-1446	160	22	p.	p.	NOUN
cuesj-1446	160	23	mlejnek	mlejnek	NOUN
cuesj-1446	160	24	,	,	PUNCT
cuesj-1446	160	25	j.	j.	PROPN
cuesj-1446	160	26	zicha	zicha	PROPN
cuesj-1446	160	27	,	,	PUNCT
cuesj-1446	160	28	j.	j.	PROPN
cuesj-1446	160	29	hrdlička	hrdlička	PROPN
cuesj-1446	160	30	,	,	PUNCT
cuesj-1446	160	31	m.	m.	NOUN
cuesj-1446	160	32	pravenec	pravenec	NOUN
cuesj-1446	160	33	and	and	CCONJ
cuesj-1446	160	34	i.	i.	PROPN
cuesj-1446	160	35	vaněčková	vaněčková	PROPN
cuesj-1446	160	36	.	.	PUNCT
cuesj-1446	161	1	beneficial	beneficial	ADJ
cuesj-1446	161	2	effects	effect	NOUN
cuesj-1446	161	3	of	of	ADP
cuesj-1446	161	4	empagliflozin	empagliflozin	PROPN
cuesj-1446	161	5	are	be	AUX
cuesj-1446	161	6	mediated	mediate	VERB
cuesj-1446	161	7	by	by	ADP
cuesj-1446	161	8	reduced	reduce	VERB
cuesj-1446	161	9	renal	renal	ADJ
cuesj-1446	161	10	inflammation	inflammation	NOUN
cuesj-1446	161	11	and	and	CCONJ
cuesj-1446	161	12	oxidative	oxidative	ADJ
cuesj-1446	161	13	stress	stress	NOUN
cuesj-1446	161	14	in	in	ADP
cuesj-1446	161	15	spontaneously	spontaneously	ADV
cuesj-1446	161	16	hypertensive	hypertensive	ADJ
cuesj-1446	161	17	rats	rat	NOUN
cuesj-1446	161	18	expressing	express	VERB
cuesj-1446	161	19	human	human	ADJ
cuesj-1446	161	20	c	c	NOUN
cuesj-1446	161	21	-	-	PUNCT
cuesj-1446	161	22	reactive	reactive	ADJ
cuesj-1446	161	23	protein	protein	NOUN
cuesj-1446	161	24	.	.	PUNCT
cuesj-1446	162	1	biomedicines	biomedicine	NOUN
cuesj-1446	162	2	,	,	PUNCT
cuesj-1446	162	3	vol	vol	NOUN
cuesj-1446	162	4	.	.	PROPN
cuesj-1446	163	1	10	10	NUM
cuesj-1446	163	2	,	,	PUNCT
cuesj-1446	163	3	no	no	INTJ
cuesj-1446	163	4	.	.	NOUN
cuesj-1446	163	5	9	9	NUM
cuesj-1446	163	6	,	,	PUNCT
cuesj-1446	163	7	p.	p.	NOUN
cuesj-1446	163	8	2066	2066	NUM
cuesj-1446	163	9	,	,	PUNCT
cuesj-1446	163	10	2022	2022	NUM
cuesj-1446	163	11	.	.	PUNCT
cuesj-1446	164	1	18	18	NUM
cuesj-1446	164	2	.	.	PUNCT
cuesj-1446	164	3	m.	m.	PROPN
cuesj-1446	164	4	r.	r.	PROPN
cuesj-1446	164	5	jawad	jawad	PROPN
cuesj-1446	164	6	and	and	CCONJ
cuesj-1446	164	7	g.	g.	PROPN
cuesj-1446	164	8	a.	a.	PROPN
cuesj-1446	164	9	jasim	jasim	PROPN
cuesj-1446	164	10	.	.	PUNCT
cuesj-1446	165	1	biochemical	biochemical	ADJ
cuesj-1446	165	2	and	and	CCONJ
cuesj-1446	165	3	histopathological	histopathological	ADJ
cuesj-1446	165	4	evaluation	evaluation	NOUN
cuesj-1446	165	5	of	of	ADP
cuesj-1446	165	6	prostatic	prostatic	ADJ
cuesj-1446	165	7	tissue	tissue	NOUN
cuesj-1446	165	8	under	under	ADP
cuesj-1446	165	9	effect	effect	NOUN
cuesj-1446	165	10	of	of	ADP
cuesj-1446	165	11	pterostilbene	pterostilbene	NOUN
cuesj-1446	165	12	in	in	ADP
cuesj-1446	165	13	benign	benign	ADJ
cuesj-1446	165	14	prostatic	prostatic	ADJ
cuesj-1446	165	15	hyperplasia	hyperplasia	NOUN
cuesj-1446	165	16	rat	rat	NOUN
cuesj-1446	165	17	model	model	NOUN
cuesj-1446	165	18	.	.	PUNCT
cuesj-1446	166	1	al	al	PROPN
cuesj-1446	166	2	mustansiriyah	mustansiriyah	PROPN
cuesj-1446	166	3	journal	journal	PROPN
cuesj-1446	166	4	of	of	ADP
cuesj-1446	166	5	pharmaceutical	pharmaceutical	NOUN
cuesj-1446	166	6	sciences	science	NOUN
cuesj-1446	166	7	,	,	PUNCT
cuesj-1446	166	8	vol	vol	NOUN
cuesj-1446	166	9	.	.	PROPN
cuesj-1446	166	10	23	23	NUM
cuesj-1446	166	11	,	,	PUNCT
cuesj-1446	166	12	no	no	INTJ
cuesj-1446	166	13	.	.	NOUN
cuesj-1446	166	14	2	2	NUM
cuesj-1446	166	15	,	,	PUNCT
cuesj-1446	166	16	pp	pp	ADJ
cuesj-1446	166	17	.	.	PUNCT
cuesj-1446	167	1	196	196	NUM
cuesj-1446	167	2	-	-	SYM
cuesj-1446	167	3	213	213	NUM
cuesj-1446	167	4	,	,	PUNCT
cuesj-1446	167	5	2023	2023	NUM
cuesj-1446	167	6	.	.	PUNCT
cuesj-1446	168	1	19	19	NUM
cuesj-1446	168	2	.	.	PUNCT
cuesj-1446	168	3	j.	j.	PROPN
cuesj-1446	168	4	m.	m.	PROPN
cuesj-1446	168	5	abdulla	abdulla	PROPN
cuesj-1446	168	6	and	and	CCONJ
cuesj-1446	168	7	b.	b.	PROPN
cuesj-1446	168	8	n.	n.	PROPN
cuesj-1446	168	9	al	al	PROPN
cuesj-1446	168	10	-	-	PROPN
cuesj-1446	168	11	okaily	okaily	ADV
cuesj-1446	168	12	.	.	PUNCT
cuesj-1446	169	1	histomorphometric	histomorphometric	ADJ
cuesj-1446	169	2	and	and	CCONJ
cuesj-1446	169	3	histopathological	histopathological	ADJ
cuesj-1446	169	4	alterations	alteration	NOUN
cuesj-1446	169	5	of	of	ADP
cuesj-1446	169	6	rat	rat	NOUN
cuesj-1446	169	7	testis	testis	NOUN
cuesj-1446	169	8	following	follow	VERB
cuesj-1446	169	9	exposure	exposure	NOUN
cuesj-1446	169	10	to	to	ADP
cuesj-1446	169	11	hydrogen	hydrogen	NOUN
cuesj-1446	169	12	peroxide	peroxide	NOUN
cuesj-1446	169	13	:	:	PUNCT
cuesj-1446	169	14	protective	protective	ADJ
cuesj-1446	169	15	role	role	NOUN
cuesj-1446	169	16	of	of	ADP
cuesj-1446	169	17	resveratrol	resveratrol	NOUN
cuesj-1446	169	18	supplement	supplement	NOUN
cuesj-1446	169	19	.	.	PUNCT
cuesj-1446	170	1	the	the	DET
cuesj-1446	170	2	iraqi	iraqi	ADJ
cuesj-1446	170	3	journal	journal	NOUN
cuesj-1446	170	4	of	of	ADP
cuesj-1446	170	5	veterinary	veterinary	ADJ
cuesj-1446	170	6	medicine	medicine	NOUN
cuesj-1446	170	7	,	,	PUNCT
cuesj-1446	170	8	vol	vol	NOUN
cuesj-1446	170	9	.	.	PROPN
cuesj-1446	170	10	46	46	NUM
cuesj-1446	170	11	,	,	PUNCT
cuesj-1446	170	12	no	no	INTJ
cuesj-1446	170	13	.	.	NOUN
cuesj-1446	170	14	1	1	NUM
cuesj-1446	170	15	,	,	PUNCT
cuesj-1446	170	16	pp	pp	ADJ
cuesj-1446	170	17	.	.	PUNCT
cuesj-1446	171	1	17	17	NUM
cuesj-1446	171	2	-	-	SYM
cuesj-1446	171	3	23	23	NUM
cuesj-1446	171	4	,	,	PUNCT
cuesj-1446	171	5	2022	2022	NUM
cuesj-1446	171	6	.	.	PUNCT
cuesj-1446	172	1	20	20	NUM
cuesj-1446	172	2	.	.	PUNCT
cuesj-1446	172	3	d.	d.	PROPN
cuesj-1446	172	4	choi	choi	PROPN
cuesj-1446	172	5	,	,	PUNCT
cuesj-1446	172	6	j.	j.	PROPN
cuesj-1446	172	7	kim	kim	PROPN
cuesj-1446	172	8	,	,	PUNCT
cuesj-1446	172	9	j.	j.	PROPN
cuesj-1446	172	10	an	an	PROPN
cuesj-1446	172	11	,	,	PUNCT
cuesj-1446	172	12	s.	s.	PROPN
cuesj-1446	172	13	hong	hong	PROPN
cuesj-1446	172	14	,	,	PUNCT
cuesj-1446	172	15	y.	y.	PROPN
cuesj-1446	172	16	song	song	NOUN
cuesj-1446	172	17	and	and	CCONJ
cuesj-1446	172	18	h.	h.	PROPN
cuesj-1446	172	19	kong	kong	PROPN
cuesj-1446	172	20	.	.	PUNCT
cuesj-1446	173	1	amelioration	amelioration	NOUN
cuesj-1446	173	2	of	of	ADP
cuesj-1446	173	3	benign	benign	ADJ
cuesj-1446	173	4	prostatic	prostatic	ADJ
cuesj-1446	173	5	hyperplasia	hyperplasia	NOUN
cuesj-1446	173	6	by	by	ADP
cuesj-1446	173	7	costunolide	costunolide	NOUN
cuesj-1446	173	8	and	and	CCONJ
cuesj-1446	173	9	dehydrocostus	dehydrocostus	PROPN
cuesj-1446	173	10	lactone	lactone	PROPN
cuesj-1446	173	11	in	in	ADP
cuesj-1446	173	12	wistar	wistar	PROPN
cuesj-1446	173	13	rats	rat	NOUN
cuesj-1446	173	14	.	.	PUNCT
cuesj-1446	174	1	the	the	DET
cuesj-1446	174	2	world	world	PROPN
cuesj-1446	174	3	journal	journal	NOUN
cuesj-1446	174	4	of	of	ADP
cuesj-1446	174	5	mens	mens	PROPN
cuesj-1446	174	6	health	health	NOUN
cuesj-1446	174	7	,	,	PUNCT
cuesj-1446	174	8	vol	vol	NOUN
cuesj-1446	174	9	.	.	PROPN
cuesj-1446	174	10	39	39	NUM
cuesj-1446	174	11	,	,	PUNCT
cuesj-1446	174	12	no	no	INTJ
cuesj-1446	174	13	.	.	NOUN
cuesj-1446	174	14	2	2	NUM
cuesj-1446	174	15	,	,	PUNCT
cuesj-1446	174	16	pp	pp	ADJ
cuesj-1446	174	17	.	.	PUNCT
cuesj-1446	175	1	315	315	NUM
cuesj-1446	175	2	-	-	SYM
cuesj-1446	175	3	323	323	NUM
cuesj-1446	175	4	,	,	PUNCT
cuesj-1446	175	5	2021	2021	NUM
cuesj-1446	175	6	.	.	PUNCT
cuesj-1446	176	1	21	21	NUM
cuesj-1446	176	2	.	.	X
cuesj-1446	176	3	d.	d.	PROPN
cuesj-1446	176	4	m.	m.	PROPN
cuesj-1446	176	5	a.	a.	PROPN
cuesj-1446	176	6	elsherbini	elsherbini	PROPN
cuesj-1446	176	7	,	,	PUNCT
cuesj-1446	176	8	h.	h.	PROPN
cuesj-1446	176	9	m.	m.	PROPN
cuesj-1446	176	10	almohaimeed	almohaimeed	PROPN
cuesj-1446	176	11	,	,	PUNCT
cuesj-1446	176	12	m.	m.	NOUN
cuesj-1446	176	13	el	el	PROPN
cuesj-1446	176	14	-	-	PROPN
cuesj-1446	176	15	sherbiny	sherbiny	PROPN
cuesj-1446	176	16	,	,	PUNCT
cuesj-1446	176	17	z.	z.	PROPN
cuesj-1446	176	18	m.	m.	PROPN
cuesj-1446	176	19	mohammedsaleh	mohammedsaleh	PROPN
cuesj-1446	176	20	,	,	PUNCT
cuesj-1446	176	21	n.	n.	PROPN
cuesj-1446	176	22	m.	m.	PROPN
cuesj-1446	176	23	elsherbiny	elsherbiny	PROPN
cuesj-1446	176	24	,	,	PUNCT
cuesj-1446	176	25	s.	s.	PROPN
cuesj-1446	176	26	a.	a.	PROPN
cuesj-1446	176	27	gabr	gabr	PROPN
cuesj-1446	176	28	and	and	CCONJ
cuesj-1446	176	29	h.	h.	PROPN
cuesj-1446	176	30	a.	a.	PROPN
cuesj-1446	176	31	ebrahim	ebrahim	PROPN
cuesj-1446	176	32	.	.	PUNCT
cuesj-1446	177	1	origanum	origanum	ADJ
cuesj-1446	177	2	majorana	majorana	PROPN
cuesj-1446	177	3	l.	l.	PROPN
cuesj-1446	177	4	extract	extract	PROPN
cuesj-1446	177	5	attenuated	attenuate	VERB
cuesj-1446	177	6	benign	benign	ADJ
cuesj-1446	177	7	prostatic	prostatic	ADJ
cuesj-1446	177	8	hyperplasia	hyperplasia	NOUN
cuesj-1446	177	9	in	in	ADP
cuesj-1446	177	10	rat	rat	NOUN
cuesj-1446	177	11	model	model	NOUN
cuesj-1446	177	12	:	:	PUNCT
cuesj-1446	177	13	effect	effect	NOUN
cuesj-1446	177	14	on	on	ADP
cuesj-1446	177	15	oxidative	oxidative	ADJ
cuesj-1446	177	16	stress	stress	NOUN
cuesj-1446	177	17	,	,	PUNCT
cuesj-1446	177	18	apoptosis	apoptosis	NOUN
cuesj-1446	177	19	,	,	PUNCT
cuesj-1446	177	20	and	and	CCONJ
cuesj-1446	177	21	proliferation	proliferation	NOUN
cuesj-1446	177	22	.	.	PUNCT
cuesj-1446	178	1	antioxidants(basel	antioxidants(basel	PROPN
cuesj-1446	178	2	)	)	PUNCT
cuesj-1446	179	1	,	,	PUNCT
cuesj-1446	179	2	vol	vol	NOUN
cuesj-1446	179	3	.	.	PROPN
cuesj-1446	179	4	11	11	NUM
cuesj-1446	179	5	,	,	PUNCT
cuesj-1446	179	6	no	no	INTJ
cuesj-1446	179	7	.	.	NOUN
cuesj-1446	179	8	6	6	NUM
cuesj-1446	179	9	,	,	PUNCT
cuesj-1446	179	10	p.	p.	NOUN
cuesj-1446	179	11	1149	1149	NUM
cuesj-1446	179	12	,	,	PUNCT
cuesj-1446	179	13	2022	2022	NUM
cuesj-1446	179	14	.	.	PUNCT
cuesj-1446	180	1	22	22	NUM
cuesj-1446	180	2	.	.	PUNCT
cuesj-1446	180	3	i.	i.	PROPN
cuesj-1446	180	4	s.	s.	PROPN
cuesj-1446	180	5	shin	shin	PROPN
cuesj-1446	180	6	,	,	PUNCT
cuesj-1446	180	7	m.	m.	PROPN
cuesj-1446	180	8	y.	y.	PROPN
cuesj-1446	180	9	lee	lee	PROPN
cuesj-1446	180	10	,	,	PUNCT
cuesj-1446	180	11	h.	h.	PROPN
cuesj-1446	180	12	k.	k.	PROPN
cuesj-1446	181	1	ha	ha	PROPN
cuesj-1446	181	2	,	,	PUNCT
cuesj-1446	181	3	c.	c.	PROPN
cuesj-1446	181	4	s.	s.	PROPN
cuesj-1446	181	5	seo	seo	PROPN
cuesj-1446	181	6	and	and	CCONJ
cuesj-1446	181	7	h.	h.	PROPN
cuesj-1446	181	8	k.	k.	PROPN
cuesj-1446	181	9	shin	shin	PROPN
cuesj-1446	181	10	.	.	PUNCT
cuesj-1446	182	1	inhibitory	inhibitory	ADJ
cuesj-1446	182	2	effect	effect	NOUN
cuesj-1446	182	3	of	of	ADP
cuesj-1446	182	4	yukmijihwang	yukmijihwang	PROPN
cuesj-1446	182	5	-	-	PUNCT
cuesj-1446	182	6	tang	tang	PROPN
cuesj-1446	182	7	,	,	PUNCT
cuesj-1446	182	8	a	a	DET
cuesj-1446	182	9	traditional	traditional	ADJ
cuesj-1446	182	10	herbal	herbal	ADJ
cuesj-1446	182	11	formula	formula	NOUN
cuesj-1446	182	12	against	against	ADP
cuesj-1446	182	13	testosterone	testosterone	NOUN
cuesj-1446	182	14	-	-	PUNCT
cuesj-1446	182	15	induced	induce	VERB
cuesj-1446	182	16	benign	benign	ADJ
cuesj-1446	182	17	prostatic	prostatic	ADJ
cuesj-1446	182	18	hyperplasia	hyperplasia	NOUN
cuesj-1446	182	19	in	in	ADP
cuesj-1446	182	20	rats	rat	NOUN
cuesj-1446	182	21	.	.	PUNCT
cuesj-1446	183	1	bmc	bmc	ADJ
cuesj-1446	183	2	complementary	complementary	ADJ
cuesj-1446	183	3	and	and	CCONJ
cuesj-1446	183	4	alternative	alternative	ADJ
cuesj-1446	183	5	medicine	medicine	NOUN
cuesj-1446	183	6	,	,	PUNCT
cuesj-1446	183	7	vol	vol	NOUN
cuesj-1446	183	8	.	.	PROPN
cuesj-1446	183	9	12	12	NUM
cuesj-1446	183	10	,	,	PUNCT
cuesj-1446	183	11	no	no	INTJ
cuesj-1446	183	12	.	.	NOUN
cuesj-1446	183	13	1	1	NUM
cuesj-1446	183	14	,	,	PUNCT
cuesj-1446	183	15	p.	p.	NOUN
cuesj-1446	183	16	48	48	NUM
cuesj-1446	183	17	,	,	PUNCT
cuesj-1446	183	18	2012	2012	NUM
cuesj-1446	183	19	.	.	PUNCT
cuesj-1446	184	1	23	23	NUM
cuesj-1446	184	2	.	.	PUNCT
cuesj-1446	184	3	d.	d.	PROPN
cuesj-1446	184	4	h.	h.	PROPN
cuesj-1446	184	5	youn	youn	PROPN
cuesj-1446	184	6	,	,	PUNCT
cuesj-1446	184	7	j.	j.	PROPN
cuesj-1446	184	8	park	park	PROPN
cuesj-1446	184	9	,	,	PUNCT
cuesj-1446	184	10	h.	h.	PROPN
cuesj-1446	184	11	l.	l.	PROPN
cuesj-1446	184	12	kim	kim	PROPN
cuesj-1446	184	13	,	,	PUNCT
cuesj-1446	184	14	y.	y.	PROPN
cuesj-1446	184	15	jung	jung	PROPN
cuesj-1446	184	16	,	,	PUNCT
cuesj-1446	184	17	j.	j.	PROPN
cuesj-1446	184	18	kang	kang	PROPN
cuesj-1446	184	19	,	,	PUNCT
cuesj-1446	184	20	m.	m.	PROPN
cuesj-1446	184	21	y.	y.	PROPN
cuesj-1446	184	22	jeong	jeong	PROPN
cuesj-1446	184	23	,	,	PUNCT
cuesj-1446	184	24	g.	g.	PROPN
cuesj-1446	184	25	sethi	sethi	PROPN
cuesj-1446	184	26	,	,	PUNCT
cuesj-1446	184	27	k.	k.	PROPN
cuesj-1446	184	28	s.	s.	PROPN
cuesj-1446	184	29	ahn	ahn	PROPN
cuesj-1446	184	30	and	and	CCONJ
cuesj-1446	184	31	j.	j.	PROPN
cuesj-1446	184	32	y.	y.	PROPN
cuesj-1446	184	33	um	um	PROPN
cuesj-1446	184	34	.	.	PUNCT
cuesj-1446	184	35	chrysophanic	chrysophanic	PROPN
cuesj-1446	184	36	acid	acid	NOUN
cuesj-1446	184	37	reduces	reduce	VERB
cuesj-1446	184	38	testosterone	testosterone	NOUN
cuesj-1446	184	39	-	-	PUNCT
cuesj-1446	184	40	induced	induce	VERB
cuesj-1446	184	41	benign	benign	ADJ
cuesj-1446	184	42	prostatic	prostatic	ADJ
cuesj-1446	184	43	hyperplasia	hyperplasia	NOUN
cuesj-1446	184	44	in	in	ADP
cuesj-1446	184	45	rats	rat	NOUN
cuesj-1446	184	46	by	by	ADP
cuesj-1446	184	47	suppressing	suppress	VERB
cuesj-1446	184	48	5α	5α	ADJ
cuesj-1446	184	49	-	-	PUNCT
cuesj-1446	184	50	reductase	reductase	NOUN
cuesj-1446	184	51	and	and	CCONJ
cuesj-1446	184	52	extracellular	extracellular	ADJ
cuesj-1446	184	53	signal	signal	NOUN
cuesj-1446	184	54	-	-	PUNCT
cuesj-1446	184	55	regulated	regulate	VERB
cuesj-1446	184	56	kinase	kinase	NOUN
cuesj-1446	184	57	.	.	PUNCT
cuesj-1446	185	1	oncotarget	oncotarget	NOUN
cuesj-1446	185	2	,	,	PUNCT
cuesj-1446	185	3	vol	vol	NOUN
cuesj-1446	185	4	.	.	PROPN
cuesj-1446	185	5	8	8	NUM
cuesj-1446	185	6	,	,	PUNCT
cuesj-1446	185	7	no	no	INTJ
cuesj-1446	185	8	.	.	NOUN
cuesj-1446	185	9	6	6	NUM
cuesj-1446	185	10	,	,	PUNCT
cuesj-1446	185	11	pp	pp	ADJ
cuesj-1446	185	12	.	.	PUNCT
cuesj-1446	186	1	9500	9500	NUM
cuesj-1446	186	2	-	-	SYM
cuesj-1446	186	3	9512	9512	NUM
cuesj-1446	186	4	,	,	PUNCT
cuesj-1446	186	5	2017	2017	NUM
cuesj-1446	186	6	.	.	PUNCT
cuesj-1446	187	1	24	24	NUM
cuesj-1446	187	2	.	.	PUNCT
cuesj-1446	188	1	j.	j.	PROPN
cuesj-1446	188	2	m.	m.	PROPN
cuesj-1446	188	3	gray	gray	PROPN
cuesj-1446	188	4	,	,	PUNCT
cuesj-1446	188	5	a.	a.	PROPN
cuesj-1446	188	6	a.	a.	PROPN
cuesj-1446	188	7	nunez	nunez	PROPN
cuesj-1446	188	8	,	,	PUNCT
cuesj-1446	188	9	l.	l.	PROPN
cuesj-1446	188	10	i.	i.	PROPN
cuesj-1446	188	11	siegel	siegel	PROPN
cuesj-1446	188	12	and	and	CCONJ
cuesj-1446	188	13	g.	g.	PROPN
cuesj-1446	188	14	n.	n.	PROPN
cuesj-1446	188	15	wade	wade	PROPN
cuesj-1446	188	16	.	.	PUNCT
cuesj-1446	189	1	effects	effect	NOUN
cuesj-1446	189	2	of	of	ADP
cuesj-1446	189	3	testosterone	testosterone	NOUN
cuesj-1446	189	4	on	on	ADP
cuesj-1446	189	5	body	body	NOUN
cuesj-1446	189	6	weight	weight	NOUN
cuesj-1446	189	7	and	and	CCONJ
cuesj-1446	189	8	adipose	adipose	ADJ
cuesj-1446	189	9	tissue	tissue	NOUN
cuesj-1446	189	10	:	:	PUNCT
cuesj-1446	189	11	role	role	NOUN
cuesj-1446	189	12	of	of	ADP
cuesj-1446	189	13	aromatization	aromatization	NOUN
cuesj-1446	189	14	.	.	PUNCT
cuesj-1446	190	1	physiology	physiology	NOUN
cuesj-1446	190	2	and	and	CCONJ
cuesj-1446	190	3	behavior	behavior	NOUN
cuesj-1446	190	4	,	,	PUNCT
cuesj-1446	190	5	vol	vol	NOUN
cuesj-1446	190	6	.	.	PROPN
cuesj-1446	190	7	23	23	NUM
cuesj-1446	190	8	,	,	PUNCT
cuesj-1446	190	9	no	no	INTJ
cuesj-1446	190	10	.	.	NOUN
cuesj-1446	190	11	3	3	NUM
cuesj-1446	190	12	,	,	PUNCT
cuesj-1446	190	13	pp	pp	ADJ
cuesj-1446	190	14	.	.	PUNCT
cuesj-1446	191	1	465	465	NUM
cuesj-1446	191	2	-	-	SYM
cuesj-1446	191	3	469	469	NUM
cuesj-1446	191	4	,	,	PUNCT
cuesj-1446	191	5	1979	1979	NUM
cuesj-1446	191	6	.	.	PUNCT
cuesj-1446	192	1	25	25	NUM
cuesj-1446	192	2	.	.	PUNCT
cuesj-1446	193	1	k.	k.	PROPN
cuesj-1446	193	2	izumi	izumi	PROPN
cuesj-1446	193	3	,	,	PUNCT
cuesj-1446	193	4	a.	a.	NOUN
cuesj-1446	193	5	mizokami	mizokami	PROPN
cuesj-1446	193	6	,	,	PUNCT
cuesj-1446	193	7	w.	w.	PROPN
cuesj-1446	193	8	j.	j.	PROPN
cuesj-1446	193	9	lin	lin	PROPN
cuesj-1446	193	10	,	,	PUNCT
cuesj-1446	193	11	k.	k.	PROPN
cuesj-1446	194	1	p.	p.	PROPN
cuesj-1446	194	2	lai	lai	PROPN
cuesj-1446	194	3	and	and	CCONJ
cuesj-1446	194	4	c.	c.	PROPN
cuesj-1446	194	5	chang	chang	PROPN
cuesj-1446	194	6	.	.	PUNCT
cuesj-1446	195	1	androgen	androgen	NOUN
cuesj-1446	195	2	receptor	receptor	NOUN
cuesj-1446	195	3	roles	role	NOUN
cuesj-1446	195	4	in	in	ADP
cuesj-1446	195	5	the	the	DET
cuesj-1446	195	6	development	development	NOUN
cuesj-1446	195	7	of	of	ADP
cuesj-1446	195	8	benign	benign	ADJ
cuesj-1446	195	9	prostate	prostate	NOUN
cuesj-1446	195	10	hyperplasia	hyperplasia	NOUN
cuesj-1446	195	11	.	.	PUNCT
cuesj-1446	196	1	the	the	DET
cuesj-1446	196	2	american	american	PROPN
cuesj-1446	196	3	journal	journal	PROPN
cuesj-1446	196	4	of	of	ADP
cuesj-1446	196	5	pathology	pathology	PROPN
cuesj-1446	196	6	,	,	PUNCT
cuesj-1446	196	7	vol	vol	NOUN
cuesj-1446	196	8	.	.	PROPN
cuesj-1446	196	9	182	182	NUM
cuesj-1446	196	10	,	,	PUNCT
cuesj-1446	196	11	no	no	INTJ
cuesj-1446	196	12	.	.	NOUN
cuesj-1446	196	13	6	6	NUM
cuesj-1446	196	14	,	,	PUNCT
cuesj-1446	196	15	pp	pp	ADJ
cuesj-1446	196	16	.	.	PUNCT
cuesj-1446	196	17	19421949	19421949	NUM
cuesj-1446	196	18	,	,	PUNCT
cuesj-1446	196	19	2013	2013	NUM
cuesj-1446	196	20	.	.	PUNCT
cuesj-1446	197	1	26	26	NUM
cuesj-1446	197	2	.	.	PUNCT
cuesj-1446	197	3	d.	d.	PROPN
cuesj-1446	197	4	shanmugasundaram	shanmugasundaram	PROPN
cuesj-1446	197	5	,	,	PUNCT
cuesj-1446	197	6	c.	c.	PROPN
cuesj-1446	197	7	dwan	dwan	PROPN
cuesj-1446	197	8	,	,	PUNCT
cuesj-1446	197	9	b.	b.	PROPN
cuesj-1446	197	10	c.	c.	PROPN
cuesj-1446	197	11	wimmer	wimmer	PROPN
cuesj-1446	197	12	and	and	CCONJ
cuesj-1446	197	13	s.	s.	PROPN
cuesj-1446	197	14	srivastava	srivastava	PROPN
cuesj-1446	197	15	.	.	PUNCT
cuesj-1446	198	1	fucoidan	fucoidan	PROPN
cuesj-1446	198	2	ameliorates	ameliorate	VERB
cuesj-1446	198	3	testosterone	testosterone	NOUN
cuesj-1446	198	4	-	-	PUNCT
cuesj-1446	198	5	induced	induce	VERB
cuesj-1446	198	6	benign	benign	ADJ
cuesj-1446	198	7	prostatic	prostatic	ADJ
cuesj-1446	198	8	hyperplasia	hyperplasia	NOUN
cuesj-1446	198	9	(	(	PUNCT
cuesj-1446	198	10	bph	bph	NOUN
cuesj-1446	198	11	)	)	PUNCT
cuesj-1446	198	12	in	in	ADP
cuesj-1446	198	13	rats	rat	NOUN
cuesj-1446	198	14	.	.	PUNCT
cuesj-1446	199	1	research	research	NOUN
cuesj-1446	199	2	and	and	CCONJ
cuesj-1446	199	3	reports	report	NOUN
cuesj-1446	199	4	in	in	ADP
cuesj-1446	199	5	urology	urology	NOUN
cuesj-1446	199	6	,	,	PUNCT
cuesj-1446	199	7	vol	vol	NOUN
cuesj-1446	199	8	.	.	PROPN
cuesj-1446	199	9	16	16	NUM
cuesj-1446	199	10	,	,	PUNCT
cuesj-1446	199	11	pp	pp	ADJ
cuesj-1446	199	12	.	.	PUNCT
cuesj-1446	200	1	283	283	NUM
cuesj-1446	200	2	-	-	SYM
cuesj-1446	200	3	297	297	NUM
cuesj-1446	200	4	,	,	PUNCT
cuesj-1446	200	5	2024	2024	NUM
cuesj-1446	200	6	.	.	PUNCT
cuesj-1446	201	1	27	27	NUM
cuesj-1446	201	2	.	.	PUNCT
cuesj-1446	201	3	a.	a.	PROPN
cuesj-1446	201	4	j.	j.	PROPN
cuesj-1446	201	5	alamoudi	alamoudi	PROPN
cuesj-1446	201	6	,	,	PUNCT
cuesj-1446	201	7	s.	s.	PROPN
cuesj-1446	201	8	a.	a.	PROPN
cuesj-1446	201	9	alessi	alessi	PROPN
cuesj-1446	201	10	,	,	PUNCT
cuesj-1446	201	11	w.	w.	PROPN
cuesj-1446	201	12	y.	y.	PROPN
cuesj-1446	201	13	rizg	rizg	PROPN
cuesj-1446	201	14	,	,	PUNCT
cuesj-1446	201	15	a.	a.	NOUN
cuesj-1446	201	16	m.	m.	NOUN
cuesj-1446	201	17	jali	jali	PROPN
cuesj-1446	201	18	,	,	PUNCT
cuesj-1446	201	19	a.	a.	PROPN
cuesj-1446	201	20	y.	y.	PROPN
cuesj-1446	201	21	safhi	safhi	PROPN
cuesj-1446	201	22	,	,	PUNCT
cuesj-1446	201	23	f.	f.	PROPN
cuesj-1446	201	24	y.	y.	PROPN
cuesj-1446	201	25	sabei	sabei	PROPN
cuesj-1446	201	26	,	,	PUNCT
cuesj-1446	201	27	s.	s.	PROPN
cuesj-1446	201	28	alshehri	alshehri	PROPN
cuesj-1446	201	29	,	,	PUNCT
cuesj-1446	201	30	k.	k.	PROPN
cuesj-1446	201	31	m.	m.	PROPN
cuesj-1446	201	32	hosny	hosny	PROPN
cuesj-1446	201	33	and	and	CCONJ
cuesj-1446	201	34	a.	a.	PROPN
cuesj-1446	201	35	b.	b.	PROPN
cuesj-1446	201	36	abdel	abdel	PROPN
cuesj-1446	201	37	-	-	PUNCT
cuesj-1446	201	38	naim	naim	PROPN
cuesj-1446	201	39	.	.	PUNCT
cuesj-1446	202	1	cordycepin	cordycepin	ADJ
cuesj-1446	202	2	attenuates	attenuate	VERB
cuesj-1446	202	3	testosterone	testosterone	NOUN
cuesj-1446	202	4	-	-	PUNCT
cuesj-1446	202	5	induced	induce	VERB
cuesj-1446	202	6	benign	benign	ADJ
cuesj-1446	202	7	prostatic	prostatic	ADJ
cuesj-1446	202	8	hyperplasia	hyperplasia	NOUN
cuesj-1446	202	9	in	in	ADP
cuesj-1446	202	10	rats	rat	NOUN
cuesj-1446	202	11	via	via	ADP
cuesj-1446	202	12	modulation	modulation	NOUN
cuesj-1446	202	13	of	of	ADP
cuesj-1446	202	14	ampk	ampk	PROPN
cuesj-1446	202	15	and	and	CCONJ
cuesj-1446	202	16	akt	akt	PROPN
cuesj-1446	202	17	activation	activation	NOUN
cuesj-1446	202	18	.	.	PUNCT
cuesj-1446	203	1	pharmaceutics	pharmaceutic	NOUN
cuesj-1446	203	2	,	,	PUNCT
cuesj-1446	203	3	vol	vol	NOUN
cuesj-1446	203	4	.	.	PROPN
cuesj-1446	203	5	14	14	NUM
cuesj-1446	203	6	,	,	PUNCT
cuesj-1446	203	7	no	no	INTJ
cuesj-1446	203	8	.	.	NOUN
cuesj-1446	203	9	8	8	NUM
cuesj-1446	203	10	,	,	PUNCT
cuesj-1446	203	11	p.	p.	NOUN
cuesj-1446	203	12	1652	1652	NUM
cuesj-1446	203	13	,	,	PUNCT
cuesj-1446	203	14	2022	2022	NUM
cuesj-1446	203	15	.	.	PUNCT
cuesj-1446	204	1	28	28	NUM
cuesj-1446	204	2	.	.	PUNCT
cuesj-1446	205	1	g.	g.	PROPN
cuesj-1446	205	2	w.	w.	PROPN
cuesj-1446	205	3	kusuma	kusuma	PROPN
cuesj-1446	205	4	duarsa	duarsa	PROPN
cuesj-1446	205	5	,	,	PUNCT
cuesj-1446	205	6	y.	y.	PROPN
cuesj-1446	205	7	a.	a.	NOUN
cuesj-1446	205	8	sari	sari	PROPN
cuesj-1446	205	9	,	,	PUNCT
cuesj-1446	205	10	a.	a.	PROPN
cuesj-1446	205	11	a.	a.	PROPN
cuesj-1446	205	12	gde	gde	PROPN
cuesj-1446	205	13	oka	oka	PROPN
cuesj-1446	205	14	,	,	PUNCT
cuesj-1446	205	15	k.	k.	PROPN
cuesj-1446	205	16	b.	b.	PROPN
cuesj-1446	205	17	santosa	santosa	PROPN
cuesj-1446	205	18	,	,	PUNCT
cuesj-1446	205	19	i.	i.	PROPN
cuesj-1446	205	20	w.	w.	PROPN
cuesj-1446	205	21	yudiana	yudiana	PROPN
cuesj-1446	205	22	,	,	PUNCT
cuesj-1446	205	23	p.	p.	PROPN
cuesj-1446	205	24	m.	m.	NOUN
cuesj-1446	205	25	wisnu	wisnu	PROPN
cuesj-1446	205	26	tirtayasa	tirtayasa	PROPN
cuesj-1446	205	27	,	,	PUNCT
cuesj-1446	205	28	i.	i.	PROPN
cuesj-1446	205	29	b.	b.	PROPN
cuesj-1446	205	30	putra	putra	PROPN
cuesj-1446	205	31	pramana	pramana	PROPN
cuesj-1446	205	32	and	and	CCONJ
cuesj-1446	205	33	y.	y.	PROPN
cuesj-1446	205	34	p.	p.	PROPN
cuesj-1446	205	35	kloping	kloping	NOUN
cuesj-1446	205	36	.	.	PUNCT
cuesj-1446	206	1	serum	serum	NOUN
cuesj-1446	206	2	testosterone	testosterone	NOUN
cuesj-1446	206	3	and	and	CCONJ
cuesj-1446	206	4	prostate	prostate	NOUN
cuesj-1446	206	5	-	-	PUNCT
cuesj-1446	206	6	specific	specific	ADJ
cuesj-1446	206	7	antigen	antigen	ADJ
cuesj-1446	206	8	levels	level	NOUN
cuesj-1446	206	9	are	be	AUX
cuesj-1446	206	10	major	major	ADJ
cuesj-1446	206	11	risk	risk	NOUN
cuesj-1446	206	12	factors	factor	NOUN
cuesj-1446	206	13	for	for	ADP
cuesj-1446	206	14	prostatic	prostatic	ADJ
cuesj-1446	206	15	volume	volume	NOUN
cuesj-1446	206	16	increase	increase	NOUN
cuesj-1446	206	17	among	among	ADP
cuesj-1446	206	18	benign	benign	ADJ
cuesj-1446	206	19	prostatic	prostatic	ADJ
cuesj-1446	206	20	hyperplasia	hyperplasia	NOUN
cuesj-1446	206	21	patients	patient	NOUN
cuesj-1446	206	22	.	.	PUNCT
cuesj-1446	207	1	asian	asian	ADJ
cuesj-1446	207	2	journal	journal	PROPN
cuesj-1446	207	3	of	of	ADP
cuesj-1446	207	4	urology	urology	NOUN
cuesj-1446	207	5	,	,	PUNCT
cuesj-1446	207	6	vol	vol	NOUN
cuesj-1446	207	7	.	.	PROPN
cuesj-1446	207	8	8	8	NUM
cuesj-1446	207	9	,	,	PUNCT
cuesj-1446	207	10	no	no	INTJ
cuesj-1446	207	11	.	.	NOUN
cuesj-1446	207	12	3	3	NUM
cuesj-1446	207	13	,	,	PUNCT
cuesj-1446	207	14	pp	pp	ADJ
cuesj-1446	207	15	.	.	PUNCT
cuesj-1446	208	1	289	289	NUM
cuesj-1446	208	2	-	-	SYM
cuesj-1446	208	3	297	297	NUM
cuesj-1446	208	4	,	,	PUNCT
cuesj-1446	208	5	2021	2021	NUM
cuesj-1446	208	6	.	.	PUNCT
cuesj-1446	209	1	29	29	NUM
cuesj-1446	209	2	.	.	PUNCT
cuesj-1446	210	1	k.	k.	PROPN
cuesj-1446	210	2	khodamoradi	khodamoradi	PROPN
cuesj-1446	210	3	,	,	PUNCT
cuesj-1446	210	4	z.	z.	PROPN
cuesj-1446	210	5	khosravizadeh	khosravizadeh	PROPN
cuesj-1446	210	6	,	,	PUNCT
cuesj-1446	210	7	m.	m.	NOUN
cuesj-1446	210	8	parmar	parmar	PROPN
cuesj-1446	210	9	,	,	PUNCT
cuesj-1446	210	10	m.	m.	NOUN
cuesj-1446	210	11	kuchakulla	kuchakulla	PROPN
cuesj-1446	210	12	,	,	PUNCT
cuesj-1446	210	13	r.	r.	PROPN
cuesj-1446	210	14	ramasamy	ramasamy	PROPN
cuesj-1446	210	15	and	and	CCONJ
cuesj-1446	210	16	h.	h.	PROPN
cuesj-1446	210	17	arora	arora	PROPN
cuesj-1446	210	18	.	.	PUNCT
cuesj-1446	211	1	exogenous	exogenous	ADJ
cuesj-1446	211	2	testosterone	testosterone	NOUN
cuesj-1446	211	3	replacement	replacement	NOUN
cuesj-1446	211	4	therapy	therapy	NOUN
cuesj-1446	211	5	versus	versus	ADP
cuesj-1446	211	6	raising	raise	VERB
cuesj-1446	211	7	endogenous	endogenous	ADJ
cuesj-1446	211	8	testosterone	testosterone	NOUN
cuesj-1446	211	9	levels	level	NOUN
cuesj-1446	211	10	:	:	PUNCT
cuesj-1446	211	11	current	current	ADJ
cuesj-1446	211	12	and	and	CCONJ
cuesj-1446	211	13	future	future	ADJ
cuesj-1446	211	14	prospects	prospect	NOUN
cuesj-1446	211	15	.	.	PUNCT
cuesj-1446	212	1	fs	fs	ADP
cuesj-1446	212	2	reviews	review	NOUN
cuesj-1446	212	3	,	,	PUNCT
cuesj-1446	212	4	vol	vol	NOUN
cuesj-1446	212	5	.	.	PROPN
cuesj-1446	212	6	2	2	NUM
cuesj-1446	212	7	,	,	PUNCT
cuesj-1446	212	8	no	no	INTJ
cuesj-1446	212	9	.	.	NOUN
cuesj-1446	212	10	1	1	NUM
cuesj-1446	212	11	,	,	PUNCT
cuesj-1446	212	12	pp	pp	ADJ
cuesj-1446	212	13	.	.	PUNCT
cuesj-1446	213	1	32	32	NUM
cuesj-1446	213	2	-	-	SYM
cuesj-1446	213	3	42	42	NUM
cuesj-1446	213	4	,	,	PUNCT
cuesj-1446	213	5	2021	2021	NUM
cuesj-1446	213	6	.	.	PUNCT
cuesj-1446	214	1	30	30	NUM
cuesj-1446	214	2	.	.	PUNCT
cuesj-1446	214	3	r.	r.	PROPN
cuesj-1446	214	4	margiana	margiana	PROPN
cuesj-1446	214	5	,	,	PUNCT
cuesj-1446	214	6	m.	m.	PROPN
cuesj-1446	214	7	f.	f.	PROPN
cuesj-1446	214	8	abdullah	abdullah	PROPN
cuesj-1446	214	9	,	,	PUNCT
cuesj-1446	214	10	i.	i.	PROPN
cuesj-1446	214	11	ilhamsyah	ilhamsyah	PROPN
cuesj-1446	214	12	,	,	PUNCT
cuesj-1446	214	13	s.	s.	PROPN
cuesj-1446	214	14	supardi	supardi	PROPN
cuesj-1446	214	15	and	and	CCONJ
cuesj-1446	214	16	p.	p.	PROPN
cuesj-1446	214	17	narulita	narulita	PROPN
cuesj-1446	214	18	.	.	PUNCT
cuesj-1446	215	1	comparison	comparison	NOUN
cuesj-1446	215	2	of	of	ADP
cuesj-1446	215	3	short	short	ADJ
cuesj-1446	215	4	and	and	CCONJ
cuesj-1446	215	5	long	long	ADV
cuesj-1446	215	6	-	-	PUNCT
cuesj-1446	215	7	acting	act	VERB
cuesj-1446	215	8	testosterone	testosterone	NOUN
cuesj-1446	215	9	replacement	replacement	NOUN
cuesj-1446	215	10	therapy	therapy	NOUN
cuesj-1446	215	11	for	for	ADP
cuesj-1446	215	12	better	well	ADJ
cuesj-1446	215	13	sperm	sperm	NOUN
cuesj-1446	215	14	production	production	NOUN
cuesj-1446	215	15	and	and	CCONJ
cuesj-1446	215	16	testosterone	testosterone	NOUN
cuesj-1446	215	17	levels	level	NOUN
cuesj-1446	215	18	in	in	ADP
cuesj-1446	215	19	male	male	ADJ
cuesj-1446	215	20	late	late	ADJ
cuesj-1446	215	21	-	-	PUNCT
cuesj-1446	215	22	onset	onset	NOUN
cuesj-1446	215	23	hypogonadism	hypogonadism	NOUN
cuesj-1446	215	24	.	.	PUNCT
cuesj-1446	216	1	international	international	ADJ
cuesj-1446	216	2	journal	journal	PROPN
cuesj-1446	216	3	of	of	ADP
cuesj-1446	216	4	health	health	PROPN
cuesj-1446	216	5	sciences	sciences	PROPN
cuesj-1446	216	6	,	,	PUNCT
cuesj-1446	216	7	vol	vol	NOUN
cuesj-1446	216	8	.	.	PROPN
cuesj-1446	216	9	6	6	NUM
cuesj-1446	216	10	,	,	PUNCT
cuesj-1446	216	11	pp	pp	ADJ
cuesj-1446	216	12	.	.	PUNCT
cuesj-1446	217	1	968	968	NUM
cuesj-1446	217	2	-	-	SYM
cuesj-1446	217	3	982	982	NUM
cuesj-1446	217	4	,	,	PUNCT
cuesj-1446	217	5	2022	2022	NUM
cuesj-1446	217	6	.	.	PUNCT
cuesj-1446	218	1	31	31	NUM
cuesj-1446	218	2	.	.	PUNCT
cuesj-1446	219	1	n.	n.	PROPN
cuesj-1446	219	2	d.	d.	PROPN
cuesj-1446	219	3	patel	patel	PROPN
cuesj-1446	219	4	and	and	CCONJ
cuesj-1446	219	5	j.	j.	PROPN
cuesj-1446	219	6	k.	k.	PROPN
cuesj-1446	219	7	parsons	parsons	PROPN
cuesj-1446	219	8	.	.	PUNCT
cuesj-1446	220	1	epidemiology	epidemiology	NOUN
cuesj-1446	220	2	and	and	CCONJ
cuesj-1446	220	3	etiology	etiology	NOUN
cuesj-1446	220	4	of	of	ADP
cuesj-1446	220	5	benign	benign	ADJ
cuesj-1446	220	6	prostatic	prostatic	ADJ
cuesj-1446	220	7	hyperplasia	hyperplasia	NOUN
cuesj-1446	220	8	and	and	CCONJ
cuesj-1446	220	9	bladder	bladder	NOUN
cuesj-1446	220	10	outlet	outlet	NOUN
cuesj-1446	220	11	obstruction	obstruction	NOUN
cuesj-1446	220	12	.	.	PUNCT
cuesj-1446	221	1	indian	indian	PROPN
cuesj-1446	221	2	journal	journal	PROPN
cuesj-1446	221	3	of	of	ADP
cuesj-1446	221	4	urology	urology	NOUN
cuesj-1446	221	5	,	,	PUNCT
cuesj-1446	221	6	vol	vol	NOUN
cuesj-1446	221	7	.	.	PROPN
cuesj-1446	221	8	30	30	NUM
cuesj-1446	221	9	,	,	PUNCT
cuesj-1446	221	10	no	no	INTJ
cuesj-1446	221	11	.	.	NOUN
cuesj-1446	221	12	2	2	NUM
cuesj-1446	221	13	,	,	PUNCT
cuesj-1446	221	14	p.	p.	NOUN
cuesj-1446	221	15	170	170	NUM
cuesj-1446	221	16	,	,	PUNCT
cuesj-1446	221	17	2014	2014	NUM
cuesj-1446	221	18	.	.	PUNCT
cuesj-1446	222	1	32	32	NUM
cuesj-1446	222	2	.	.	PUNCT
cuesj-1446	223	1	d.	d.	PROPN
cuesj-1446	223	2	w.	w.	PROPN
cuesj-1446	223	3	strand	strand	PROPN
cuesj-1446	223	4	,	,	PUNCT
cuesj-1446	223	5	d.	d.	PROPN
cuesj-1446	223	6	n.	n.	PROPN
cuesj-1446	223	7	costa	costa	PROPN
cuesj-1446	223	8	,	,	PUNCT
cuesj-1446	223	9	f.	f.	PROPN
cuesj-1446	223	10	francis	francis	PROPN
cuesj-1446	223	11	,	,	PUNCT
cuesj-1446	223	12	w.	w.	PROPN
cuesj-1446	223	13	a.	a.	PROPN
cuesj-1446	223	14	ricke	ricke	PROPN
cuesj-1446	223	15	and	and	CCONJ
cuesj-1446	223	16	c.	c.	PROPN
cuesj-1446	223	17	g.	g.	PROPN
cuesj-1446	223	18	roehrborn	roehrborn	VERB
cuesj-1446	223	19	.	.	PUNCT
cuesj-1446	224	1	targeting	target	VERB
cuesj-1446	224	2	phenotypic	phenotypic	ADJ
cuesj-1446	224	3	heterogeneity	heterogeneity	NOUN
cuesj-1446	224	4	in	in	ADP
cuesj-1446	224	5	benign	benign	ADJ
cuesj-1446	224	6	prostatic	prostatic	ADJ
cuesj-1446	224	7	hyperplasia	hyperplasia	NOUN
cuesj-1446	224	8	.	.	PUNCT
cuesj-1446	225	1	differentiation	differentiation	NOUN
cuesj-1446	225	2	,	,	PUNCT
cuesj-1446	225	3	vol	vol	NOUN
cuesj-1446	225	4	.	.	PROPN
cuesj-1446	225	5	96	96	NUM
cuesj-1446	225	6	,	,	PUNCT
cuesj-1446	225	7	pp	pp	ADJ
cuesj-1446	225	8	.	.	PUNCT
cuesj-1446	226	1	49	49	NUM
cuesj-1446	226	2	-	-	SYM
cuesj-1446	226	3	61	61	NUM
cuesj-1446	226	4	,	,	PUNCT
cuesj-1446	226	5	2017	2017	NUM
cuesj-1446	226	6	.	.	PUNCT
cuesj-1446	227	1	33	33	NUM
cuesj-1446	227	2	.	.	PUNCT
cuesj-1446	228	1	j.	j.	PROPN
cuesj-1446	228	2	hata	hata	PROPN
cuesj-1446	228	3	,	,	PUNCT
cuesj-1446	228	4	y.	y.	PROPN
cuesj-1446	228	5	harigane	harigane	PROPN
cuesj-1446	228	6	,	,	PUNCT
cuesj-1446	228	7	k.	k.	PROPN
cuesj-1446	228	8	matsuoka	matsuoka	PROPN
cuesj-1446	228	9	,	,	PUNCT
cuesj-1446	228	10	h.	h.	PROPN
cuesj-1446	228	11	akaihata	akaihata	PROPN
cuesj-1446	228	12	,	,	PUNCT
cuesj-1446	228	13	k.	k.	PROPN
cuesj-1446	228	14	yaginuma	yaginuma	PROPN
cuesj-1446	228	15	,	,	PUNCT
cuesj-1446	228	16	s.	s.	PROPN
cuesj-1446	228	17	meguro	meguro	PROPN
cuesj-1446	228	18	,	,	PUNCT
cuesj-1446	228	19	s.	s.	PROPN
cuesj-1446	228	20	hoshi	hoshi	PROPN
cuesj-1446	228	21	,	,	PUNCT
cuesj-1446	228	22	y.	y.	PROPN
cuesj-1446	228	23	sato	sato	PROPN
cuesj-1446	228	24	,	,	PUNCT
cuesj-1446	228	25	s.	s.	PROPN
cuesj-1446	228	26	ogawa	ogawa	PROPN
cuesj-1446	228	27	,	,	PUNCT
cuesj-1446	228	28	m.	m.	NOUN
cuesj-1446	228	29	uemura	uemura	PROPN
cuesj-1446	228	30	and	and	CCONJ
cuesj-1446	228	31	y.	y.	PROPN
cuesj-1446	228	32	kojima	kojima	PROPN
cuesj-1446	228	33	.	.	PUNCT
cuesj-1446	229	1	mechanism	mechanism	NOUN
cuesj-1446	229	2	of	of	ADP
cuesj-1446	229	3	androgen	androgen	NOUN
cuesj-1446	229	4	-	-	PUNCT
cuesj-1446	229	5	independent	independent	ADJ
cuesj-1446	229	6	stromal	stromal	ADJ
cuesj-1446	229	7	proliferation	proliferation	NOUN
cuesj-1446	229	8	in	in	ADP
cuesj-1446	229	9	benign	benign	ADJ
cuesj-1446	229	10	prostatic	prostatic	ADJ
cuesj-1446	229	11	hyperplasia	hyperplasia	NOUN
cuesj-1446	229	12	.	.	PUNCT
cuesj-1446	230	1	international	international	ADJ
cuesj-1446	230	2	journal	journal	NOUN
cuesj-1446	230	3	of	of	ADP
cuesj-1446	230	4	molecular	molecular	ADJ
cuesj-1446	230	5	sciences	science	NOUN
cuesj-1446	230	6	,	,	PUNCT
cuesj-1446	230	7	vol	vol	NOUN
cuesj-1446	230	8	.	.	PROPN
cuesj-1446	230	9	24	24	NUM
cuesj-1446	230	10	,	,	PUNCT
cuesj-1446	230	11	no	no	INTJ
cuesj-1446	230	12	.	.	NOUN
cuesj-1446	230	13	14	14	NUM
cuesj-1446	230	14	,	,	PUNCT
cuesj-1446	230	15	p.	p.	NOUN
cuesj-1446	230	16	11634	11634	NUM
cuesj-1446	230	17	,	,	PUNCT
cuesj-1446	230	18	2023	2023	NUM
cuesj-1446	230	19	.	.	PUNCT
cuesj-1446	231	1	34	34	NUM
cuesj-1446	231	2	.	.	PUNCT
cuesj-1446	232	1	y.	y.	PROPN
cuesj-1446	232	2	li	li	PROPN
cuesj-1446	232	3	,	,	PUNCT
cuesj-1446	232	4	j.	j.	PROPN
cuesj-1446	232	5	ma	ma	PROPN
cuesj-1446	232	6	,	,	PUNCT
cuesj-1446	232	7	x.	x.	PROPN
cuesj-1446	232	8	h.	h.	PROPN
cuesj-1446	232	9	qin	qin	PROPN
cuesj-1446	232	10	and	and	CCONJ
cuesj-1446	232	11	c.	c.	PROPN
cuesj-1446	232	12	y.	y.	PROPN
cuesj-1446	232	13	hu	hu	PROPN
cuesj-1446	232	14	.	.	PUNCT
cuesj-1446	233	1	the	the	DET
cuesj-1446	233	2	efficacy	efficacy	NOUN
cuesj-1446	233	3	and	and	CCONJ
cuesj-1446	233	4	safety	safety	NOUN
cuesj-1446	233	5	of	of	ADP
cuesj-1446	233	6	dutasteride	dutasteride	NOUN
cuesj-1446	233	7	and	and	CCONJ
cuesj-1446	233	8	finasteride	finasteride	ADV
cuesj-1446	233	9	in	in	ADP
cuesj-1446	233	10	patients	patient	NOUN
cuesj-1446	233	11	with	with	ADP
cuesj-1446	233	12	benign	benign	ADJ
cuesj-1446	233	13	prostatic	prostatic	ADJ
cuesj-1446	233	14	hyperplasia	hyperplasia	NOUN
cuesj-1446	233	15	:	:	PUNCT
cuesj-1446	233	16	a	a	DET
cuesj-1446	233	17	systematic	systematic	ADJ
cuesj-1446	233	18	review	review	NOUN
cuesj-1446	233	19	and	and	CCONJ
cuesj-1446	233	20	meta	meta	ADJ
cuesj-1446	233	21	-	-	PUNCT
cuesj-1446	233	22	analysis	analysis	NOUN
cuesj-1446	233	23	.	.	PUNCT
cuesj-1446	234	1	translational	translational	ADJ
cuesj-1446	234	2	andrology	andrology	NOUN
cuesj-1446	234	3	and	and	CCONJ
cuesj-1446	234	4	urology	urology	NOUN
cuesj-1446	234	5	,	,	PUNCT
cuesj-1446	234	6	vol	vol	NOUN
cuesj-1446	234	7	.	.	PROPN
cuesj-1446	234	8	11	11	NUM
cuesj-1446	234	9	,	,	PUNCT
cuesj-1446	234	10	no	no	INTJ
cuesj-1446	234	11	.	.	NOUN
cuesj-1446	234	12	3	3	NUM
cuesj-1446	234	13	,	,	PUNCT
cuesj-1446	234	14	pp	pp	ADJ
cuesj-1446	234	15	.	.	PUNCT
cuesj-1446	235	1	313	313	NUM
cuesj-1446	235	2	-	-	SYM
cuesj-1446	235	3	324	324	NUM
cuesj-1446	235	4	,	,	PUNCT
cuesj-1446	235	5	2022	2022	NUM
cuesj-1446	235	6	.	.	PUNCT
cuesj-1446	236	1	35	35	NUM
cuesj-1446	236	2	.	.	PUNCT
cuesj-1446	237	1	j.	j.	PROPN
cuesj-1446	237	2	k.	k.	PROPN
cuesj-1446	237	3	alhussien	alhussien	PROPN
cuesj-1446	237	4	,	,	PUNCT
cuesj-1446	237	5	m.	m.	PROPN
cuesj-1446	237	6	j.	j.	PROPN
cuesj-1446	237	7	al	al	PROPN
cuesj-1446	237	8	-	-	PUNCT
cuesj-1446	237	9	kurdy	kurdy	PROPN
cuesj-1446	237	10	and	and	CCONJ
cuesj-1446	237	11	s.	s.	PROPN
cuesj-1446	237	12	a.	a.	PROPN
cuesj-1446	237	13	hussein	hussein	PROPN
cuesj-1446	237	14	.	.	PUNCT
cuesj-1446	238	1	in	in	ADP
cuesj-1446	238	2	vivo	vivo	ADJ
cuesj-1446	238	3	assessment	assessment	NOUN
cuesj-1446	238	4	of	of	ADP
cuesj-1446	238	5	the	the	DET
cuesj-1446	238	6	anti	anti	ADJ
cuesj-1446	238	7	-	-	ADJ
cuesj-1446	238	8	benign	benign	ADJ
cuesj-1446	238	9	prostatic	prostatic	ADJ
cuesj-1446	238	10	hyperplasia	hyperplasia	NOUN
cuesj-1446	238	11	effect	effect	NOUN
cuesj-1446	238	12	of	of	ADP
cuesj-1446	238	13	hot	hot	ADJ
cuesj-1446	238	14	ethanolic	ethanolic	ADJ
cuesj-1446	238	15	extract	extract	NOUN
cuesj-1446	238	16	of	of	ADP
cuesj-1446	238	17	flax	flax	ADJ
cuesj-1446	238	18	seeds	seed	NOUN
cuesj-1446	238	19	in	in	ADP
cuesj-1446	238	20	male	male	ADJ
cuesj-1446	238	21	rats	rat	NOUN
cuesj-1446	238	22	.	.	PUNCT
cuesj-1446	239	1	open	open	ADJ
cuesj-1446	239	2	veterinary	veterinary	ADJ
cuesj-1446	239	3	journal	journal	NOUN
cuesj-1446	239	4	,	,	PUNCT
cuesj-1446	239	5	vol	vol	NOUN
cuesj-1446	239	6	.	.	PROPN
cuesj-1446	239	7	14	14	NUM
cuesj-1446	239	8	,	,	PUNCT
cuesj-1446	239	9	no	no	INTJ
cuesj-1446	239	10	.	.	NOUN
cuesj-1446	239	11	8	8	NUM
cuesj-1446	239	12	,	,	PUNCT
cuesj-1446	239	13	p.	p.	NOUN
cuesj-1446	239	14	1928	1928	NUM
cuesj-1446	239	15	-	-	SYM
cuesj-1446	239	16	1935	1935	NUM
cuesj-1446	239	17	,	,	PUNCT
cuesj-1446	239	18	2024	2024	NUM
cuesj-1446	239	19	.	.	PUNCT
cuesj-1446	240	1	36	36	NUM
cuesj-1446	240	2	.	.	PUNCT
cuesj-1446	240	3	e.	e.	PROPN
cuesj-1446	240	4	m.	m.	PROPN
cuesj-1446	240	5	elbaz	elbaz	PROPN
cuesj-1446	240	6	,	,	PUNCT
cuesj-1446	240	7	a.	a.	PROPN
cuesj-1446	240	8	darwish	darwish	PROPN
cuesj-1446	240	9	,	,	PUNCT
cuesj-1446	240	10	a.	a.	NOUN
cuesj-1446	240	11	m.	m.	NOUN
cuesj-1446	240	12	gad	gad	PROPN
cuesj-1446	240	13	,	,	PUNCT
cuesj-1446	240	14	a.	a.	PROPN
cuesj-1446	240	15	a.	a.	PROPN
cuesj-1446	240	16	s.	s.	PROPN
cuesj-1446	240	17	abdel	abdel	PROPN
cuesj-1446	240	18	rahman	rahman	PROPN
cuesj-1446	240	19	and	and	CCONJ
cuesj-1446	240	20	m.	m.	PROPN
cuesj-1446	240	21	h.	h.	PROPN
cuesj-1446	240	22	safwat	safwat	PROPN
cuesj-1446	240	23	.	.	PUNCT
cuesj-1446	241	1	canagliflozin	canagliflozin	PROPN
cuesj-1446	241	2	alleviates	alleviate	VERB
cuesj-1446	241	3	experimentally	experimentally	ADV
cuesj-1446	241	4	induced	induce	VERB
cuesj-1446	241	5	benign	benign	ADJ
cuesj-1446	241	6	prostate	prostate	NOUN
cuesj-1446	241	7	hyperplasia	hyperplasia	NOUN
cuesj-1446	241	8	in	in	ADP
cuesj-1446	241	9	a	a	DET
cuesj-1446	241	10	rat	rat	NOUN
cuesj-1446	241	11	model	model	NOUN
cuesj-1446	241	12	:	:	PUNCT
cuesj-1446	241	13	exploring	explore	VERB
cuesj-1446	241	14	potential	potential	ADJ
cuesj-1446	241	15	mechanisms	mechanism	NOUN
cuesj-1446	241	16	involving	involve	VERB
cuesj-1446	241	17	mir-128b	mir-128b	X
cuesj-1446	241	18	/	/	SYM
cuesj-1446	241	19	egfr	egfr	PROPN
cuesj-1446	241	20	/	/	SYM
cuesj-1446	241	21	egf	egf	PROPN
cuesj-1446	241	22	and	and	CCONJ
cuesj-1446	241	23	jak2	jak2	PROPN
cuesj-1446	241	24	/	/	SYM
cuesj-1446	241	25	stat3	stat3	NOUN
cuesj-1446	241	26	signaling	signal	VERB
cuesj-1446	241	27	pathways	pathway	NOUN
cuesj-1446	241	28	through	through	ADP
cuesj-1446	241	29	in	in	ADP
cuesj-1446	241	30	silico	silico	NOUN
cuesj-1446	241	31	and	and	CCONJ
cuesj-1446	241	32	in	in	ADP
cuesj-1446	241	33	vivo	vivo	ADJ
cuesj-1446	241	34	investigations	investigation	NOUN
cuesj-1446	241	35	.	.	PUNCT
cuesj-1446	242	1	european	european	ADJ
cuesj-1446	242	2	journal	journal	PROPN
cuesj-1446	242	3	of	of	ADP
cuesj-1446	242	4	pharmacology	pharmacology	NOUN
cuesj-1446	242	5	,	,	PUNCT
cuesj-1446	242	6	vol	vol	NOUN
cuesj-1446	242	7	.	.	NOUN
cuesj-1446	242	8	957	957	NUM
cuesj-1446	242	9	,	,	PUNCT
cuesj-1446	242	10	p.	p.	NOUN
cuesj-1446	242	11	175993	175993	NUM
cuesj-1446	242	12	,	,	PUNCT
cuesj-1446	242	13	2023	2023	NUM
cuesj-1446	242	14	.	.	PUNCT
cuesj-1446	243	1	37	37	NUM
cuesj-1446	243	2	.	.	PUNCT
cuesj-1446	244	1	s.	s.	PROPN
cuesj-1446	244	2	raje	raje	PROPN
cuesj-1446	244	3	,	,	PUNCT
cuesj-1446	244	4	e.	e.	PROPN
cuesj-1446	244	5	callegari	callegari	PROPN
cuesj-1446	244	6	,	,	PUNCT
cuesj-1446	244	7	v.	v.	ADP
cuesj-1446	244	8	sahasrabudhe	sahasrabudhe	PROPN
cuesj-1446	244	9	,	,	PUNCT
cuesj-1446	244	10	a.	a.	PROPN
cuesj-1446	244	11	vaz	vaz	PROPN
cuesj-1446	244	12	,	,	PUNCT
cuesj-1446	244	13	h.	h.	PROPN
cuesj-1446	244	14	shi	shi	PROPN
cuesj-1446	244	15	,	,	PUNCT
cuesj-1446	244	16	e.	e.	PROPN
cuesj-1446	244	17	fluhler	fluhler	PROPN
cuesj-1446	244	18	,	,	PUNCT
cuesj-1446	244	19	e.	e.	PROPN
cuesj-1446	244	20	j.	j.	PROPN
cuesj-1446	244	21	woolf	woolf	PROPN
cuesj-1446	244	22	,	,	PUNCT
cuesj-1446	244	23	k.	k.	PROPN
cuesj-1446	244	24	schildknegt	schildknegt	PROPN
cuesj-1446	244	25	,	,	PUNCT
cuesj-1446	244	26	k.	k.	PROPN
cuesj-1446	244	27	matschke	matschke	PROPN
cuesj-1446	244	28	,	,	PUNCT
cuesj-1446	244	29	c.	c.	PROPN
cuesj-1446	244	30	alvey	alvey	PROPN
cuesj-1446	244	31	,	,	PUNCT
cuesj-1446	244	32	s.	s.	PROPN
cuesj-1446	244	33	zhou	zhou	PROPN
cuesj-1446	244	34	,	,	PUNCT
cuesj-1446	244	35	d.	d.	PROPN
cuesj-1446	244	36	papadopoulos	papadopoulos	PROPN
cuesj-1446	244	37	,	,	PUNCT
cuesj-1446	244	38	r.	r.	PROPN
cuesj-1446	244	39	fountaine	fountaine	PROPN
cuesj-1446	244	40	,	,	PUNCT
cuesj-1446	244	41	d.	d.	PROPN
cuesj-1446	244	42	saur	saur	PROPN
cuesj-1446	244	43	,	,	PUNCT
cuesj-1446	244	44	…	…	PUNCT
cuesj-1446	244	45	&	&	CCONJ
cuesj-1446	244	46	d.	d.	PROPN
cuesj-1446	244	47	l.	l.	PROPN
cuesj-1446	244	48	cutler	cutler	PROPN
cuesj-1446	244	49	.	.	PUNCT
cuesj-1446	245	1	novel	novel	ADJ
cuesj-1446	245	2	application	application	NOUN
cuesj-1446	245	3	of	of	ADP
cuesj-1446	245	4	the	the	DET
cuesj-1446	245	5	two‐period	two‐period	PROPN
cuesj-1446	245	6	microtracer	microtracer	NOUN
cuesj-1446	245	7	approach	approach	NOUN
cuesj-1446	245	8	to	to	PART
cuesj-1446	245	9	determine	determine	VERB
cuesj-1446	245	10	absolute	absolute	ADJ
cuesj-1446	245	11	oral	oral	ADJ
cuesj-1446	245	12	bioavailability	bioavailability	NOUN
cuesj-1446	245	13	and	and	CCONJ
cuesj-1446	245	14	fraction	fraction	NOUN
cuesj-1446	245	15	absorbed	absorb	VERB
cuesj-1446	245	16	of	of	ADP
cuesj-1446	245	17	ertugliflozin	ertugliflozin	NOUN
cuesj-1446	245	18	.	.	PUNCT
cuesj-1446	246	1	clinical	clinical	ADJ
cuesj-1446	246	2	and	and	CCONJ
cuesj-1446	246	3	translational	translational	ADJ
cuesj-1446	246	4	science	science	NOUN
cuesj-1446	246	5	,	,	PUNCT
cuesj-1446	246	6	vol	vol	NOUN
cuesj-1446	246	7	.	.	PROPN
cuesj-1446	246	8	11	11	NUM
cuesj-1446	246	9	,	,	PUNCT
cuesj-1446	246	10	no	no	INTJ
cuesj-1446	246	11	.	.	NOUN
cuesj-1446	246	12	4	4	NUM
cuesj-1446	246	13	,	,	PUNCT
cuesj-1446	246	14	pp	pp	ADJ
cuesj-1446	246	15	.	.	PUNCT
cuesj-1446	247	1	405	405	NUM
cuesj-1446	247	2	-	-	SYM
cuesj-1446	247	3	411	411	NUM
cuesj-1446	247	4	,	,	PUNCT
cuesj-1446	247	5	2018	2018	NUM
cuesj-1446	247	6	.	.	PUNCT
cuesj-1446	248	1	38	38	NUM
cuesj-1446	248	2	.	.	PUNCT
cuesj-1446	249	1	j.	j.	PROPN
cuesj-1446	249	2	w.	w.	PROPN
cuesj-1446	249	3	manoel	manoel	PROPN
cuesj-1446	249	4	,	,	PUNCT
cuesj-1446	249	5	g.	g.	PROPN
cuesj-1446	249	6	b.	b.	PROPN
cuesj-1446	249	7	primieri	primieri	PROPN
cuesj-1446	249	8	,	,	PUNCT
cuesj-1446	249	9	n.	n.	PROPN
cuesj-1446	249	10	m.	m.	PROPN
cuesj-1446	249	11	volpato	volpato	PROPN
cuesj-1446	249	12	and	and	CCONJ
cuesj-1446	249	13	m.	m.	NOUN
cuesj-1446	249	14	steppe	steppe	PROPN
cuesj-1446	249	15	.	.	PUNCT
cuesj-1446	250	1	development	development	NOUN
cuesj-1446	250	2	and	and	CCONJ
cuesj-1446	250	3	validation	validation	NOUN
cuesj-1446	250	4	of	of	ADP
cuesj-1446	250	5	a	a	DET
cuesj-1446	250	6	dissolution	dissolution	NOUN
cuesj-1446	250	7	test	test	NOUN
cuesj-1446	250	8	for	for	ADP
cuesj-1446	250	9	empagliflozin	empagliflozin	PROPN
cuesj-1446	250	10	in	in	ADP
cuesj-1446	250	11	film	film	NOUN
cuesj-1446	250	12	-	-	PUNCT
cuesj-1446	250	13	coated	coat	VERB
cuesj-1446	250	14	tablets	tablet	NOUN
cuesj-1446	250	15	.	.	PUNCT
cuesj-1446	251	1	drug	drug	NOUN
cuesj-1446	251	2	analytical	analytical	ADJ
cuesj-1446	251	3	research	research	NOUN
cuesj-1446	251	4	,	,	PUNCT
cuesj-1446	251	5	vol	vol	NOUN
cuesj-1446	251	6	.	.	PROPN
cuesj-1446	251	7	5	5	NUM
cuesj-1446	251	8	,	,	PUNCT
cuesj-1446	251	9	no	no	INTJ
cuesj-1446	251	10	.	.	NOUN
cuesj-1446	251	11	2	2	NUM
cuesj-1446	251	12	,	,	PUNCT
cuesj-1446	251	13	pp	pp	ADJ
cuesj-1446	251	14	.	.	PUNCT
cuesj-1446	252	1	11	11	NUM
cuesj-1446	252	2	-	-	SYM
cuesj-1446	252	3	16	16	NUM
cuesj-1446	252	4	,	,	PUNCT
cuesj-1446	252	5	2021	2021	NUM
cuesj-1446	252	6	.	.	PUNCT
cuesj-1446	253	1	39	39	NUM
cuesj-1446	253	2	.	.	PUNCT
cuesj-1446	254	1	d.	d.	PROPN
cuesj-1446	254	2	j.	j.	PROPN
cuesj-1446	254	3	fediuk	fediuk	PROPN
cuesj-1446	254	4	,	,	PUNCT
cuesj-1446	254	5	g.	g.	PROPN
cuesj-1446	254	6	nucci	nucci	PROPN
cuesj-1446	254	7	,	,	PUNCT
cuesj-1446	254	8	v.	v.	PROPN
cuesj-1446	254	9	k.	k.	PROPN
cuesj-1446	254	10	dawra	dawra	PROPN
cuesj-1446	254	11	,	,	PUNCT
cuesj-1446	254	12	d.	d.	PROPN
cuesj-1446	254	13	l.	l.	PROPN
cuesj-1446	254	14	cutler	cutler	PROPN
cuesj-1446	254	15	,	,	PUNCT
cuesj-1446	254	16	n.	n.	PROPN
cuesj-1446	254	17	b.	b.	PROPN
cuesj-1446	254	18	amin	amin	PROPN
cuesj-1446	254	19	,	,	PUNCT
cuesj-1446	254	20	s.	s.	PROPN
cuesj-1446	254	21	g.	g.	PROPN
cuesj-1446	254	22	terra	terra	PROPN
cuesj-1446	254	23	,	,	PUNCT
cuesj-1446	254	24	r.	r.	PROPN
cuesj-1446	254	25	a.	a.	PROPN
cuesj-1446	254	26	boyd	boyd	PROPN
cuesj-1446	254	27	,	,	PUNCT
cuesj-1446	254	28	r.	r.	PROPN
cuesj-1446	254	29	krishna	krishna	PROPN
cuesj-1446	254	30	and	and	CCONJ
cuesj-1446	254	31	v.	v.	ADP
cuesj-1446	254	32	sahasrabudhe	sahasrabudhe	NOUN
cuesj-1446	254	33	.	.	PUNCT
cuesj-1446	255	1	overview	overview	NOUN
cuesj-1446	255	2	of	of	ADP
cuesj-1446	255	3	the	the	DET
cuesj-1446	255	4	clinical	clinical	ADJ
cuesj-1446	255	5	pharmacology	pharmacology	NOUN
cuesj-1446	255	6	of	of	ADP
cuesj-1446	255	7	ertugliflozin	ertugliflozin	PROPN
cuesj-1446	255	8	,	,	PUNCT
cuesj-1446	255	9	a	a	DET
cuesj-1446	255	10	novel	novel	ADJ
cuesj-1446	255	11	sodium	sodium	NOUN
cuesj-1446	255	12	-	-	PUNCT
cuesj-1446	255	13	glucose	glucose	NOUN
cuesj-1446	255	14	cotransporter	cotransporter	NOUN
cuesj-1446	255	15	2	2	NUM
cuesj-1446	255	16	(	(	PUNCT
cuesj-1446	255	17	sglt2	sglt2	NOUN
cuesj-1446	255	18	)	)	PUNCT
cuesj-1446	255	19	inhibitor	inhibitor	NOUN
cuesj-1446	255	20	.	.	PUNCT
cuesj-1446	256	1	clinical	clinical	ADJ
cuesj-1446	256	2	pharmacokinetics	pharmacokinetic	NOUN
cuesj-1446	256	3	,	,	PUNCT
cuesj-1446	256	4	vol	vol	NOUN
cuesj-1446	256	5	.	.	PROPN
cuesj-1446	256	6	59	59	NUM
cuesj-1446	256	7	,	,	PUNCT
cuesj-1446	256	8	no	no	INTJ
cuesj-1446	256	9	.	.	NOUN
cuesj-1446	256	10	8	8	NUM
cuesj-1446	256	11	,	,	PUNCT
cuesj-1446	256	12	pp	pp	ADJ
cuesj-1446	256	13	.	.	PUNCT
cuesj-1446	257	1	949	949	NUM
cuesj-1446	257	2	-	-	SYM
cuesj-1446	257	3	965	965	NUM
cuesj-1446	257	4	,	,	PUNCT
cuesj-1446	257	5	2020	2020	NUM
cuesj-1446	257	6	.	.	PUNCT
cuesj-1446	258	1	40	40	NUM
cuesj-1446	258	2	.	.	PUNCT
cuesj-1446	259	1	l.	l.	PROPN
cuesj-1446	259	2	chen	chen	PROPN
cuesj-1446	259	3	,	,	PUNCT
cuesj-1446	259	4	y.	y.	PROPN
cuesj-1446	259	5	mao	mao	PROPN
cuesj-1446	259	6	,	,	PUNCT
cuesj-1446	259	7	d.	d.	PROPN
cuesj-1446	259	8	e.	e.	PROPN
cuesj-1446	259	9	sharp	sharp	PROPN
cuesj-1446	259	10	,	,	PUNCT
cuesj-1446	259	11	s.	s.	PROPN
cuesj-1446	259	12	schadt	schadt	PROPN
cuesj-1446	259	13	,	,	PUNCT
cuesj-1446	259	14	s.	s.	PROPN
cuesj-1446	259	15	pagels	pagels	PROPN
cuesj-1446	259	16	,	,	PUNCT
cuesj-1446	259	17	r.	r.	PROPN
cuesj-1446	259	18	press	press	PROPN
cuesj-1446	259	19	,	,	PUNCT
cuesj-1446	259	20	t.	t.	PROPN
cuesj-1446	259	21	cheng	cheng	PROPN
cuesj-1446	259	22	,	,	PUNCT
cuesj-1446	259	23	m.	m.	PROPN
cuesj-1446	259	24	j.	j.	PROPN
cuesj-1446	259	25	potchoiba	potchoiba	PROPN
cuesj-1446	259	26	and	and	CCONJ
cuesj-1446	259	27	w.	w.	PROPN
cuesj-1446	259	28	collins	collins	PROPN
cuesj-1446	259	29	.	.	PUNCT
cuesj-1446	260	1	pharmacokinetics	pharmacokinetic	NOUN
cuesj-1446	260	2	,	,	PUNCT
cuesj-1446	260	3	biotransformation	biotransformation	NOUN
cuesj-1446	260	4	,	,	PUNCT
cuesj-1446	260	5	distribution	distribution	NOUN
cuesj-1446	260	6	and	and	CCONJ
cuesj-1446	260	7	excretion	excretion	NOUN
cuesj-1446	260	8	of	of	ADP
cuesj-1446	260	9	empagliflozin	empagliflozin	PROPN
cuesj-1446	260	10	,	,	PUNCT
cuesj-1446	260	11	a	a	DET
cuesj-1446	260	12	sodium	sodium	NOUN
cuesj-1446	260	13	-	-	PUNCT
cuesj-1446	260	14	glucose	glucose	NOUN
cuesj-1446	260	15	co	co	NOUN
cuesj-1446	260	16	-	-	NOUN
cuesj-1446	260	17	transporter	transporter	NOUN
cuesj-1446	260	18	(	(	PUNCT
cuesj-1446	260	19	sglt	sglt	ADJ
cuesj-1446	260	20	2	2	NUM
cuesj-1446	260	21	)	)	PUNCT
cuesj-1446	260	22	inhibitor	inhibitor	NOUN
cuesj-1446	260	23	,	,	PUNCT
cuesj-1446	260	24	in	in	ADP
cuesj-1446	260	25	mice	mouse	NOUN
cuesj-1446	260	26	,	,	PUNCT
cuesj-1446	260	27	rats	rat	NOUN
cuesj-1446	260	28	,	,	PUNCT
cuesj-1446	260	29	and	and	CCONJ
cuesj-1446	260	30	dogs	dog	NOUN
cuesj-1446	260	31	.	.	PUNCT
cuesj-1446	261	1	journal	journal	NOUN
cuesj-1446	261	2	of	of	ADP
cuesj-1446	261	3	pharmaceutics	pharmaceutic	NOUN
cuesj-1446	261	4	and	and	CCONJ
cuesj-1446	261	5	drug	drug	NOUN
cuesj-1446	261	6	development	development	NOUN
cuesj-1446	261	7	,	,	PUNCT
cuesj-1446	261	8	vol	vol	NOUN
cuesj-1446	261	9	.	.	PROPN
cuesj-1446	262	1	3	3	NUM
cuesj-1446	262	2	,	,	PUNCT
cuesj-1446	262	3	no	no	INTJ
cuesj-1446	262	4	.	.	NOUN
cuesj-1446	262	5	3	3	NUM
cuesj-1446	262	6	,	,	PUNCT
cuesj-1446	262	7	p.	p.	NOUN
cuesj-1446	262	8	302	302	NUM
cuesj-1446	262	9	,	,	PUNCT
cuesj-1446	262	10	2015	2015	NUM
cuesj-1446	262	11	.	.	PUNCT
cuesj-1446	263	1	41	41	NUM
cuesj-1446	263	2	.	.	PUNCT
cuesj-1446	263	3	a.	a.	NOUN
cuesj-1446	263	4	blessing	blessing	PROPN
cuesj-1446	263	5	,	,	PUNCT
cuesj-1446	263	6	l.	l.	PROPN
cuesj-1446	263	7	xu	xu	PROPN
cuesj-1446	263	8	,	,	PUNCT
cuesj-1446	263	9	g.	g.	PROPN
cuesj-1446	263	10	gao	gao	PROPN
cuesj-1446	263	11	,	,	PUNCT
cuesj-1446	263	12	l.	l.	PROPN
cuesj-1446	263	13	r.	r.	PROPN
cuesj-1446	263	14	bollu	bollu	PROPN
cuesj-1446	263	15	,	,	PUNCT
cuesj-1446	263	16	j.	j.	PROPN
cuesj-1446	263	17	ren	ren	PROPN
cuesj-1446	263	18	,	,	PUNCT
cuesj-1446	263	19	h.	h.	PROPN
cuesj-1446	263	20	li	li	PROPN
cuesj-1446	263	21	,	,	PUNCT
cuesj-1446	263	22	x.	x.	PROPN
cuesj-1446	263	23	wu	wu	PROPN
cuesj-1446	263	24	,	,	PUNCT
cuesj-1446	263	25	f.	f.	PROPN
cuesj-1446	263	26	su	su	PROPN
cuesj-1446	263	27	,	,	PUNCT
cuesj-1446	263	28	w.	w.	PROPN
cuesj-1446	263	29	c.	c.	PROPN
cuesj-1446	263	30	huang	huang	PROPN
cuesj-1446	263	31	,	,	PUNCT
cuesj-1446	263	32	m.	m.	PROPN
cuesj-1446	263	33	hung	hung	PROPN
cuesj-1446	263	34	,	,	PUNCT
cuesj-1446	263	35	l.	l.	PROPN
cuesj-1446	263	36	huo	huo	PROPN
cuesj-1446	263	37	,	,	PUNCT
cuesj-1446	263	38	g.	g.	PROPN
cuesj-1446	263	39	s.	s.	PROPN
cuesj-1446	263	40	palapattu	palapattu	PROPN
cuesj-1446	263	41	and	and	CCONJ
cuesj-1446	263	42	z.	z.	PROPN
cuesj-1446	263	43	weihua	weihua	PROPN
cuesj-1446	263	44	.	.	PUNCT
cuesj-1446	264	1	sodium	sodium	NOUN
cuesj-1446	264	2	/	/	SYM
cuesj-1446	264	3	glucose	glucose	NOUN
cuesj-1446	264	4	co	co	NOUN
cuesj-1446	264	5	-	-	NOUN
cuesj-1446	264	6	transporter	transporter	ADJ
cuesj-1446	264	7	1	1	NUM
cuesj-1446	264	8	expression	expression	NOUN
cuesj-1446	264	9	increases	increase	NOUN
cuesj-1446	264	10	in	in	ADP
cuesj-1446	264	11	human	human	ADJ
cuesj-1446	264	12	diseased	diseased	ADJ
cuesj-1446	264	13	prostate	prostate	NOUN
cuesj-1446	264	14	.	.	PUNCT
cuesj-1446	265	1	journal	journal	PROPN
cuesj-1446	265	2	of	of	ADP
cuesj-1446	265	3	cancer	cancer	NOUN
cuesj-1446	265	4	science	science	NOUN
cuesj-1446	265	5	and	and	CCONJ
cuesj-1446	265	6	therapy	therapy	NOUN
cuesj-1446	265	7	,	,	PUNCT
cuesj-1446	265	8	vol	vol	NOUN
cuesj-1446	265	9	.	.	PROPN
cuesj-1446	265	10	4	4	NUM
cuesj-1446	265	11	,	,	PUNCT
cuesj-1446	265	12	no	no	INTJ
cuesj-1446	265	13	.	.	NOUN
cuesj-1446	265	14	9	9	NUM
cuesj-1446	265	15	,	,	PUNCT
cuesj-1446	265	16	pp	pp	ADJ
cuesj-1446	265	17	.	.	PUNCT
cuesj-1446	266	1	306	306	NUM
cuesj-1446	266	2	-	-	SYM
cuesj-1446	266	3	312	312	NUM
cuesj-1446	266	4	,	,	PUNCT
cuesj-1446	266	5	2012	2012	NUM
cuesj-1446	266	6	.	.	PUNCT